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Abstract  
Alpha-synuclein (α-syn) is a natively unfolded protein that is closely linked to Parkinson’s 
disease (PD) by genetic, neuropathologic and biochemical evidence. Aggregated and fibrillar 
forms of α-syn are the main components of intracellular protein inclusions found in PD patients’ 
brains, termed Lewy Bodies (LB). Both in animal models and in vitro, α-syn forms fibrillar 
aggregates that resemble those observed in PD brain tissues. Although disease-associated 
mutations have been shown to promote the fibrillization of α-syn, the exact mechanisms 
responsible for triggering α-syn aggregation and toxicity in sporadic PD remain unknown. 
Addressing this gap of knowledge is crucial for understanding the molecular basis of the disease 
and developing effective therapies for the treatment of PD and other synucleinopathies. This 
project was initiated on the basis of the working hypothesis that post-translational modifications 
(PTM) may play important roles in modulating α-syn function and/or regulating its aggregation 
and toxicity. More specifically, α-syn is ubiquitously N-terminally acetylated, and 
phosphorylated (serines 87 and S129), ubiquitinated (lysines 12, 21 and 23) and truncated forms 
of α-syn have been observed in association with wild-type α-syn in LB and in brain tissues from 
PD patients and transgenic animals. Other modifications, such as phosphorylation at tyrosine 
125 (Y125), were significantly reduced in diseased brains. Despite the discovery of candidate 
enzymes that mediate α-syn phosphorylation, ubiquitination and truncation, little is known about 
how each of these modifications alters α-syn structure, function, aggregation and toxicity in 
vivo. This is primarily due to the lack of tools that allow site-specific introduction of these 
modifications and the lack of natural mutations that can mimic the effect of these modifications, 
including phosphorylation. 
The primary focus of this thesis was to develop strategies to overcome these limitations so as to 
elucidate the effect of phosphorylation at Y125 and monoubiquitination at lysine 6 (K6) on α-
syn structure, fibril formation, membrane binding and subcellular localization. Towards this 
goal, we developed two semisynthetic strategies that allow site-specific introduction of PTM in 
α-syn based on the ligation of synthetic peptides containing the desired modified amino acid 
with recombinantly expressed proteins using Expressed Protein Ligation. This approach enables 
the introduction of single or multiple PTM in the N- or C-terminal regions of α-syn, and the 
preparation of modified α-syn in milligram quantities. Using these approaches, we were able to 
show for the first time that ubiquitination stabilizes the monomeric form of the protein and 
inhibits, rather than promotes, α-syn aggregation, while phosphorylation at Y125 does not 
significantly change the structure and aggregation propensity of α-syn. With the semisynthetic 
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pY125 α-syn in our hands, we were also able to investigate for the first time the sub-cellular 
localization of pY125 α-syn through its microinjection into primary neurons. This was not 
previously possible due to technical limitations related to the absence of appropriate antibodies 
against pY125 α-syn for immunocytochemical studies and difficulties in generating site-
specifically modified α-syn. Furthermore, we were able to investigate the effect of α-syn 
phosphorylation on its interactions with other proteins, by probing the effect of pS129 and 
pY125 on the binding to a nanobody that was specifically selected by phage-display to tightly 
bind to the C-terminal domain of α-syn. Accordingly, we demonstrated that phosphorylation at a 
single residue is capable of disrupting the binding of full-length α-syn to another protein. These 
results have wide-ranging implications for the potential role of phosphorylation and other PTM 
in regulating α-syn’s function(s).  
We also exploited our ability to combine semisynthetic and enzymatic approaches to investigate 
potential cross-talk between different PTM, namely phosphorylation at Y125 and S129 and 
monoubiquitination at K6. These advances would eventually allow investigating the effect of 
cross-talk between other N and C-terminal modifications on α-syn’s properties and to 
investigate PTM-dependent protein-protein and protein-ligand interactions in vitro and in 
cellular models of synucleinopathies. 
Together, our semisynthetic approaches provide novel means for the introduction of site-specific 
modifications in the N- and C-termini of α-syn. Current efforts in our laboratory are focused on 
extending these approaches to investigate the dynamics of PTM through the use of photocaged 
modified amino acids and to prepare novel fluorescently labeled α-syn variants to investigate its 
folding at the single-molecule level in living cells. The results presented in this thesis and 
preliminary studies from our group demonstrate that semisynthetic α-syn can provide unique 
opportunities to investigate structure-function of α-syn and the role of PTM in the biology of α-
syn in health and disease.  
Keywords: Parkinson’s disease (PD); alphα-synuclein (α-syn); Lewy Bodies (LB); 
Aggregation; Amyloid; Oligomers; Dopamine (DA); Solid-phase peptide synthesis (SPPS); 
Native Chemical Ligation (NCL); Expressed Protein Ligation (EPL); Intein; Circular Dichroism 
(CD); Nuclear Magnetic Resonance (NMR); Transmission Electron Microscopy (TEM); 
Microinjection; Immunocytochemistry; Fluorescent Microscopy; Nanobodies; Isothermal 
Titration Calorimetry (ITC).  
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Resumé et Mots-clés 
La protéine alpha-synuclein (α-syn) est impliquée dans la maladie de Parkinson suite à des 
données génétiques, neuropathologiques and biochimiques. Sous forme agrégée, α-syn constitue 
la composante majoritaire des inclusions cytoplasmiques trouvées dans les neurones des patients 
de la maladie de Parkinson, communément appelées Corps de Lewy. Dans les modèles animaux 
ou dans des expériences in vitro, α-syn forme des fibrilles ressemblant aux inclusions qui ont été 
identifiées dans les cerveaux des patients. Des mutations pathogéniques ont été identifiées dans 
la séquence d’α-syn et sont capables d’engendrer une augmentation de l’agrégation de la 
protéine. Cependant, la majorité des patients de la maladie n’ont pas de mutations dans leurs 
gènes et l’identité des facteurs qui induisent l’agrégation d’α-syn dans les cas sporadiques est 
inconnue. L’étude approfondie de ces facteurs est nécessaire afin de mieux comprendre les 
bases moléculaires de la maladie et pour mieux développer des thérapies effectives pour le 
traitement de la maladie. Ce projet a été initié suite à la spéculation que les modifications post-
traductionnelles (MPT) jouent probablement un rôle important dans la régulation de la fonction 
d’α-syn, de son agrégation et de sa toxicité. 
α-syn est acétylée (N-terminale), et des formes phosphorylées (sur les serines 87, 129), 
ubiquitinées (aux lysines 12, 21 et 23) et tronquées (1-134, 1-133, 1-126, 1-122, 1-119, 1-115 
and 1-96) ont été observées dans les corps de Lewy. La quantité d’autres modifications, la 
phosphorylation à la tyrosine 125 par exemple, diminuent avec la progression de la maladie. 
Malgré la découverte de plusieurs enzymes responsables de la phosphorylation, ubiquitination et 
troncation d’α-syn, nous n’avons pas d’indications sur les effets de ces modifications sur la 
structure, fonction, agrégation et toxicité in vivo, probablement dû au fait que ces enzymes ne 
sont pas spécifiques par rapport aux acides aminées d’intérêt et que les mutants utilisés pour 
mimer ces modifications peuvent modifier intrinsèquement la structure de la protéine.  
Le but ultime de ma thèse était de développer des stratégies qui visent à surmonter ces 
limitations et à utiliser ces stratégies pour élucider l’effet de la phosphorylation à Y125 et la 
mono-ubiquitination à la lysine 6 (K6) sur la formation des fibrilles, l’interaction avec les 
membranes et la localisation dans la cellule d’α-syn. Nous avons développé deux stratégies 
semi-synthétiques qui permettent l’introduction de MPT à des positions spécifiques de la 
protéine en se basant sur une combinaison de synthèse peptidique pour la flexibilité d’acides 
aminés non naturels qui peuvent être introduits et la production de protéine recombinante dans 
E.coli. Cette méthodologie est connue sous le nom de Ligation de Protéine Exprimée.  Grace à 
cette approche, nous pouvons introduire des MPT dans le domaine N-terminal ou C-terminal 
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d’α-syn. Nous pouvons montrer pour la première fois, que la protéine mono-ubiquitinée inhibe 
l’agrégation alors que la phosphorylation à Y125 n’induit pas de changements significatifs sur la 
structure et la capacité d’agrégation de la protéine.  
De plus, nous avons pu déterminer la localisation de la protéine phosphorylée à Y125 dans la 
cellule grâce à la micro-injection de la protéine dans des neurones primaires de rat. Les études 
précédentes n’avaient pas pu accéder à ce type d’informations sur la localisation à cause de 
difficultés techniques liées à la cross-réactivité de l’anticorps anti-pY125, ce qui élimine son 
utilisation pour des études d’immunocytochimie. Nous avons aussi étudié l’effet de la 
phosphorylation sur l’interaction d’α-syn avec d’autres protéines. Nous avons choisi d’étudier 
l’effet de la phosphorylation à S129 et Y125 sur l’interaction de la protéine avec un 
« nanobody » qui a été spécifiquement sélectionné par la méthode de  « phage-display » pour 
interagir avec le domaine C-terminal d’α-syn. Les études précédentes d’interaction d’α-syn 
étaient basées sur l’utilisation de fragment de peptides C-terminaux. Nous démontrons pour la 
première fois que la phosphorylation d’un résidu unique est capable d’empêcher l’interaction de 
la protéine entière à une autre protéine. Ces résultats ont plusieurs implications concernant le 
rôle de la phosphorylation et d’autres MPT qui régulent la fonction et la dysfonction d’α-syn. 
En résumé, notre nouvelle approche semi-synthétique permet d’introduire des MPT dans le 
domaine N-terminal et C-terminal d’α-syn. La richesse de cette approche réside dans sa capacité 
d’étudier l’effet de modifications de résidus qui n’étaient pas accessibles précédemment avec les 
méthodes génétiques et chimiques standards. Nos résultats devraient permettre de préparer 
d’autres formes modifiées d’α-syn à travers l’utilisation de l’approche semi-synthétique et 
l’étude de l’influence de ces MPT d’α-syn sur la fonction physiologique et pathologique d’α-
syn.  
Mots-clés : Maladie de Parkinson ; alphα-synuclein ; Corps de Lewy ; agrégation ; fibres 
amyloïdes ; Modifications post-traductionnelles ; Oligomères ; Dopamine ; Synthèse peptidique 
en phase solide ; Ligation chimique native ; Ligation de Protéine Exprimée ; Inteine ; 
Dichroïsme circulaire ; Résonnance Magnétique Nucléaire ; Microscopique Electronique à 
Transmission ; Microinjection ; Immunocytochimie ; Microscopie de Fluorescence ; Titration 
Calorimétrique Isotherme 
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I. INTRODUCTION 
  
I.2. Parkinson’s disease 
Parkinson’s Disease (PD) is the second most prevalent neurodegenerative disease affecting 1-
2% of the population older than 60 years (de Lau and Breteler, 2006). The major symptoms of 
PD are bradykinesia, resting tremor or postural instability and the disease is characterized 
histologically by a progressive loss of neuromelanin-containing dopaminergic neurons of the 
substantia nigra (SN) pars compacta (Figure I-1.A) and the presence of intracellular 
proteinaceous inclusions termed Lewy Bodies (LB) (Figure I-1.B). The proteins alpha-synuclein 
(α-syn) and ubiquitin are major components of the LB (Spillantini et al., 1997, Wakabayashi et 
al., 1997, Spillantini et al., 1998b). Motor dysfunction in PD patients only manifest at a late-age 
after substantial dopaminergic neuron loss, suggesting a strong compensatory system in the 
early stages of the disease that counteracts the consequence of early neurodegeneration 
(Bernheimer et al., 1973). 
 
 
Figure I-1. Lewy Bodies and dopaminergic lesions in PD 
A. Schematic depiction of the loss of neuromelanin-containing neurons in the substantia nigra in PD patients. 
Image adapted from A.D.A.M images (http://www.adamimages.com/Illustration/SearchResult/1/parkinson) and B. 
Immunohistochemical analysis of dopaminergic neurons containing Lewy Bodies that are immunopositive for α-
syn (thick arrow). Figure from Spillantini et al. (Spillantini et al., 1997). 
 
The symptoms of PD appear chronologically during the different stages of the disease: non-
motor symptoms characterized by olfactory deficits, insomnia and constipation precede the 
motor symptoms whose diagnosis allows checking more precisely for the existence of PD 
  
 2 
  
(bradykinesia and rigidity) (Section I.2.3.1). Late stages of the disease are accompanied by 
cognitive decline and psychiatric syndromes (Braak et al., 2004).  
I.2.1. Genetic causes 
While the majority of PD patients with idiopathic or late-onset disease do not seem to have 
inherited the disease, gene mutations account for 5% of total PD cases (Hatano et al., 2009). A 
large number of genes have been implicated in PD but in the focus of the thesis, we will only 
mention the most common gene mutations (Figure I-2). Two genes are responsible for 
autosomal dominant inherited causes of PD: the SNCA/PARK1 gene coding for the protein α-
syn and the PARK8 gene coding for the protein LRRK2 (Gasser, 2009). Autosomal recessive 
inherited PD is triggered by mutations in the genes PARK2, PARK6 and PARK7 coding 
respectively for Parkin, PINK-1 and DJ-1 (Gasser, 2009).  
 
Figure I-2. Major genes and loci associated with PD 
A summary of the different genes that are implicated in PD. The most studied are: SNCA and LRRK2, whose 
mutations induce autosomal dominant familial PD and Parkin, DJ-1 and PINK1 that are linked to autosomal 
recessive PD. Figure from Martin et al. (Martin et al., 2011) 
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I.2.1.1. Alpha-synuclein 
α-syn was the first identified gene to cause PD (Polymeropoulos et al., 1996). α-syn contains 
three types of disease-causing mutations: single-point mutations, whole-gene multiplication 
(duplication and triplication) (Singleton et al., 2003) and gene polymorphism (Xia et al., 1996). 
• Single-point mutations 
The A53T mutation is the most commonly found mutation in PD patients and was first 
identified in Greek/Italian families (Polymeropoulos et al., 1997). A30P and E46K mutations 
were first reported in families of German and Spanish origin respectively (Kruger et al., 1998, 
Zarranz et al., 2004). Depending on the nature of α-syn mutation, PD patients exhibit different 
clinical symptoms (Corti et al., 2011). Patients with A53T mutation do not have a single 
phenotype but present largely diverse symptoms ranging from typical PD with late-onset disease 
to atypical PD with earlier-onset, faster disease progression or dementia (Golbe et al., 1990, 
Papapetropoulos et al., 2003, Ki et al., 2007, Puschmann et al., 2009). Patients with A30P 
mutation present the symptoms of idiopathic PD (late onset and mild progression) while the 
patients with E46K mutations show severe parkinsonism phenotypes (early-onset and dementia) 
(Kruger et al., 2001, Zarranz et al., 2004).  
• Gene multiplication 
In 2003, triplication of the SNCA gene was identified in the Iowa kindred where patients with 
four copies of the gene had a very early onset (mean age: 38 years) and a fast progression of the 
disease (Singleton et al., 2003). Later, patients of French and Italian origins with SNCA 
duplication showed clinical features similar to typical idiopathic PD with a late-onset (mean age 
of onset of 48) (Chartier-Harlin et al., 2004, Ibanez et al., 2004). The Lister Swedish/American 
family presents a good example of how the number of SNCA gene copies affects the phenotypic 
expression of the disease within a single family: one branch of the family diagnosed with a 
duplication of the gene showed a typical late-onset PD while the other branch, which had a 
triplication of the gene, exhibited early-onset PD with dementia (Fuchs et al., 2007). There is 
hence a proven correlation between the number of copies of the gene and hence protein 
expression levels and the severity of the disease. Aside from the impact of single-point 
mutations on the pathogenesis, this is the first time that altered levels of α-syn expression were 
speculated to lead to the progression of PD (Eriksen et al., 2005) (Figure I-3). 
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• Allele polymorphism 
Genetic variability has been reported in the α-syn promoter where a dinucleotide repeat 
polymorphic marker REP1 with an allele-length variability was mapped upstream of the 
transcription start site of the gene (Xia et al., 1996). This gene variability was suggested to show 
an association to PD in some cases (Kruger et al., 1999, Tan et al., 2000, Farrer et al., 2001b), 
while this was not confirmed in other studies (Parsian et al., 1998, Khan et al., 2001). The 
reason behind the discrepancy has been attributed to small population studies with potential 
biases. Hence, a collaborative program of 18 research sites was launched to investigate whether 
SNCA haplotypes are associated with PD and whether REP1 variability modifies the age of 
disease-onset (Maraganore et al., 2006). The results showed association of the allele-length 
variability in REP1 with PD: individuals that had the 263 base pair (bp) allele, not the 259 bp 
allele, were associated with a high risk for PD and the genotypes did not change the age of 
disease-onset (Maraganore et al., 2006). The effect of allelic variation in REP1 on transcription 
was assessed in cellular models where expression level increased 3-fold (Chiba-Falek and 
Nussbaum, 2001). Thus, α-syn levels are influenced by genetic variability in the promoter 
region. In addition to polymorphism in the promoter region, genetic variability was also 
identified in the coding (especially in exons 5 and 6) and non-coding sequence of α-syn with an 
increased tendency for PD (Mueller et al., 2005). 
I.2.1.2. Other genes involved in Parkinson’s Disease 
• LRRK2 
While α-syn mutations are rare, mutations in the gene coding for the protein LRRK2 (Leucin 
rich repeat kinase 2) are more common and occurs in 5-15 % of patients with autosomal 
dominant PD (Berg et al., 2005). One particular mutation – G2019S – is very frequent. The gene 
encodes a large proteins of 2,527 amino acids that harbors several domains: a leucine rich 
domain LRR, a GTPase domain and a kinase domain (Mata et al., 2006) (Figure I-3).  
Several missense mutations are distributed among the sequence of LRRK2 and are present in 
patients with typical late-onset familial and sporadic PD (Paisan-Ruiz et al., 2004, Zimprich et 
al., 2004). The G2019S mutation was shown to increase the kinase activity of LRRK2 and 
mutations occurring in its GTPase domain resulted in a decrease of activity (Cookson, 2010). 
Unlike α-syn, no gene dosage effect has been observed in the case of LRRK2. Despite numerous 
studies that would link LRRK2 to the proteins α-syn and tau and to the impairment of protein 
translation, the physiological function of the protein is still unknown (Cookson, 2010). 
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• Parkin 
Autosomal recessive forms of PD can be identified by the mapping of consanguineous families. 
Parkin mutations are the most common cause of early-onset PD and occur in 50% of the 
autosomal recessive familial forms of PD (Kitada et al., 1998, Periquet et al., 2003). Clinically, 
patients with Parkin mutations show similar phenotype as sporadic PD but also possess some 
particular clinical and neuropathological features: earlier-age of onset, slower disease 
progression but complicated early-motor fluctuations (Dawson and Dawson, 2010) and the 
absence of ubiquitinated LB (Farrer et al., 2001a, Hardy et al., 2003) (Figure I-3). 
A large number and diversity of mutations, ranging from large deletions and multiplications to 
small deletions and insertions and single-point mutations have been identified (Corti et al., 
2011). The Parkin protein is an E3 ubiquitin ligase of 465 residues with different known 
substrates such as synphilin, α/β tubulin, the p38 subunit of an aminoacyl tRNA synthase, and 
Parkin-associated endothelin receptor-like receptor (Shimura et al., 2000). Mutations in Parkin 
were hypothesized to lead to the loss of the E3 ligase activity and the accumulation of non-
ubiquitinated substrates. However, in vitro studies using single-point mutations of Parkin do not 
affect its ligase activity but rather its solubility (Matsuda et al., 2006).  
• PINK1 
PINK1 (Phosphatase and tensin homologue (PTEN)-induced novel kinase 1) mutations are the 
second most common cause for early-onset PD with clinical symptoms in patients closely linked 
to patients with Parkin mutations (Valente et al., 2004a, Valente et al., 2004b, Ibanez et al., 
2006) (Figure I-3). Missense mutations in PINK1 have been reported and induce a loss-of-
function of the protein (Valente et al., 2004a). The PINK1 protein is a tumor suppressor that 
contains several domains: an N-terminal mitochondrial targeting motif, a trans-membrane 
region and a Ser/Thr kinase domain. Endogenous PINK1 has been reported to be localized 
within the inner and outer mitochondrial membrane while over-expressed PINK1 is present on 
the mitochondrial cristae (Silvestri et al., 2005). The kinase domain has been shown to face the 
cytosol while the N-terminal domain is attached inside the mitochondria (Zhou et al., 2008). 
• DJ-1 
Mutations in the DJ-1 gene are the least occurring in autosomal recessive PD (1% of the cases) 
(Bonifati et al., 2003a, Bonifati et al., 2003b) (Figure I-3). They include large deletion, missense 
mutations, frame shift and deletions of exons (Corti et al., 2011). The DJ-1 protein is a 
molecular chaperone that is activated during oxidative stress and translocates to the outer 
mitochondrial membrane (Dawson et al., 2010).  
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Studies on mutations in the different genes that induce PD when mutated provided critical 
insights into potential mechanisms through which the encoded proteins could cause PD. Those 
genes could yield therapeutic targets in the future if their normal and pathogenic functions could 
be unraveled. Until then, they shed light on the implication of cellular pathways such as 
mitochondrial dysfunction and oxidative stress on the pathogenesis, mainly due to data collected 
via the expression and genetic manipulations of these genes in cellular and animal models 
(example of Parkin and PINK1).  
 
Figure I-3. Pathogenic mutations in the proteins involved in PD 
Structural and functional domains of the proteins involved in PD. LRRK2 domains: ANK (Ankyrin repeat), LRR 
(Leucine Rich Region), ROC (homologous sequence to Ras-related superfamily of GTPases), COR (domain 
responsible for dimerization) and WD40 (structural motif). PINK1 domains: MTS (mitochondria targeting 
sequence), TM (transmembrane domain) and kinase domain. Parkin domains: UBL (ubiquitin-like domain), RING1 
(Really Interesting New Gene 1), IBR (in between RING fingers) and RING2. Figure from Martin et al.(Martin et 
al., 2011).  
 
I.2.2. Environmental factors that trigger Parkinson’s Disease: 
95% of PD cases are sporadic (Hatano et al., 2009). The environmental and molecular factors 
that trigger the pathogenesis are still unknown. Some studies have suggested that individuals 
who are exposed to manganese and copper or work on a farm using pesticides have a higher risk 
of developing PD (Gorell et al., 1999, Priyadarshi et al., 2001). The only confirmed study on the 
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link between environmental factor and PD pathogenesis is based on the discovery of toxin-
induced phenotypes. 
I.2.2.1. MPTP 
In 1982, an outbreak of parkinsonism cases emerged in drug-abusers in northern California that 
was traced back to the injection of an illicit drug, 1-methyl-4-phenyl-4-proprionoxy-piperidine 
(MPPP). The compound MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine), a side product 
of the chemical synthesis reaction of MPPP, was found to induce the PD phenotype in these 
individuals (Langston et al., 1983). The selectivity of MPTP-induced toxicity to dopaminergic 
neurons is due to the conversion of this agent to MPP+ pyridinium ion by the enzyme 
monoamine oxidase B (MAO-B), which is subsequently taken up by DA transporters where it 
inhibits the complex I in DA neurons (Moore et al., 2005) (Figure I-4). MPTP exposure in drug 
users caused damage to the nigrostriatal dopaminergic pathway (Bove et al., 2005). Oxidative 
stress and decline in the activity of mitochondrial complex I of the respiratory chain in the SN of 
PD patients suggested the involvement of mitochondrial dysfunction as one possible pathway 
for neurodegeneration (Schapira et al., 1990, Jenner, 2003).  
I.2.2.2. Paraquat 
Another agent whose chemical structure closely resembles MPTP is the herbicide paraquat. 
Paraquat does not easily cross the blood-brain barrier but is still capable of inducing severe 
damage to the brain of individuals that were exposed to it (Bove et al., 2005) (Figure I-4).  
I.2.2.3. Rotenone 
Rotenone is also a major complex I inhibitor (Sherer et al., 2002a). It is a flavonoid found in the 
roots and stems of several plants and was commonly used as a pesticide and insecticide. Data on 
the stability and half-life suggest it may not have been involved in an epidemiologically-induced 
PD (Bove et al., 2005). Rotenone easily crosses the blood-brain barrier, but unlike MPP+, it is 
not selectively taken up by DA neurons (Talpade et al., 2000, Sherer et al., 2002a) (Figure I-4).  
It is important to note that the link between the inhibitors of the complex I of the respiratory 
chain, oxidative stress, and neuronal loss is still missing. Current efforts are underway to resolve 
this issue through the generation of toxin-based animal models of PD (section I.2.4.2).  
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Figure I-4. Chemical structure of MPTP, MPP+, paraquat and rotenone 
 
I.2.3. Diagnosis and treatment of PD 
I.2.3.1. Diagnosis of PD 
• Motor symptoms 
The features that best characterize PD are tremor at rest, bradykinesia, rigidity, and postural 
instability (Vingerhoets et al., 1997, Bohnen et al., 2008). Rating scales have hence been used to 
assess motor impairment in PD patients although with varying reliability (Jankovic, 2008). The 
Hoehn and Yahr scale and the Unified Parkinson’s Disease Rating Scale (UPDRS) are the most 
widely used for assessing disability and impairment (Ebersbach et al., 2006, Jankovic, 2008).  
• Imaging techniques 
The most prominent diagnosis  currently available for PD is brain imaging (Brooks and Pavese, 
2011). Brain abnormalities can be visualized using Transcranial ultrasonography (TCS) which 
detects increased echogenicity due to an augmentation of ferritin quantities in PD patients’ 
brains (Becker et al., 1995, Berg et al., 2001) and Magnetic Resonance Imaging (MRI) which 
reports changes (atrophy) in brain volume (Geng et al., 2006).  
Positron Emission Tomography (PET) and Single Photon Emission Computed Tomography 
(SPECT) allow investigation of dopamine terminal dysfunction through the use of radiolabelled 
tracers. A 50% reduction of 18F-dopa uptake has been reported in PD patients (Morrish et al., 
1998) and uptake was inversely correlated with the degree of rigidity and bradykinesia 
(Vingerhoets et al., 1997) (Figure I-5). Other radiolabelled tracers are also used to monitor the 
transport of DA from the cytoplasm into secretory vesicles (Bohnen et al., 2006). 
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Figure I-5. PET images assessing the uptake of 18F-dopa 
Control brain (a) shows high uptake in the striatum while PD patient (b) exhibit marked reduction. The difference 
in uptake between (a) and (b) is shown in (c). Figure adapted from Obeso et al. (Obeso et al., 2010). 
 
• Non-motor symptoms 
Some non-motor symptoms such as depression, sleep disorders and constipation occurs in PD 
patients (Chahine and Stern, 2011) precede motor dysfunction in PD patients. Olfactory 
dysfunction (identification, and discrimination of smells) is also present in more than 90% of 
PD patients and standardized tests are starting to be used to detect these olfactory impairment 
(Ansari and Johnson, 1975, Doty et al., 1995, Bohnen et al., 2008). Genetic testing for disease-
linked mutation could present an appealing method to detect PD since several mutations have 
been identified. However, the variable penetrance of those mutations prevents the wide use of 
genetic testing as a diagnostic tool. Direct analysis of the blood plasma could be a useful method 
to determine if modified forms of α-syn (phosphorylated and oligomeric) are present (El-Agnaf 
et al., 2006, Foulds et al., 2011).  
While clinical diagnosis of PD patients currently relies mainly on the observation of motor 
symptoms, the detection of the histopathological hallmark of PD, i.e. the LB, still relies on post-
mortem observation of PD brain samples. New molecules that would bind to α-syn selectively in 
the LB and allow its detection in PET and SPECT could provide a drastic improvement in PD 
patient diagnosis. 
I.2.3.2. Treatment of PD 
All the treatments mentioned herein are symptomatic and no current treatment that is able to 
reverse the pathology of PD has been discovered. 
• Oral medications 
L-Dopa 
In 1960, Hornykiewicz and colleagues showed a prominent loss of dopamine (DA) in the 
putamen and the caudate nucleus of PD patients (Ehringer and Hornykiewicz, 1960). Indeed, it 
is now widely accepted that the loss of DA as the result of the degeneration of dopaminergic 
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neurons in the SN pars compacta is the major pathological hallmark of PD. DA-replacement 
therapy emerged after the isolation of L-dopa, the naturally-occurring isomer of the amino acid 
D-dopa (L-dihydroxyphenylalanine) from the bean of Vicia faba, and a successful clinical trial 
of its use in patients with a dramatic anti-akinesia effects has been reported (Birkmayer and 
Hornykiewicz, 1961) (Figure I-6). L-dopa has since been considered a “gold-standard” in drug 
therapy for PD patients. However, it has been shown that, as the disease progresses, 
involuntarily muscle movements termed dyskinesia are being seen in the treated patients. 
Around 90% of the patients experience these motor response fluctuations after 10 years of 
treatment (Ahlskog and Muenter, 2001). PET imaging studies have showed increased DA levels 
correlated with dyskinetic symptoms in the caudate-putamen (de la Fuente-Fernandez et al., 
2004). The increase of unnaturally high levels of extracellular DA may be the cause of the 
emergence of dyskinesia (Carta and Bezard, 2011). The obscure relationship between L-dopa 
administration and the clinical response has to be elucidated to design L-dopa-like drugs with 
better pharmacokinetics properties.  
 
Figure I-6. Structure of dopamine and L-dopa 
 
Anticholinergic drugs 
Anticholinergic drugs were the first treatment option for PD patients but have been supplanted 
by the use of L-dopa in patients (Brocks, 1999). The rationale for the use of anticholinergic 
drugs in therapy was based on the report of the loss of DA in PD patients and the subsequent 
imbalance between dopaminergic and cholinergic pathways (Brocks, 1999). Anticholinergic 
drugs such as beperiden and benztropine have been used in young PD patients but the treatment 
was stopped due to side-effects that were reported in the elderly (constipation and tachycardia). 
Other side-effects were reported for use of anticholinergic drugs and the inductions of 
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cholinergic deficit that could result in hallucinations in treated patients (Zahodne and Fernandez, 
2008).    
Antiglutamatergic drugs 
Excessive activation of N-methyl-D-aspartate (NMDA) receptors in PD patients is due to the 
depletion of striatal DA and the loss of its inhibitory effect on these receptors. As a 
consequence, a massive influx of Ca2+ in the neurons triggers neuronal death (Koutsilieri and 
Riederer, 2007). Amantadine and Memantine are two antiglutamatergic drugs that were used for 
the treatment of PD but their efficiency is not comparable to DA-replacement medication 
(Koutsilieri and Riederer, 2007). Also, excessive inhibition of glutamatergic function has been 
shown to be associated with schizophrenia, rendering the administration of these drugs to 
patients quite risky (Lange et al., 1997).  
• Surgical interventions 
Ablative surgery 
Advances in imaging techniques used to monitor PD progression in patient brains along with the 
growing amount of data that shows that oral medications do not revert the disease has triggered 
the development of surgical interventions in the following brain regions: motor thalamus, the 
globus pallidus, and the subthalamic nucleus (STN) (Starr et al., 1998). The choice of these 
brain regions is based on the occurrence of motor dysfunction in PD patients and the abnormal 
physiology of the globus pallidus and the STN. The patients that have undergone ablative 
surgery exhibited improvement of motor symptoms with major relief from tremors in the 
majority of cases. However, some side-effects were reported in these patients such as lip and 
hand numbness and confusion (Starr et al., 1998, Walter and Vitek, 2004).      
Deep brain stimulation 
Deep Brain Stimulation (DBS) potentially offers an alternative to the motor-complication side-
effects of DA-replacement therapy and the potential complications related to ablative surgery. 
To relieve PD patients of the symptoms of the disease, DBS relies on the use of high-frequency 
stimulation via surgically implanted electrodes in specific regions in the brain (the subthalamic 
nucleus STN and globus pallidus), with each region of the brain having different intra- and 
inter-network connectivities. It has subsequently been used to treat bradykinesia and rigidity and 
offers the promise to become the method of choice for the treatment of PD (Hamani et al., 2005, 
Fasano et al., 2012). The molecular mechanism through which DBS alleviates the symptoms is 
still unknown but it was speculated that it acts as a reversible local inactivation of an ion 
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channel or by blockage of neuronal membrane depolarization (Benazzouz et al., 1993). Apathy, 
sleep deficiency, mood disorders and anxiety, pathological gambling and compulsive eating can 
occur as side effects after stimulation of the STN (Anderson and Mullins, 2003, Guehl et al., 
2003, Fasano et al., 2012). Even though DBS can be applied to treat PD patients, it is still 
regarded as an experimental method that requires further study and optimization for the choice 
of brain area, type of electrodes to be used according to the different brain regions and better 
criteria for the selection of the patients according to their age and disease progression (Fasano et 
al., 2012). 
• Cell-replacement therapy 
Stem cell transplantation 
The aforementioned treatments above have proved effective to a point, especially when applied 
in the early stages of the disease, but they present adverse effects and do not counteract the 
progression of the disease. Grafts of human fetal ventral mesencephalic tissue have arisen as a 
way to replace dying dopaminergic neurons in the striatum (Politis and Lindvall, 2012). The 
source of the transplanted stem cells is mostly from pluripotent embryonic or somatic cells or 
from neuronal stem cells. However, due to the poor survival of the pluripotent stem cells in the 
brain and the significant risk of tumor formation, stem cells derived from fetal or adult nervous 
system have been used (Pardal and Lopez-Barneo, 2012). Excellent results were shown for PD 
patients with a dramatic reduction in rigidity and bradykinesia (Lindvall et al., 1990, Bjorklund 
et al., 2003, Mendez et al., 2008, Olanow et al., 2009). The main limitation for this technique 
resides in the availability of the donor tissue. The dissection step that precedes the 
transplantation generates a mixture of neural population with different resistance to cell death. 
Hence, due to the high cell mortality, a large number of human embryos will be needed for cell 
preparation. Due to the origin of these stem cells, ethical, moral, and legal issues will be faced in 
many countries. Motor complications such as dyskinesia were also reported in some patients, 
due to aberrant synaptic connections between transplanted and endogenous neurons. In 
summary, major research efforts will be required prior to generalizing the procedure of cell 
transplantation in PD patients. Additionally, the effect of immune reactions, the risk of tumor 
progression and the generation of motor complications will need to be investigated.  
I.2.4. Animal models of PD 
PD is a neurodegenerative disease. Considering that human brain is not an easily accessible 
organ for biochemical analysis, animal models have to be generated with the corresponding 
phenotype of the disease. While cellular models offer an easy and affordable way to identify 
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specific pathways and molecular targets, the results derived from those studies cannot be 
extended to the progression of the disease in vivo and in patients. Hence, animal models are 
needed as the next step to validate the findings, especially in the context of neurodegenerative 
diseases where complex neuronal circuitry direct the progression of the disease. Therefore, the 
availability of animal models would permit scientists to study disease mechanisms, validate 
potential molecular targets and test novel therapeutic strategies.  
I.2.4.1. Criteria for the perfect PD model 
A PD model needs to fulfill several criteria: i) the degeneration of neurons should be age-
dependent and progressive, ii) motor dysfunction such as rigidity and postural instability should 
be present and reversible in presence of dopamine-replacement therapy, iii) Lewy bodies and 
Lewy neurites should be reported in the brain slices (Dawson et al., 2010).  
I.2.4.2. Toxin-based models 
• 6-Hydroxydopamine 
6-Hydroxydopamine (6-OHDA) is the hydroxyl form of DA. It has been used as a neurotoxin 
for catecholaminergic neurons in animal models, due to the induced release of radicals and the 
inhibition of complex I and IV of the mitochondrial respiratory chain (Schober, 2004, Alvarez-
Fischer et al., 2008b). 6-OHDA does not cross the blood-brain barrier and thus stereotactic 
injections are required for the administration of the toxin to the SN or the striatum. Unilateral 
injection of the toxin is carried out in rats (where the non-injected hemisphere acts as a control) 
resulting in the loss of more than 80% of nigrostriatal neurons (Kirik et al., 1998, Schober, 
2004) and motor impairment (Lindner et al., 1999, Alvarez-Fischer et al., 2008b). However, the 
absence of protein inclusions and the acute and non-progressive neuronal damage were the 
major drawbacks of these models (Schober, 2004). 
• MPTP 
MPTP is an inhibitor of the complex I of the mitochondrial respiratory chain that was implicated 
in the emergence of PD phenotypes in drug users (Langston et al., 1983) (section I.2.2.1). 
Administration of the toxin to animal can be carried out by stereotactical injection or by 
intravenous or intraperitoneal injection in which case it rapidly reaches the blood brain barrier 
(Schober, 2004). Treatment of animals with MPTP became the basis for animal model of PD 
because of its selective uptake by dopaminergic neurons and the precedent proofs of its effect in 
humans (section I.2.2.1). Non-human primates that were treated with MPTP showed α-syn 
positive LB-like structures and presented similar clinical, pathological, neurochemical and 
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pharmacological response responses as idiopathic PD (Markey et al., 1984, Forno et al., 1988). 
Mouse models using mild continuous MPTP intoxication showed upregulation of α-syn 
expression within DA neurons, cell loss and damage in the nigrostriatal dopamine pathway (Vila 
et al., 2000, Fornai et al., 2005). However, the issue of the presence of LB-like inclusions in 
these models remains controversial (Shimoji et al., 2005, Alvarez-Fischer et al., 2008a). It is 
interesting to note that few rodent models of MPTP-induced PD exist because of the resistance 
of rats to the toxin, even mouse models have exhibited less sensitivity than primates and were 
able to recover after 48 hours of treatment (Schober, 2004).  
• Paraquat and rotenone 
Paraquat and rotenone are used as herbicide and pesticide and were shown to induce PD 
symptoms in individuals that were exposed to them (Sherer et al., 2002a, Bove et al., 2005) 
(section I.2.2.2 and I.2.2.3). Upon systemic injection of paraquat to mice, DA neuron loss, 
reduced motor activity and most importantly an up-regulation of α-syn are seen and could 
potentially suggest that the paraquat animal model reproduce the major aspects of PD (Brooks et 
al., 1999, Manning-Bog et al., 2002). Later studies have shown that the combined administration 
of paraquat and manganese exacerbated the toxicity and caused more deficits in the 
dopaminergic system (Thiruchelvam et al., 2000).  
In the rotenone-based rodent model, the toxin was administered via inhalation, subcutaneous 
injections or oral delivery (Uversky, 2004). The rats elicited motor dysfunctions (rigidity and 
postural instability) that were reversed by L-Dopa treatment (Betarbet et al., 2000, Bove et al., 
2005) along with dopaminergic neuronal loss (Uversky, 2004). Among the toxin-based models, 
rotenone-infused rats were the sole model showing LB-like inclusions that were positive for α-
syn and ubiquitin (Betarbet et al., 2000, Sherer et al., 2003). 
The use of toxin-induced animal models represents a good model of PD: substantial nigrostriatal 
degeneration is observed, along with good replication of PD motor symptoms. However, the 
absence of LB-like inclusions (except in the rotenone models) prevents the use of these models 
to study aggregation-dependent neurodegeneration. 
I.2.4.3. Genetic models 
Several animal models have relied on the expression of proteins that are involved in PD 
(LRRK2, Parkin, DJ-1 and PINK1) and the data that emerged from their use have been 
reviewed extensively (Dawson et al., 2010, Martin et al., 2011). In the scope of the manuscript 
we will focus on α-syn-based models.  
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• Transgenic models 
Mouse models 
The first transgenic (Tg) mouse model that over-expressed WT α-syn was generated by Masliah 
and colleagues, under the platelet-derived growth factor (PDGFβ) promoter (Masliah et al., 
2000). The mice showed motor impairment on the rotarod assay and the progressive 
accumulation of non-fibrillar neuronal inclusions which are positive for α-syn and ubiquitin. 
However, this model showed neither the loss of dopaminergic neurons nor the formation of LB. 
Subsequent studies suggested that the nature of the promoter used to drive the transgene 
expression dictates the pattern of expression of α-syn in the brain and the region of the brain that 
are targeted, hence defining the phenotypes of these models (Chesselet, 2008).  
The Thy1 promoter induces the expression of high levels of α-syn in cortical and subcortical 
neurons, including the SN pars compacta (Rockenstein et al., 2002). In some of the Thy1 Tg 
mice, α-syn- and ubiquitin-positive inclusions were reported, along with age-dependent motor 
impairment. However, those inclusions lacked the amyloid-like characteristic of the LB (van der 
Putten et al., 2000). In other studies, fibrillar inclusions were detected in mice over-expressing 
WT and A30P α-syn, but the localization of these inclusions was different than in PD patients; 
indeed, in old mice, the inclusions were localized to the spinal cord, amygdala and the brain 
stem (Freichel et al., 2007). 
The use of the Prion (Prp) promoter drives widespread high expression of α-syn in the 
extranigral region, and some of the phenotypes that resulted are not consistent with human PD 
(glial pathology, motor neuron degeneration). The A30P mouse model under Prp promoter only 
showed some motor dysfunction, as well as the presence of truncated species (Gomez-Isla et al., 
2003). The PD-associated mutations such as A53T have been investigated in mouse models, 
revealing protein inclusions in the spinal cord, brain stem and thalamus, leaving the 
hippocampus and the SN spared (Giasson et al., 2002, Lee et al., 2002c). Motor impairment was 
also reported for A53T compared to WT and A30P model (Lee et al., 2002c) (Figure I-7).  
The animal models that relied on the use of the tyrosine hydroxylase (TH) promoter (which 
directs expression in dopaminergic neurons) are the only ones which present nigrostriatal 
neurodegeneration. PD is undeniably a complex disease and nigrostrital degeneration may only 
represent one aspect of the disease pathology. But for these models again, only the double-
mutated variant of α-syn A53T/A30P was able to show loss of TH-positive neurons as well as 
motor impairment and age-dependent DA level reduction but without the presence of 
inclusions(Thiruchelvam et al., 2004). The other models expressing A53T, A30P or WT α-syn 
failed to show any dopaminergic neuron degeneration (Matsuoka et al., 2001, Richfield et al., 
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2002). However, the physiological relevance of the doubly-mutated variant is not clear since no 
report of PD patients carrying both A53T and A30P mutations is known. 
Truncated variants of α-syn 1-120 and 1-130 were also investigated in mouse models under the 
TH promoter and the results have been variable: over-expression of α-syn 1-130 yielded 
selective but non-progressive loss of DA neurons, as well as motor dysfunction in the mice, 
whereas the mice that over-expressed α-syn 1-120 presented some protein inclusions but not 
neuron loss (Tofaris et al., 2006, Wakamatsu et al., 2008). The mouse model produced by 
Tofaris et al. (1-120 truncation expressed in α-syn KO mice) was the first to show presence of 
inclusions (Tofaris et al., 2006) and importantly, this was done in the absence of endogenous 
murine α-syn . Small amounts of mouse α-syn were capable of inhibiting the fibrillization of 
human α-syn in vitro (Rochet et al., 2000) and the presence of endogenous mouse α-syn in Tg 
mice over-expressing human α-syn would potentially impair its fibrillization propensity in vivo. 
The correlation between the inhibition of α-syn fibril formation in vitro and the decreased 
number of inclusions in vivo was also confirmed with studies involving β-syn, another member 
of the synuclein family: in vitro studies have revealed the inhibitory effect of β-syn on α-syn 
fibrillization and protofibril formation (Uversky et al., 2002b, Park and Lansbury, 2003) and a 
reduced number of inclusions was reported in double-transgenic mice for α-syn and β-syn 
compared to α-syn Tg mice (Hashimoto et al., 2001). 
A mouse strain expressing an α-syn conditional transgene under a tetracycline promoter was 
generated by Nuber and colleagues (Nuber et al., 2008). The model failed to present fibrillar 
inclusions but showed loss of DA neurons in the SN as well as a progressive motor decline. 
Most importantly, when the expression of the transgene was turned off, the progression of the 
disease was halted but the symptoms were not reversed.  
Drosophila models 
While no single rodent model can fulfill all the criteria for a perfect PD model, Drosophila 
models over-expressing WT and mutant α-syn exhibit an age-dependent and progressive DA 
neurons loss, α-syn positive fibrillar inclusions and a decline of climbing ability (Feany and 
Bender, 2000) (Figure I-7). However, the loss of DA neurons that was initially reported by 
Feany and colleagues was not reproduced by other groups (Pesah et al., 2005) and the variability 
could be attributed to technical considerations (methods of fixing brain slices mainly) 
(Drobysheva et al., 2008). Due to the ease of genetic manipulation in Drosophila, several factors 
that could potentially influence α-syn-induced toxicity were examined (Mizuno et al., 2010): 
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studies of post-translational modifications of α-syn confirmed the presence of cross-talk 
between phosphorylation at residue 125 and 129 (Chen and Feany, 2005, Chen et al., 2009), 
expression of Parkin and PINK1 in Tg flies was shown to suppress motor impairment and 
retinal degeneration (Haywood and Staveley, 2004, 2006, Todd and Staveley, 2008) and 
dopaminergic neuronal loss was prevented by the expression of the chaperone Hsp70(Auluck et 
al., 2002) which interacts with α-syn in vitro and in vivo (section I.3.7) . 
Caenorhabditis elegans models 
Nematode models over-expressing α-syn presented accelerated dopaminergic neuron loss but no 
LB-like inclusions (Lakso et al., 2003, Kuwahara et al., 2006) (Figure I-7) .The effect of PD 
mutations on DA neurons loss was also probed in these models but did not show major 
differences with respect to the WT. Nevertheless, a reduction in DA levels was observed in the 
case where A53T or A30P were expressed (Kuwahara et al., 2006). C.elegans models do not 
allow accurate assessment of motor impairment but they have been used to perform genetic 
screenings. More than 900 gene targets were screened via RNAi knockdown and 20 genes were 
identified to potentially affect the folding of α-syn and the degeneration of neurons (Hamamichi 
et al., 2008). The effect of environment and toxins was also probed in this model confirming  
data observed in mouse and fly models on the increase of α-syn toxicity in presence of rotenone 
and 6-OHDA (Calahorro and Ruiz-Rubio, 2011) .  
 
Figure I-7. Summary of the different transgenic PD models 
Table summarizing the findings that were reported from the use of C.elegans, Drosophila and mouse models. 
Figure courtesy of Dr. Bernard Schneider, EPFL 
 
  
 18 
  
• AAV-delivery models 
To develop a rat model of PD, lentiviral vectors expressing α-syn were injected into the SN of 
rats. In contrast to transgenic mice models, a selective loss of nigral dopaminergic neurons 
associated with a dopaminergic denervation of the striatum was observed in rats expressing WT 
or mutant forms of α-syn (Lo Bianco et al., 2002). Expression of WT and A53T α-syn in adult 
rats resulted in 30-80% loss of the nigral dopaminergic neurons and the presence of α-syn-
positive inclusions (Kirik et al., 2002, Klein et al., 2002, Lo Bianco et al., 2002). However, the 
expression of rat α-syn resulted in aggregation but no cell loss, suggesting that α-syn inclusions 
are not cytotoxic (Lo Bianco et al., 2002). The use of lentiviruses and adeno-associated viruses 
is more troublesome than the generation of transgenic mice since it requires stereotactic 
injection within the cell bodies of the SN pars compacta. Experts in virology are also needed to 
ensure proper handling of the virus and to confirm reproducibility (Chesselet, 2008). However, 
this methodology has major advantages: since the injection can be done in adult rats, the effects 
of early developmental expression of α-syn as well as the possibility of activation of 
compensatory mechanisms are circumvented (Waxman and Giasson, 2009). It also allows 
testing for genetic modifiers and other targets more rapidly at a lesser cost. The use of viral 
vector delivery in rat allowed the screening of phosphomimetic mutations of α-syn aiming at 
investigating the role of phosphorylation on inclusion formation and toxicity (Gorbatyuk et al., 
2008, Azeredo da Silveira et al., 2009, Oueslati et al., 2012) as well as the study of proteins and 
toxins on the rescue (Yamada et al., 2005) or the exacerbation of α-syn toxicity(Sato et al., 
2011, Mulcahy et al., 2012) (by Parkin and rotenone and GRK-6-mediated phosphorylation 
respectively). 
C.elegans and Drosophila have been used for the rapid genetic and pharmacological screening 
compounds and for the easy and quick genetic manipulation. The major limitation for the use of 
these models is their failure to exhibit complex muscle complication which are key for PD 
pathogenesis, such as bradykinesia, rigidity and postural instability. Mouse models are 
considered as a close model to humans, because of the short life-span (2 years) of the mice 
which can allow modeling a disease in a short time(Dawson et al., 2010). 
• Cellular models 
Saccharomyces cerevisiae models 
In the S.Cerevisiae model, no ortholog of α-syn is known but it provides a readily manipulable 
system to screen genes. Studies in S.cerevisiae have shown that α-syn localizes to the plasma 
membrane and forms cytoplasmic inclusions when its concentration increases (Outeiro and 
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Lindquist, 2003). A53T α-syn expression revealed the same phenotype but A30P mutant did not 
form inclusions (Outeiro and Lindquist, 2003). These inclusions however were not constituted 
of amyloid but rather α-syn associated with vesicles (Soper et al., 2008). Toxicity levels were 
also assessed and apoptotic signals, such as the accumulation of reactive oxygen species and the 
release of cytochrome c, were reported after the expression of WT or mutants α-syn (A30P and 
A53T) (Flower et al., 2005). The yeast model has been widely used for genetic screening and 
yielded novel findings such as the contribution of α-syn to the impairment of endocytosis and 
vesicle trafficking (Zabrocki et al., 2008); the α-syn-induced inhibition of ER-Golgi  trafficking 
(Cooper et al., 2006) and the modulation of the phospholipase D activity (Outeiro and Lindquist, 
2003). Moreover, different subcellular localizations of α-syn were revealed since A30P α-syn 
mutant localized to the cytoplasm (lower binding affinity to lipid vesicles in vitro) whereas WT 
and A53T bound preferentially to the plasma membrane (Sharma et al., 2006, Zabrocki et al., 
2008). Interestingly, the localization of α-syn to the membrane was associated with 
phosphorylation by the CK kinase (Zabrocki et al., 2008) and initiation of aggregation (Zabrocki 
et al., 2005). 
Mammalian cells models 
The mere expression of α-syn in cells does not result in the formation of fibrillar inclusions, 
except for a few reports using adenoviral infection of COS7 cells (Gosavi et al., 2002, Lee and 
Lee, 2002). Co-expression of other proteins or submitting the cells to oxidative stress are 
essential for the formation of cellular aggregates. Co-expression of the protein synphilin (which 
was shown to be present in the LBs) and α-syn promotes the formation of cytoplasmic 
inclusions (Engelender et al., 1999, Smith et al., 2005). The expression of the enzyme 
transglutaminase (that catalyzes the cross-linking of α-syn in vitro and in vivo) was responsible 
for the formation of inclusions in 8% of the cells (Junn et al., 2003) and a construct consisting of 
the fusion of GFP to the C-terminus of α-syn was shown to undergo truncation (in the GFP 
domain) in 5% of the cells and to induce aggregation of α-syn (McLean et al., 2001, Badiola et 
al., 2011). The low percentage of inclusion-positive cells is a major drawback of these cellular 
models. Other cellular models for α-syn aggregation were reported using toxins. Oxidative stress 
seems to promote the formation of α-syn aggregates in 5-20% of the cells that were treated with 
peroxynitrite (Paxinou et al., 2001), rotenone (Lee et al., 2002b) and FeCl2 (Hasegawa et al., 
2004, Shendelman et al., 2004, Roberti et al., 2007).  
Other cellular models relied on the uptake of extracellular α-syn that would act as a seed for the 
fibrillization of the intracellular protein. Uptake was mediated by calcium phosphate (Waxman 
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and Giasson, 2010), microinjection (Roberti et al., 2007), Lipofectamine (Nonaka et al., 2010) 
and cationic-liposomes (Luk et al., 2009). Extracellular α-syn was shown to be toxic to 
neighboring cells and to activate apoptosis signaling cascade (Danzer et al., 2011) and to 
activate microglia (Zhang et al., 2005). In one report, the toxicity was shown to be dependent on 
the concentration of the protein: extracellular α-syn fused to the TAT cell-penetrating peptide 
was able to protect the cells against H2O2 insult in the nanomolar range but gained toxicity at 
micromolar concentration (Albani et al., 2004). Cell culture studies reveal also numerous data 
discrepancies concerning the toxicity of intracellular α-syn: in some assays, the expression of 
WT α-syn rendered the cells more sensitive to cellular stress (Saha et al., 2000, Iwata et al., 
2001, Petrucelli et al., 2002), whereas in other studies, α-syn was shown to be protective (da 
Costa et al., 2000, Hashimoto et al., 2002). These discrepancies probably arise from the use of 
different cell lines and transfection methods, of different promoters and tags on the protein 
(Waxman and Giasson, 2009).  
To date, while no animal models are able to mimic all the pathological and neurological features 
of PD, each model has its own advantages and limitations. The toxin-induced model (MPTP, 
paraquat and rotenone) shows a good replication of motor dysfunction, along with neuronal loss 
but no LB-formation. In contrast, LB have been observed in transgenic models in some cases 
but a consistency in neuronal loss is still missing. As the scientific community is waiting for the 
the perfect PD model, transgenic animal models are used to investigate the role of particular 
proteins and molecular pathways through genetic screening and the toxin-induced models would 
on the other hand facilitate the screening for a therapeutic treatment.  
 
I.3. Alpha-synuclein 
I.3.1. A brief historical overview 
The first synuclein gene was discovered in 1988 by Maroteaux et al. while screening an 
expression library with an antiserum against cholinergic vesicles from the electric lobe of the 
Pacific electric ray Torpedo Californica (Maroteaux et al., 1988) (Figure I-8). A cDNA coding 
for a 140 amino acid-protein was identified and was named synuclein because of the protein’s 
localization in both the nucleus and at the presynaptic terminals. The protein was found to 
express only in nervous system tissue and it was hypothesized that synuclein could be involved 
in regulating events at the synaptic cleft via structural or regulatory pathways (Maroteaux et al., 
1988).  
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In 1993, the analysis of all protein sequences of an amyloid-plaque sample by Ueda et al. 
resulted in the identification of unknown short peptides (termed NAC for Non-Amyloid Beta 
Component) (Ueda et al., 1993).  The two NAC sequences, which exhibited high propensity to 
form amyloid fibrils (Ueda et al., 1993) corresponded to residue 61-80 and 81-95 of a 140 
amino acid precursor known to be especially expressed in the brain that was initially given the 
name NACP and later called alpha-synuclein (α-syn).  Two additional proteins with a very high 
sequence homology were later identified in human and rat brains; β-synuclein (134 residue, also 
called phosphoneuroprotein 14) (Nakajo et al., 1993) and γ-synuclein (127 amino acids) (Jakes 
et al., 1994, Lavedan et al., 1998).  
 
Figure I-8. Schematic representation of the major discoveries on α-syn 
1988: discovery of the first synuclein gene in the Pacific electric ray Torpedo Californica. 1993: the NAC fragment 
of α-syn was identified in amyloid plaques. 1997: discovery of the first disease mutation in α-syn gene A53T. 1998: 
report of the second mutation A30P and the identification of α-syn as the main component of the LB. 2004: 
discovery of the third mutation E46K. 
Photo credits: http://www.visualphotos.com/image/1x6470358/pacific_electric_ray_torpedo_californica 
http://www.liv.ac.uk/researchintelligence/issue30/alzheimers.html 
http://frontalcortex.com/?page=oll&topic=24&qid=413 
http://www.biotek.uio.no/english/research/news-and-events/news/2010/VNM_VB_artikkel_HD.html 
 
 
 
In 1997, the first α-syn mutation A53T was discovered in one Italian and three Greek families 
with an autosomal dominant inheritable form of PD (Polymeropoulos et al., 1997). The second 
mutation, A30P, was discovered very shortly after in German families (Kruger et al., 1998). In 
the meantime, while the link between α-syn and the genetics of PD was starting to emerge, the 
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missing link between the protein and the neuropathological hallmark of PD – the Lewy Bodies – 
was identified. Using antibodies against α-syn, immunohistochemical studies revealed the 
presence of the protein in neuronal cytoplasmic inclusions (NCIs) and oligodendrocytic glial 
cytoplasmic inclusions (GCIs) in multiple system atrophy (MSA) patients’ brains, and in the 
Lewy Bodies (LB) from PD patients and dementia with Lewy Bodies (DLB) patients 
(Spillantini et al., 1997, Arima et al., 1998, Spillantini et al., 1998b). A third single-point 
mutation in α-syn gene, E46K, was discovered in 2004 in a Spanish kindred and duplication and 
triplication of the gene were also reported to be associated with autosomal dominant forms of 
familial PD (Singleton et al., 2003, Chartier-Harlin et al., 2004, Zarranz et al., 2004) (Figure 
I-8).  
I.3.2. α-syn gene, transcript and protein 
The human α-syn gene SNCA lies on chromosome 4q21.3-q22 and spans a region of 111kb 
(Campion et al., 1995, Chen et al., 1995, Shibasaki et al., 1995). It is organized in 7 exons (of 
which 5 are coding) (Lavedan et al., 1998). The ATG starting codon is encoded by exon 2, the 
stop codon by exon 6 and the NAC region (that was identified in amyloid plaques in AD 
patients) is encoded by exon 4 (Figure I-9).  
 
 
Figure I-9. Organization of the α-syn gene and alternative splicing isoforms 
The α-syn gene is organized in 7 exons: the initiating methionine is encoded by exon 2, exon 3 encodes the NAC 
domain and the stop codon is present in exon 6. b) Alternative splicing of α-syn’s exons 3 and 5 results in proteins 
of 140, 126, 112 and 98 residues. Adapted from Venda et al. (Venda et al., 2010) 
 
The overall organization of the gene is conserved across animal species. Patients with 
duplication and triplication of SNCA have amplified exon 3 and 4 probably due the intrinsic 
instability of the region 4q21-23 on chromosome 4 (Chartier-Harlin et al., 2004). As for the 
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other synuclein genes, β-syn gene has been mapped to chromosome 5q35 with a total of 6 exons 
(of which 5 are coding); and the γ-syn gene lies on chromosome 10q23.2-q23.4 and has 5 exons 
(all protein-coding) (George, 2002) (Figure I-10). 
The predominant α-syn isoform consists of 140 amino acids and corresponds to the transcription 
of exons 2,3,4,5 and 6. Other isoforms of α-syn caused by alternative splicing of exons 3 and 5 
results in the production of shorter proteins. SNCA126 is produced by deletion of exon3, 
SNCA112 has a deletion of exon 5 and SNCA96 is produced by deletion of both exons 3 and 5. 
SNCA112 is the second most abundant isoforms and has been found in the brains of patients 
with LB disease (Venda et al., 2010). 
 
 
 
Figure I-10. Amino acid sequences of alpha, beta and gammα-synuclein  
The main characteristic of β-syn is the absence of 11 residues of the NAC domain, while γ-syn exhibits deletion of 
residues in the C-terminal domain compared to α-syn.  
 
 
The molecular mass of α-syn is 14460 Da and its sequence can be divided into three domains 
(Figure I-11): the amphipathic N-terminal domain and the hydrophobic NAC regions that are 
both highly conserved between species and the C-terminal domain that is variable in size and 
sequence (Surguchov, 2008).  
 
 
Figure I-11. Amino acid sequence of α-syn and its structural domains 
 
The N-terminal domain spans from residue 1 to 60 and is characterized by six imperfect repeats 
of the consensus motif KTKEGV and forms amphipathic α-helices when bound to membranes 
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and synthetic lipid vesicles (Bussell and Eliezer, 2003, Jao et al., 2004, Bisaglia et al., 2006). 
The central NAC region from residues 60 to 95 is highly hydrophobic and is essential for fibril 
formation (Giasson et al., 2001). The C-terminal domain is highly disordered and acidic (rich in 
glutamate and aspartate residues). The α-syn protein is highly conserved among mammals and 
does not exist in invertebrates (Figure I-12). The comparison of the N-terminal domain of α-syn 
between mammal and bird species shows only 4 differences within 84 residues, while the 
majority of amino acids differences reside mainly in the C-terminal domain of the protein. 
Interestingly, in the majority of vertebrates α-syn contains the A53T disease-linked mutation 
(A53T), while α-syn in primates and human has an alanine at this position (Surguchov, 2008).  
 
Figure I-12. Comparison of α-syn amino acid sequence between species 
Sequence alignment of α-syn protein from human, rat, mouse, bovine, pig, primate and chicken species. The A53T 
mutation has been highlighted in red. Alignment was based on Uniprot sequences P37840, P37377, O55042, 
Q3T0G8, Q3I5G7, P61144 and Q9I9H1.  
 
I.3.3. alpha-synuclein’s structure 
I.3.3.1. In solution 
Since α-syn does not adopt stable secondary structures in solution, it has been referred to as a 
natively unfolded protein (Weinreb et al., 1996, Fauvet et al., 2012b). It be is also heat-resistant 
and the boiling step that is commonly used in purification procedures to remove contaminating 
proteins does not affect α-syn (i.e. heating does not cause the protein to precipitate). The Stokes 
radius of α-syn is estimated to be 34 Ǻ, which would correspond to a 58kD globular protein (α-
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syn is 14kD) (Weinreb et al., 1996). When run on SDS-PAGE, the band corresponding to α-syn 
migrates at an apparent mass of around 19kD. The slow migration of α-syn in SDS-PAGE has 
been attributed to the high density of negative charges in the C-terminal domain which could 
lead to reduction in SDS binding.  
I.3.3.2. In presence of membranes 
The imperfect 6-mer repeats present in the N-terminal domain of α-syn (Figure I-13) were 
shown to be “homologous” to other repeats of 11-residues in a plant protein (LEA76, a member 
of the family of late-embryo-abundant (LEA) group III)  that shifts from random coil to α-
helical conformation upon fast drying (Wolkers et al., 2001, George, 2002). Other 11-residue 
imperfect repeats also encode a class-A2 lipid binding motif that was described in exchangeable 
apolipoproteins (Segrest et al., 1992). A theoretical wheel projection of the α-helix of α-syn was 
constructed in 1995 after the discovery of the zebra finch homologue of α-syn (synelfin). The 
representation of residues 1-18 of canary synelfin (which are identical to the corresponding 
sequence of human and rat α-syn) showed a segregation of polar and nonpolar residues in 
opposite faces of the helix in order to form hydrophobic and polar faces, similar to the 
consensus A2 amphipatic α-helix (George et al., 1995) (Figure I-13).  
 
Figure I-13. Comparison of helical wheel projection between α-syn and other proteins 
Top: Helical wheel projection of A: Human α-syn, B: synelfin (zebra finch homolog), C: apolipoprotein, D: 
LEA76. Apolar residues are shown in black. Figure from George et al.(George et al., 1995). Bottom: The imperfect 
6 repeats in α-syn N-terminal domain were highlighted in red.  
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These results suggested that α-syn can adopt a conformation that is likely to associate with lipids 
via an α-helical conformation. Indeed, it was later shown that α-syn does bind to anionic 
phospholipid vesicles and lipid-membrane mimetics (SDS micelles) (Eliezer et al., 2001) and 
adopts an α-helical conformation (Davidson et al., 1998). The N-terminal domain of α-syn is 
responsible for the interaction with phospholipids. Among the disease-associated mutations, 
only A30P exhibited weaker membrane binding affinity in vitro (Perrin et al., 2000) and in yeast 
(Outeiro and Lindquist, 2003). The loss of the A30P mutant’s vesicle-binding property was also 
confirmed in vivo as well the implication of the N-terminal domain of α-syn for the binding via 
the fractionation of adult rat brain extracts (Jensen et al., 1998).   
The region of α-syn that mediates the interaction with the micelles has been mapped to residue 
1-102/103, with the C-terminal domain of α-syn remaining unbound and unstructured (Eliezer et 
al., 2001, Jao et al., 2004). NMR-based structural studies revealed that α-syn forms two 
antiparallel broken helices (helix 1: residue 3-37 and helix 2: residue 45-92) when bound to SDS 
micelles or lipid vesicles (Bussell and Eliezer, 2003, Chandra et al., 2003, Bortolus et al., 2008, 
Drescher et al., 2008) (Figure I-14). However, it was later shown that the curvature of the 
micelles dictates the conformation of SDS-bound α-syn, i.e. whether it forms an extended single 
helix or two broken helices (Trexler and Rhoades, 2009). FRET studies have shown the 
prevalence of an extended helix in presence of large vesicles (100nm), whereas the two helix 
conformation predominates in the presence of highly-curved micelles (Trexler and Rhoades, 
2009). 
 
Figure I-14. Solution NMR structure of α-syn forming two broken helices when bound to SDS-micelles 
PDB structure: 1XQ8 
 
I.3.4. Fibrillization of alpha-synuclein 
The conversion of α-syn from soluble monomers to insoluble aggregates has been implicated in 
the formation of LB in PD and other synucleinopathies. α-syn-positive fibrillar inclusions were 
detected in the brain of patients with neurodegenerative diseases, such as PD, DLB, MSA and 
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AD using immunohistochemistry (Forno, 1996, Polymeropoulos et al., 1997, Arima et al., 1998, 
Kruger et al., 1998, Spillantini et al., 1998b, Hamilton, 2000, Cookson, 2005). The fibrillar 
nature of these α-syn-positive inclusions was confirmed by immunogold-labelling and by 
staining with fluorescent dyes that specifically bind to fibrillar amyloid-like structure 
(Thioflavin S and Congo Red dyes) (Surguchov, 2008). In vitro, α-syn readily forms long 
mature amyloid fibrils that resemble closely α-syn fibrils from post mortem PD brains (Giasson 
et al., 1999, Conway et al., 2000a) (Figure I-16).  
Although the molecular determinants of α-syn fibril formation remain unknown, studies during 
the past two decades have consistently shown that the NAC region is essential for α-syn 
aggregation (Giasson et al., 2001, Qin et al., 2007). This hypothesis is supported by the findings 
that 1) deletion of residues 71-82 from α-syn completely abolished α-syn fibril formation 
(Giasson et al., 2001); 2) the NAC region occurs within the sequence that forms the core of α-
syn fibrils as revealed by solid-state NMR studies (more specifically residues 38-95) (Heise et 
al., 2005, Kloepper et al., 2007) by limited proteolysis studies (residues mapped: 32-100) (Qin 
et al., 2007) and 3) deletion of the C-terminal domain, which results in further exposure of the 
NAC region, increases the fibrillization of α-syn in vitro, with the fragments 1-87 and 1-120 
showing the fastest aggregation rates (Crowther et al., 1998, Serpell et al., 2000, Murray et al., 
2003).  
• Mechanism of aggregation and structure of intermediates 
α-syn fibril formation follows a nucleation-dependent mechanism (Wood et al., 1999) 
characterized by an initial lag phase that is associated with the formation of a fibrillization 
competent nuclei (oligomers) followed by a rapid growth phase associated with fibril formation 
and growth, via addition of monomers until an equilibrium (plateau) is reached between the 
monomers and fibrils (Figure I-15). Consistent with a nucleated polymerization mechanism, the 
addition of preformed shortened fibrils to monomeric α-syn solutions results in elimination of 
the lag phase (Wood et al., 1999).  
I.3.4.2. Fibrils   
α-syn forms amyloid fibers that are usually 10 nm wide and 0.1-10 μm long as seen by 
transmission electron microscopy (TEM) and atomic force microscopy (AFM) (Giasson et al., 
1999, Conway et al., 2000a). These fibrils possess a cross-β-structure as discerned by X-ray 
fiber diffraction, which shows an intense reflection parallel to the axis of the fibril at around 4.7-
4.8 Ǻ (equal to the distance between two β-strands of the same β-sheet) and a signal 
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perpendicular to the axis of the fibril at around 10 Ǻ (distance between two adjacent β-sheets) 
(Figure I-16) (Serpell et al., 2000).  
 
 
Figure I-15. Proposed mechanism of α-syn aggregation 
α-syn’s aggregation has been suggested to proceed via discrete intermediates. α-syn monomers assemble to form 
oligomers, some of them have pore-like properties, and further polymerize to form amyloid fibers. In vivo. the 
assembly result in the formation of LB. Adapted from a figure courtesy of Bruno Fauvet, EPFL. 
 
 
 
 
 
Figure I-16. Fibrillization of α-syn 
A: TEM image of α-syn fibrils. The scale bar represents 200nm. B: X-ray diffraction of WT, A30P, A53T and C-
terminally truncated α-syn. A reflection at 0.47 nm parallel to the fiber axis depicts the distance between two β-
strands of the same β-sheet while the weaker reflection at 1-1.1nm is perpendicular to the fiber axis and represents 
the distance between two neighboring β-sheets of the cross-β-structure. Figure B is from Serpell et al.(Serpell et al., 
2000).  
 
I.3.4.3. Oligomers 
In vitro aggregation studies revealed that α-syn fibril formation proceeds through a series of 
transient distinct oligomers. These oligomers are short-lived and very heterogenous in size 
(from 35 to 125 nm) and morphology (Hong et al., 2011). TEM and AFM studies have shown 
that α-syn can form spherical, amorphous or pore-like oligomers depending on the conditions 
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used to induce α-syn oligomerization and/or fibrillogenesis (Lashuel et al., 2002, Wright et al., 
2009, Hong et al., 2011). Although direct evidence for oligomers in the brain remains lacking, 
biochemical analysis of brain homogenates and CSF samples from PD patients (El-Agnaf et al., 
2006) and animal models of synucleinopathies (Chen et al., 2009, Colla et al., 2012) have 
revealed the presence of SDS-resistant oligomers using western blots and oligomer-specific 
ELISA assays and antibodies (Kayed et al., 2003, El-Agnaf et al., 2006) (Figure I-17).  
 
 
Figure I-17. Pore-forming oligomers of α-syn 
TEM images of oligomers of A53T and A30P α-syn. Figure from Lashuel et al. (Lashuel et al., 2002). 
 
I.3.4.4. The PD-linked mutations promote α-syn oligomerization and fibril formation 
In vitro studies have showed that the three disease associated-mutants A30P, A53T and E46K 
promote α-syn oligomerization compared to the WT protein (Conway et al., 1998, Lashuel et al., 
2002, Fredenburg et al., 2007), however only the A53T mutant was shown to increase the rate of 
fibril formation (Conway et al., 1998, Giasson et al., 1999, Conway et al., 2000b). The effect of 
PD-linked mutations was also shown to influence the size distribution and final morphology of 
α-syn oliogmers (Ding et al., 2002, Lashuel et al., 2002). For example, the A30P and E46K 
mutant promoted the formation of annular, pore-like protofibrils, whereas A53T formed both 
annular and tubular protofibrillar structures (Lashuel et al., 2002). The WT protein formed 
annular oligomers, but only after longer incubation times and to a much lesser extent that the 
PD-linked mutants (Ding et al., 2002). 
I.3.4.5. Several factors influence α-syn fibril formation 
• Lipids 
α-syn binds to synthetic phospholipid vesicles in vitro and to synaptic vesicles in vivo (Davidson 
et al., 1998, Jensen et al., 1998). Studies by Lee et al showed that membrane-bound α-syn had a 
stronger propensity to aggregate and suggested that the α-syn fibril formation could be initiated 
on neuronal membranes (Lee et al., 2002a). This hypothesis has been supported by in vitro 
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studies that showed enhanced aggregation of α-syn in presence of vesicles composed of 
polyunsaturated fatty acid acyl groups (Perrin et al., 2001, Ding et al., 2002). 
• Oxidation 
Oxidative stress has been implicated in the pathogenesis of PD (Jenner et al., 1992) and is 
thought to play a major role in α-syn-mediated toxicity. Several studies have shown that 
conditions that induce oxidative stress (treatment with peroxynitrite, rotenone and FeCl2) 
enhance α-syn aggregation and fibril formation in cell-based models (Paxinou et al., 2001, Lee 
et al., 2002b, Hasegawa et al., 2004). This oxidative-stress-induced aggregation correlates with 
increased α-syn toxicity in rat models of synucleinopathies (Sherer et al., 2003, Yu et al., 2010). 
Among the α-syn residues are susceptible to oxidation, methionine is readily oxidized to a 
sulfoxide and tyrosine to nitrotyrosine. However, α-syn does not contain cysteine residues. In 
vitro, methionine oxidation inhibits the formation of fibrils of α-syn and the addition of a 4-fold 
molar excess of oxidized α-syn completely inhibited the fibrillization of the WT protein 
(Uversky et al., 2002c). Aside from methionine oxidation, α-syn’s tyrosine nitration is induced 
by oxidative stress (Danielson et al., 2009) and was shown to be present in α-syn aggregates 
both in LB and in rat brain samples (Giasson et al., 2000, Yu et al., 2010) and to seed the 
aggregation of the WT protein (Hodara et al., 2004).  
• Metals 
α-syn is a metal-binding protein and several studies have identified different residues within  the 
C-terminus (119-124) that are involved in α-syn binding to different metal ions was reported 
(Binolfi et al., 2006, Santner and Uversky, 2010, Lu et al., 2011). Different cations can bind to 
α-syn and exhibit variable effects on the rate of α-syn fibrillization and the structure of the final 
α-syn fibrils (Santner and Uversky, 2010). Copper (II) was shown to bind to the C-terminal 
domain of α-syn and to increase its fibrillization (Paik et al., 1999, Binolfi et al., 2006) and a 
comparative study of different di- and tri-valent cations showed that Al3+ was the most effective 
in the stimulation of fibrillization (Uversky et al., 2002a). α-syn oligomerization was also 
showed to be induced by metal-binding and more specifically a report by Wright et al. showed 
the presence of a copper-induced oligomeric specie that, once separated from the monomers and 
the fibrils, was responsible for cytotoxicity (Wright et al., 2009) while Fe3+-induced oligomers 
of α-syn were able to form permeating pores at a lipid-bilayer (Kostka et al., 2008).  
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I.3.5. Functions of alpha-synuclein 
While the propensity of α-syn to form fibrils, a property that is enhanced by disease-associated 
mutations, provides a direct link between the protein and PD pathology, very little is known 
about the physiological function(s) of α-syn and how alteration in its function(s) could 
contribute to the pathogenesis of PD and other synucleinopathies. α-syn KO animal and cell-
based models have been generated in the hopes of deciphering the normal function of the 
protein. As a result, hypotheses have emerged concerning the role of α-syn in several 
physiological processes such as synaptic maintenance, DA release, axonal transport, 
neurotransmission, and inhibition of the enzyme phospholipase D activity.  
I.3.5.1. Synaptic maintenance 
Synaptic plasticity is intimately regulated by vesicle trafficking. At rest, the majority of the 
synaptic vesicles are clustered in a reserve pool. Upon increase of neuronal activity, the vesicles 
exit from the pool, are directed to the site of fusion and are prepared for exocytosis. The 
transition of the vesicles from the pool to other sites is regulated by complex cellular signals 
(Bellani et al., 2010). 
The first clue to the involvement of α-syn in maintenance of the synaptic function came when 
researchers observed the strong presence of α-syn in presynaptic terminals, its association with 
the membranes of synaptic vesicles and the increased expression of the zebra finch homolog of 
α-syn in the brain region implicated in song learning (Maroteaux et al., 1988, George et al., 
1995, Irizarry et al., 1996). Experiments looking at complete or partial down-regulation of α-syn 
in animal models or cell culture hinted towards the regulation of vesicle trafficking. In 
particular, α-syn knock out (KO) mice showed a lack of abnormalities in the synaptogenesis but 
exhibited altered DA release (Abeliovich et al., 2000). Reports in primary hippocampal neuronal 
cultures confirmed that α-syn was not involved in synapse formation since its expression was 
delayed after synapse formation (Murphy et al., 2000). Using anti-sense oligonucleotides, a 
significant reduction in the size of the distal presynaptic vesicular pool was observed upon 
knockdown of α-syn (Drobysheva et al., 2008). Another report using α-syn KO mice showed 
significant impairment in synaptic response and a slower depletion of vesicles from the reserve 
pool compared to WT α-syn mice (Cabin et al., 2002). Together, these findings led to the 
hypothesis that α-syn is implicated in the process of synaptic vesicles trafficking from the 
reserve pool to the release sites (Bellani et al., 2010). Larsen et al. reported that the level of 
docked vesicles was increased in cells over-expressing WT α-syn but that the level of secreted 
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catecholamines was reduced and hence proposed that α-syn inhibits the vesicle priming step that 
would prepare them for exocytosis (Larsen et al., 2006).   
I.3.5.2. Inhibition of phospholipase D activity 
α-syn has been shown to bind preferentially to acidic phospholipids in vitro and in vivo 
(Davidson et al., 1998, Jensen et al., 1998, Perrin et al., 2000). On the other hand, the hydrolysis 
of phosphatidylcholine to phosphatidic acid is regulated by the enzyme phospholipase D (PLD) 
that has been shown to be inhibited by WT and mutant α-syn in vitro (Jenco et al., 1998, Ahn et 
al., 2002). More specifically, tyrosine phosphorylation at residue 125 increases the inhibitory 
effect of α-syn . However, the finding that α-syn inhibits PLD was challenged by a recent report 
(Rappley et al., 2009). PLD activation is linked to cell growth and neurotransmitter release (Ahn 
et al., 2002) thus, a normal balance of lipids is required for regulating a variety of signals at the 
plasma membrane and for proper synaptic function. Therefore, alteration in lipid composition 
may play a role in an α-syn -dependent toxicity. 
I.3.5.3. Chaperone role 
α-syn, a protein with no defined secondary structure, is able to act as a chaperone in order to 
inhibit the aggregation of other proteins such as esterases that are protected against heat and pH-
stress; and alcohol dehydrogenase whose activity is preserved even from heat-induced 
denaturation. α-syn was also shown to protect against chemical-induced, heat-induced and DTT-
induced precipitation of the proteins insulin, glutathione S-transferase (GST) and bovine serum 
albumin respectively (Kim et al., 2000, Souza et al., 2000b, Ahn et al., 2006). Studies by Kim et 
al. showed that the presence of the unstructured C-terminal domain of α-syn is responsible for 
its thermal stability (Park et al., 2002) and hence is important for its chaperone activity. Indeed, 
the fragment 2-97 of α-syn has been shown to be completely devoid of chaperone-like activity 
(Souza et al., 2000b).  
I.3.5.4. Neuroprotective role 
Although the majority of studies focus on the possible toxic mechanisms of α-syn, some reports 
have suggested that it may have neuroprotective properties. The over-expression of WT α-syn in 
neuronal and mammalian cell lines protected against H2O2-induced oxidative stress (Lee et al., 
2001b, Hashimoto et al., 2002) but not against MPP+ (Lee et al., 2001b). Interestingly, A30P and 
A53T mutants did not show this protective ability (Lee et al., 2001b). A subsequent study 
showed that the protective effect of α-syn against oxidative stress induced by MPP+ but not 
H2O2 nor 6-OHDA could be reproduced in cellular models of α-syn toxicity (Jensen et al., 
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2003). Moreover, WT but not A53T α-syn mutant was able to prevent the increase of caspase-3-
like (acetyl-Asp-Glu-Val-Asp-aldehyde-sensitive caspase) after pro-apoptotic stimulation of 
neurons by staurosporine and etoposide (da Costa et al., 2000). 
Some Tg animal models over-expressing WT or A53T α-syn were also shown to resist paraquat-
induced toxicity while the control mice exhibited severe neuronal loss (Manning-Bog et al., 
2003). Moreover, no correlation was found between the presence of apoptotic neurons and α-syn 
expression in rat model of 6-OHDa-induced insult (Kholodilov et al., 1999). In addition to the 
protective effect against toxin-based insults, α-syn was shown to rescue cells from the lethal 
degeneration induced by the deletion of the co-chaperone Cysteine-string protein-α (CSPα) in 
Tg mice, while A30P α-syn was unable to show any protective effect (Chandra et al., 2005). 
This protective effect may have been mediated by the rescue of the synaptic transmission 
impairment that resulted from CSPα KO.   
I.3.6. Mechanisms of α-syn toxicity 
I.3.6.1. Why is α-syn toxic to Dopaminergic neurons? 
α-syn is widely expressed in the brain but neurodegeneration occurs mainly in the SN, i.e. in the 
dopaminergic neurons, in PD (Obeso et al., 2010). Motor deficit in PD has been attributed to the 
high susceptibility and death of dopaminergic neurons in the SN, although the molecular basis 
underlying this increased susceptibility of DA neurons remain unknown. Several studies suggest 
α-syn plays an important role in regulating the production, storage, release and reuptake of DA; 
impairment in each of these processes by α-syn could contribute to neuronal death in PD (Figure 
I-18).   
• α-syn and DA Production 
The activity of Tyrosine Hydroxylase (TH), the rate-limiting enzyme for the conversion of 
tyrosine to L-dopa, is negatively modulated by α-syn both at the gene expression level and/or by 
direct interaction with the enzyme (Perez et al., 2002, Baptista et al., 2003). Hence, under 
physiological conditions, α-syn attenuates the amount of cytoplasmic DA. When monomeric α-
syn is getting scarce due to aggregation, the inhibitory mechanism exerted by α-syn on TH 
activity is impaired, resulting in an increase of cytoplasmic DA.  
• α-syn and DA Storage 
The storage of DA in vesicles is modulated by the activity of the vesicular monoamine 
transporter 2 (VMAT2), which triggers the uptake of cytoplasmic DA into vesicles for storage 
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(Venda et al., 2010). An impairment of synaptic vesicle formation could trigger the 
accumulation of DA in the cytoplasm, resulting in cell death. This was shown in PD patients’ 
brains where levels of VMAT2 were reported to be decreased in PET studies (Lee et al., 2000). 
Moreover, the overexpression of A53T α-syn has been shown to decrease the levels of VMAT2, 
which would results in an increase of cytoplasmic DA (Lotharius et al., 2002, Lotharius and 
Brundin, 2002). Under physiological conditions, α-syn is thus able to regulate the availability of 
synaptic vesicles and the storage by VMAT2, but under pathological conditions, dysfunction of 
DA storage could lead to the accumulation of toxic dopamine which could contribute to 
neurodegeneration and cell death.  
• α-syn and DA Release 
The link between the physiological function of α-syn and synaptic vesicle trafficking was 
detailed earlier in section I.3.5.1. Over-expression of the α-syn mutants A53T and E46K, but not 
A30P, was moreover shown to induce an impairment of synaptic vesicle exocytosis (Nemani et 
al., 2010).  
• α-syn and DA Uptake 
The reuptake of DA into the presynaptic neuron is mediated by the dopamine transporter DAT. 
α-syn binds to DAT and accelerates DA uptake by increasing the number of transporters at the 
membrane. Parkin disrupts this interaction and rescues the cell from increased DA-induced 
toxicity (Lee et al., 2001a, Moszczynska et al., 2007). 
In summary, the impaired activity of α-syn on several levels of DA synthesis, storage and 
release may contribute to the increased vulnerability of dopaminergic neurons in PD (Figure 
I-18). However, the toxic effect on dopaminergic neurons does not only result from α-syn nor 
DA alone, but could result from the interaction or the synergistic toxic effect of both molecules. 
Consistent with this hypothesis, several groups have shown that oxidized DA strongly inhibits 
α-syn fibrillization and promotes the accumulation of potentially toxic oligomers (Conway et al., 
2001, Rochet et al., 2004).  
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Figure I-18. Effects of α-syn on DA synthesis, storage, release and uptake 
α-syn’s toxic effects can be reflected in several steps of DA biosynthesis, storage into vesicles, release at the 
synapse and reuptake by DAT. Figure from Venda et al. (Venda et al., 2010). 
 
I.3.6.2. Lewy Bodies: toxic or protective? 
Identification of fibrillar α-syn as the main component of the LB in PD brains led to the 
hypothesis that α-syn fibril formation is the primary cause of neurodegeneration in PD. This 
hypothesis was supported by findings demonstrating that PD-linked disease mutations accelerate 
and increase the extent of α-syn fibril formation in vitro (section I.3.4) and in animal models of 
synucleinopathies (Giasson et al., 2002, Kirik et al., 2002, Lee et al., 2002c, Lo Bianco et al., 
2002). However, this hypothesis failed to explain the following experimental observations; i) 
some of the surviving neurons in PD patients contain LB (Spillantini et al., 1997); ii) there is a 
lack of correlation between the extent of LB formation and neurodegeneration in humans. 
Moreover, LB have been detected in the brain of patients who died without showing signs of PD 
or other neurodegenerative diseases (Harding and Halliday, 1998, Richard et al., 2002). These 
findings were later better understood by in vitro data demonstrating that α-syn fibril formation, 
like amyloid-β in Alzheimer’s disease (AD), proceed through a series of distinct oligomers that 
disappear upon fibril formation (section I.3.4). The accumulated evidence in support of the toxic 
oligomer hypothesis in AD and observation of a toxic effect induced by α-syn in the absence of 
fibril formation led to the hypothesis that α-syn oligomers, rather than the fibrils, are the primary 
toxic species and fibril formation results in the sequestration of toxic α-syn species. Consistent 
with this hypothesis, two independent studies recently showed that mutations 
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(A30P/A56P/A76P and E57K/E35K) that preferentially promote the formation of or stabilize α-
syn oligomers exacerbated α-syn toxicity in C.elegans, Drosophila (Karpinar et al., 2009) and 
rat models of synucleinopathies (Karpinar et al., 2009, Winner et al., 2011). However, the 
molecular factors that induce the formation of α-syn oligomers in vivo remain unknown, but 
interactions with metals (Wright et al., 2009), polyunsaturated fatty acids (Sharon et al., 2003a, 
Sharon et al., 2003b, Assayag et al., 2007), DA (Conway et al., 2001, Rochet et al., 2004) and 
lipids (Lee et al., 2002a) have been shown to trigger and/or stabilize α-syn toxic oligomers in 
vitro with some of these oligomers inducing cytotoxicity (Assayag et al., 2007, Wright et al., 
2009).  
I.3.6.3. Mitochondrial dysfunction 
PD pathogenesis is associated with the impairment of mitochondrial function and most 
specifically of complex I of the electron transport chain. A defect in complex I activity was 
detected in the SN of PD patients (Schapira et al., 1990, Sherer et al., 2002a) and known 
inhibitors of complex I – rotenone and MPTP – cause neurodegeneration in humans and animal 
models (section I.2.2.1 and I.2.2.2). This was shown to be mediated by inhibition of ATP 
production and generation of reactive oxygen species (ROS) (Sherer et al., 2002b). Furthermore, 
pathogenic mutations in PINK1, a kinase that localizes to the mitochondrial membrane, result in 
a decrease of the complex I activity, while DJ-1, a protein that acts as an antioxidant, is mutated 
in autosomal recessive PD and is translocated to the mitochondria upon oxidative stress insult.  
The link between α-syn aggregation and complex I inhibition was initially suggested based on 
cell culture studies where rotenone treatment triggered α-syn aggregation and increased both 
DNA and protein damage (Sherer et al., 2002b). Later, it was shown that MPTP treatment of 
cells resulted in α-syn aggregation and release of caspase 3 (Kalivendi et al., 2004). 
In addition, α-syn was also shown to impair mitochondria’s structure and activity through direct 
binding. Several reports have revealed that α-syn localizes to the mitochondria in human brains 
(Devi et al., 2008) and cell-culture models (Cole et al., 2008, Nakamura et al., 2008, Shavali et 
al., 2008) and is able to bind purified mitochondria in vitro (Cole et al., 2008). The translocation 
of α-syn from the cytosol to the mitochondria was reported to increase during the progression of 
the disease (Devi et al., 2008) and was hypothesized to be triggered by acidification of the 
intracellular milieu as a result of oxidative insults (Cole et al., 2008). α-syn’s import into the 
mitochondria causes fission of the organelles, a decrease of intracellular ATP, and elevated level 
of ROS resulting in cell death (Devi et al., 2008, Nakamura et al., 2011).   
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I.3.6.4. Oxidative stress 
Impairment of the complex I of the mitochondria results in oxidative stress. Elevated level of 
oxidation markers such lipid peroxidation (Dexter et al., 1989), accumulation of the DNA 
damage product 8-hydroxy-2'-deoxyguanosine (Alam et al., 1997b), protein carbonyl formation 
(Alam et al., 1997a), and α-syn nitration (Giasson et al., 2000) were reported in the SN of PD 
patients. The increase of ROS in the SN could arise from several causes (Sherer et al., 2002a): i) 
the synthesis of DA by TH and the catabolism of DA by monoamine oxidase B generate H2O2 
and ii) the spontaneous auto-oxidation of dopamine in the cytoplasm that also yields 
H2O2.Oxidative stress is hence one of the major contributors to the pathogenesis of PD (Jenner 
et al., 1992) and could even be an early feature in the pathogenesis. 
I.3.6.5. Dysfunction of the ubiquitin/proteasome pathway 
Genetic evidence on the potential impairment of the proteasomal degradation pathway in PD 
arises from the discovery of mutations in the gene coding for Parkin, an E3 ligase, that were 
linked to autosomal recessive PD and mutations in the gene for UCHL-1, a ubiquitin C-terminal 
hydrolase, which are linked to autosomal-dominant PD (Leroy et al., 1998, Shimura et al., 
2000). It was hypothesized that defective proteasomal-degradation of α-syn would result in its 
accumulation and further aggregation in cells. One cell-based study confirmed this hypothesis 
and showed accumulation of non-ubiquitinated α-syn upon inhibition of the proteasome, while 
other studies could not reproduce this finding (Paxinou et al., 2001).  
On the other hand, proteasome activity was shown to be impaired by α-syn mutations. Stable 
PC12 lines expressing A53T α-syn but not cells expressing the WT protein showed inhibition of 
the proteasome activity which resulted in the accumulation of ubiquitinated α-syn aggregates, 
along with an increase of non-apoptotic death (Stefanis et al., 2001). Furthermore, mice over-
expressing a double-mutant form of α-syn (A30P/A53T) showed significant decline in 
proteasomal activity and an increase in the level of ubiquitinated proteins (Chen et al., 2006).  
It has been proposed that α-syn -mediated inhibition of the proteasome results from the direct 
binding of the protein to the subunit S6’ in the proteasomal cap or to the catalytic core of the 
20S proteasome, thus disrupting its degradation activity (Snyder et al., 2003, Lindersson et al., 
2004). Aggregated forms of α-syn exhibited stronger affinity to the 19S subunit of the 
proteasome with an IC50 in the range of 1 and 500nM (respectively for ubiquitin-independent 
and ubiquitin-dependent degradation). The monomeric form of α-syn did not inhibit the 
ubiquitin-dependent degradation and only showed partial inhibition of the ubiquitin-independent 
pathway (Snyder et al., 2003). Other reports have shown a preferential binding of the fibrils and 
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oligomers to another subunit of the proteasome (20S) which resulted in a marked inhibition of 
the degradation activity (Lindersson et al., 2004).  
I.3.6.6. Dysfunction of the lysosomal pathway 
Previous studies have shown that only a small fraction of α-syn is degraded by the proteasome 
(Ancolio et al., 2000, Paxinou et al., 2001, Lee et al., 2004, Vogiatzi et al., 2008, Ebrahimi-
Fakhari et al., 2011) and that the majority of the protein is readily transported into lysosomes for 
degradation (Cuervo et al., 2004, Mak et al., 2010). Treatment of cells with 3-methyladenine 
dramatically increased the steady-state levels of α-syn (Webb et al., 2003). Chaperone-mediated 
autophagy was reported to be affected by PD-linked mutations: α-syn mutants A30P and A53T 
were able to block the uptake of receptors located on the lysosomal membrane, which would 
prevent their degradation and the degradation of other substrates (Cuervo et al., 2004).  
I.3.6.7. Cell to cell transmission 
The molecular mechanisms that determine how α-syn pathology spreads in the brain remain 
unknown. Recent studies suggest that α-syn pathology spreads through cell-to-cell transmission 
and propagation mechanisms whereby α-syn aggregates are secreted by one cell, cross the 
membrane of the recipient cell where they then induce/seed the formation of α-syn aggregates 
and/or exert their toxic effects via multiple mechanisms. 
Studies on post mortem tissue of PD patients who had undergone embryonic neuron 
transplantation as a cell-replacement therapy revealed the presence of LB in 12 year-old and 16-
year-old fetal mesencephalic neuron grafts (Li et al., 2008, Chu and Kordower, 2010, Li et al., 
2010). It was hence speculated that the host-to-graft disease propagation was probably due to 
the transmission of α-syn from cell to cell (Li et al., 2008). Cell-to-cell transmission of α-syn 
was also reported in Tg mice over-expressing human α-syn that had mouse cortical neuronal 
stem cell transplants in the hippocampus. After 4 weeks, 2.5 to 15% of the grafts were positive 
to human α-syn, indicating that α-syn was transferred from the host brain to the grafts (Desplats 
et al., 2009). The transmitted α-syn had a capacity to seed aggregation and inclusions were 
shown in the grafted neurons (Hansen et al., 2011). Transmission of α-syn from neurons to glia 
was also reported in Tg mice over-expressing human α-syn under the control of a neuronal 
promoter. α-syn was detected both in neurons and glial cells and was causative of an 
inflammatory response (Lee et al., 2010).  
α-syn has also been detected in the cerebrospinal fluid, blood plasma and in the saliva of PD 
patients (El-Agnaf et al., 2003, El-Agnaf et al., 2006, Tokuda et al., 2006, Devic et al., 2011). It 
is secreted from cells by exocytosis (Lee et al., 2005) and stress factors such as serum 
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deprivation and H2O2 treatment, proteasomal or lysosomal inhibition can enhance its secretion to 
the cell culture medium (Lee et al., 2005, Steiner et al., 2011). Once released in the extracellular 
milieu, α-syn can associate with membranes thanks to its lipid-binding properties (section 
I.3.3.2). However, monomeric and fibrillar α-syn display different preferred routes of entry into 
cells: monomeric α-syn penetrates cells through passive diffusion or by association to lipid rafts 
while aggregated α-syn is uptaken through endocytosis (as suggested from data where low 
temperature, dynamin inhibitors and trypsin treatment were applied to cells) (Lee et al., 2008a). 
The toxicity of extracellular α-syn is dependent on its internalization since treatment of cells 
with endocytosis inhibitors was protective (Sung et al., 2001). In cell-based models, 
extracellular α-syn can induce the formation of α-syn aggregates inside cells if it is introduced 
via cationic liposomes, calcium phosphate, Lipofectamine or without any transfection agent 
(Luk et al., 2009, Nonaka et al., 2010, Waxman and Giasson, 2010, Steiner et al., 2011). 
However, in vivo, α-syn does not need agents to cross the cellular membrane and is able to seed 
the aggregation of endogenous α-syn (Li et al., 2008, Desplats et al., 2009).  
I.3.7. Interaction between α-syn and other proteins 
α-syn has been shown to interact with a large panel of proteins with different roles in the cellular 
function and homeostasis such as membrane trafficking, ion channel modulation, redox 
metabolism, and gene regulation (Zhou et al., 2004, Woods et al., 2007). More than 70 potential 
interacting proteins were reported to interact with α-syn in the LB (Wakabayashi et al., 2007). 
Proteomics studies using C-terminal peptide fragments of α-syn and pull-down assays from 
mouse brain synaptosomes revealed that α-syn interacts mainly with mitochondrial proteins. 
Interestingly, the phosphorylated forms of this peptide are bound preferentially to cytoskeletal 
proteins and proteins involved in the endocytotic pathways (McFarland et al., 2008) (section 
I.4.2.2). Below is a brief overview of some of the key proteins that have been shown to interact 
with α-syn: tau, synphilin, β- and γ-syn, Rab, histones and chaperones.  
I.3.7.1. Tau 
The presence of neurofibrillary tangles, composed of hyperphosphorylated forms of the 
microtubule-associated protein Tau, is one of the pathological hallmarks of AD (Querfurth and 
LaFerla, 2010). Data from post mortem analysis of PD brain samples showed the presence of 
phosphorylated Tau at serine 262 in the striatum (Wills et al., 2010). The same group showed an 
increase of Tau phosphorylation and the absence of binding to the microtubules in an A53T 
transgenic mouse model of PD (Wills et al., 2011). Mice over-expressing the A30P α-syn 
mutant elicited the same findings (Frasier et al., 2005). Aside from PD-related mutations, 
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neurotoxins (such as MPTP) were shown to trigger the hyperphosphorylation of tau in cellular 
models (Qureshi and Paudel, 2011). In vivo and in vitro evidence for a direct interaction 
between α-syn and tau came from affinity purification (Jensen et al., 1999) and a mammalian 
two-hybrid assay (Benussi et al., 2005) and from the observation that α-syn induces and 
enhances the fibrillization of tau, which does not usually proceed readily in vitro but requires the 
addition of polyanionic cofactors such as heparin (Giasson et al., 2003, Kotzbauer et al., 2004). 
This finding was successfully reproduced in cell-based models where exogenous α-syn fibrillar 
seeds induced the intracellular aggregation and hyperphosphorylation of tau (Waxman and 
Giasson, 2011). 
I.3.7.2. Synphilin 
A yeast-two hybrid screen for α-syn interactants yielded synphilin as a hit (Engelender et al., 
1999). It was later reported that synphilin is a component of the LB and was linked to PD after 
the discovery of a single-point mutation - R621C - in sporadic PD patients (Marx et al., 2003). 
These findings suggested a potential role in LB formation and PD (Wakabayashi et al., 2000). 
Furthermore, the two proteins were shown to interact in vivo (Engelender et al., 1999) and the 
interaction was shown to occur via the C-terminal domain of α-syn (Kawamata et al., 2001). 
Engelender and colleagues developed a cellular model of α-syn aggregation by co-expression of 
α-syn and synphilin and showed that expression of synphilin was required for α-syn aggregation 
(Engelender et al., 1999, McLean et al., 2001) (section I.2.4.3). These findings suggested that 
impairment of synphilin’s degradation could potentially trigger the aggregation of α-syn.  
I.3.7.3.  β-and γ-syn 
The two other members of the synuclein family β-syn and γ-syn are also expressed in the brain 
(Li et al., 2002). α-syn and β-syn were shown to interact in transgenic animal brain samples or 
in cell lines expressing both proteins (Hashimoto et al., 2001). Both β- and γ-syn bind to α-syn 
in vitro and are able to inhibit its aggregation (Hashimoto et al., 2001, Uversky et al., 2002b, 
Park and Lansbury, 2003). Moreover, crossbreeding Tg mice that over-expresses β-syn with 
mice that over-express α-syn inhibited α-syn aggregation and resulted in improved motor 
symptoms (Hashimoto et al., 2001), thus providing evidence for the interaction between the two 
proteins in vivo. These findings suggest that β-syn may act as a negative regulator of α-syn 
aggregation in vivo. Furthermore, supplementing the medium for Drosophila with a β-syn-
derived peptide composed of D-amino acids was sufficient to improve locomotor activites of 
A53T α-syn -over-expressing flies (Shaltiel-Karyo et al., 2010).   
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I.3.7.4. Rab 
Rab GTPase proteins regulate membrane trafficking processes and alternate between cytosolic 
(inactive) and membrane-bound (active) states. Consistent with the localization of α-syn at the 
synapse and the proposed role as a regulator of synaptic vesicle trafficking (section I.3.5.1), it 
was postulated that α-syn may interact with Rab proteins. Indeed, higher-molecular weight 
species of α-syn were shown to interact with Rab3a (presynaptic localization), Rab5, and Rab8 
in DLB brain samples while the monomeric form of the protein interacts weakly (Dalfo et al., 
2004, Dalfo and Ferrer, 2005). Moreover, extracellular α-syn interacts with Rab11a to ensure its 
internalization in cells (Liu et al., 2009). In a yeast model where α-syn expression impaired ER-
Golgi trafficking (specifically by affecting the vesicle docking step), the expression of Ypt1p 
(the homologue of Rab1) rescued from α-syn toxicity and similar observations were made for 
Rab1, Rab3a and Rab8 both in neuronal and fly models (Cooper et al., 2006, Gitler et al., 2008). 
I.3.7.5. Histones 
The nuclear localization of α-syn has been confirmed after toxin insults by several reports 
(Goers et al., 2003a, Surguchov, 2008) and was shown to promote cell death as evidenced by 
findings used a fusion of α-syn to a nuclear localization signal (Kontopoulos et al., 2006). The 
molecular determinants that were responsible cytotoxicity involved a binding of α-syn to 
histones. α-syn was shown to bind to Histone 1 and 3 (Goers et al., 2003a, Kontopoulos et al., 
2006) and to inhibit the acetylation of Histone 3 in cell-based and in vitro assays with reports of 
toxicity in which resulted in enhanced toxicity in cell-culture and Drosophila models 
(Kontopoulos et al., 2006). Furthermore, due to interaction of α-syn with Histone 1, the 
fibrillization rate of α-syn was dramatically increased (Goers et al., 2003a).  
I.3.7.6. Chaperones 
α-syn interacts with the chaperones Hsp27, Hsp70, and Hsp90 (Outeiro et al., 2006). 
Overexpression of Hsp27 reduced α-syn-induced toxicity in cells by 30% and the other 
chaperone Hsp70 was shown to strongly inhibit α-syn fibrillization through the preferential 
binding to α-syn oligomers (Dedmon et al., 2005). The co-chaperone carboxyl terminus of 
Hsp70-interacting protein (CHIP) co-localizes with Hsp70 and α-syn in LB and decreases the 
fibrillization rate of α-syn (Shin et al., 2005). CHIP ubiquitinates α-syn (Kalia et al., 2011) and 
directs it for degradation via the proteasomal and the lysosomal pathways (Shin et al., 2005). 
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I.4. Post-translational modifications of alpha-synuclein 
The molecular factors that are responsible for triggering α-syn aggregation and mediating its 
toxicity in sporadic PD remain unknown. The identification of different post-translational 
modifications (PTM) of α-syn within the LB suggested that these modifications could play an 
active role in the initiation of α-syn aggregation and LB formation. This hypothesis was 
supported by a landmark study by Fujiwara et al. that demonstrated for the first time that the 
majority of α-syn within LB is phosphorylated at S129. This study also suggested that 
phosphorylation at S129 enhances α-syn fibril formation (Fujiwara et al., 2002). A subsequent 
and more comprehensive analysis of α-syn PTM using mass spectrometry confirmed this 
finding and revealed the presence of additional modifications, including N-terminal acetylation, 
ubiquitination and truncation (Anderson et al., 2006) (Figure I-19). The effect of some of these 
modifications on the structure, aggregation and toxicity of α-syn has been investigated both in 
vitro and in vivo and the search for enzymes regulating these PTM remains an active area of 
investigation, as these could be potential therapeutic targets for the treatment of PD and related 
synucleinopathies (Oueslati et al., 2010). 
I.4.1. Phosphorylation at Serine residues 
α-syn contains four serine residues (two in the N-terminal domain - S9 and S42 -, S87 in the 
NAC region and S129 in the C-terminus) (Figure I-20). To date, only S129 and S87 have been 
linked to PD through phosphorylation. Okochi et al. demonstrated that α-syn expressed in cell 
lines is constitutively phosphorylated at multiple sites. By expressing different S?A mutants of 
α-syn, they identified serine 129 and serine 87 as the main phosphorylation sites of α-syn 
(Okochi et al., 2000). Phosphorylation of α-syn at S87 was later discovered to be present within 
the LB (Paleologou et al., 2010).  
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Figure I-19. Most studied PTM occurring in α-syn  
Scheme summarizing α-syn’s modifications that have been shown to occur in the LB. The majority of the PTM are 
clustered in the C-terminal domain of the protein (except for ubiquitination and phosphorylation at S87). Figure 
from Oueslati et al. (Oueslati et al., 2010) 
 
 
 
Figure I-20. Conservation of the α-syn phosphorylation sites among species. 
Sequence alignment of α-syn protein from human, rat, mouse, bovine, pig, primate and chicken species. The 
phosphorylation sites that have been linked to the pathology (S87, S129 and Y125) are highlighted in red while the 
other potential phosphorylation sites are in green. Alignment was based on Uniprot sequences P37840, P37377, 
O55042, Q3T0G8, Q3I5G7, P61144 and Q9I9H1 
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The casein kinases CK1 and CK2 were implicated in phosphorylating these sites. Subsequent 
studies showed that the G-protein-coupled receptor kinases (GRKs) also phosphorylate α-syn in 
vitro and in vivo at S129 (Pronin et al., 2000, Sato et al., 2011). 
I.4.1.1. Phosphorylation at S129 
Fujiwara et al. reported that > 90% of α-syn in LB is phosphorylated at S129 compared to 4% of 
phosphorylation in total α-syn (Fujiwara et al., 2002). A comprehensive proteomics study 
carried out by Anderson et al. confirmed this finding in DLB, MSA and PD patients (Anderson 
et al., 2006). Moreover, pS129 α-syn was detected in Tg mice over-expressing α-syn (Kahle et 
al., 2002, Neumann et al., 2002, Wakamatsu et al., 2007, Rieker et al., 2011), in rat models 
expressing α-syn (Yamada et al., 2004), and in Tg flies expressing WT and mutants of α-syn 
(Takahashi et al., 2003, Chen and Feany, 2005). Interestingly, the detection of pS129 correlated 
with the formation and progression of α-syn pathology. 
Although the natural kinases and phosphatases involved in regulating the 
phosphorylation/dephosphorylation of α-syn at S129 and S87 remain unknown, some potential 
candidates have been recently identified in vitro and eventually validated in vivo (Oueslati et al., 
2010) (Figure I-21). Some of the kinases that have been identified are specific for S129: G-
coupled-receptor kinase 1,2,5 and 6 (GRK) (Pronin et al., 2000, Liu et al., 2010) and the Polo-
like kinases 2 and 3 (PLK) (Inglis et al., 2009, Mbefo et al., 2010). On the other hand, CK1 and 
CK2 have been shown to phosphorylate α-syn both at S87 and S129 (Okochi et al., 2000). CK2 
and GRK-5 have been identified in the LB (Arawaka et al., 2006, Ryu et al., 2008). It is 
important to note that not all identified kinases exhibit the same phosphorylation efficiency, and 
that some enzymes are able to phosphorylate fibrillar α-syn more efficiently than others. 
Furthermore, some kinases have been shown to phosphorylate fibrillar α-syn more preferentially 
than the monomeric form of the protein (Waxman and Giasson, 2008, Mbefo et al., 2010). The 
only phosphatase that has been identified and implicated in the dephosphorylation of pS129 α-
syn in vivo is Phosphoprotein Phosphatase 2A (PP2A) (Lee et al., 2011), whereas in vitro PP2C 
has been shown to be much more efficient (Waxman and Giasson, 2008).  
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Figure I-21. Kinases implicated in the phosphorylation of α-syn at Serine residues. 
Figure adapted from Oueslati et al. (Oueslati et al., 2010) 
 
The impact of phosphorylation at S129 on fibril formation was probed in vitro and in vivo, 
which yielded various results. In vitro phosphorylation assay using CK2 demonstrated an 
increase in α-syn aggregation (Fujiwara et al., 2002) while studies done by Paleologou et al., 
using CK1 , showed an inhibition of fibrillization (Paleologou et al., 2008). The discrepancy is 
probably due to the difference in kinases and in the extent of phosphorylation in each study 
since CK1 phosphorylates α-syn efficiently at S129 but CK2 induces only partial (< 5%) 
phosphorylation of the protein at S129.  
The expression of the kinase GRK6 in a rat model resulted in a significant increase in the levels 
of pS129 α-syn but had no effect on the fibrillization of the protein (Sato et al., 2011). Studies 
using Tg mice over-expressing α-syn, with pharmaceutically-enhanced PP2A activity, revealed 
reduced pS129 levels that were accompanied with a decrease of α-syn aggregation (Lee et al., 
2011). AAV-mediated overexpression of S129A α-syn in the SN of rats resulted in enhanced 
aggregation and loss of DA neurons (Azeredo da Silveira et al., 2009). Although these findings 
suggest that blocking phosphorylation may enhance α-syn toxicity, the increased propensity of 
S129A fibrillization in vitro (Paleologou et al., 2008) and in vivo (rats and Drosophila) (Chen 
and Feany, 2005, Gorbatyuk et al., 2008, Azeredo da Silveira et al., 2009) suggest that the 
enhanced toxicity is a result of the enhanced aggregation of this mutant rather than of the 
blocking of phosphorylation at S129.  Interestingly, while the effect of S?A substitution at 
S129 on α-syn aggregation can be correlated to toxicity in the rat model of PD, the S129A 
mutant exhibited reduced toxicity in the Drosophila model compared to WT and S129E (Chen 
and Feany, 2005, Azeredo da Silveira et al., 2009). The major causes of the discrepancies 
between the results remain unknown, but may be explained by the fact that Drosophila do not 
express α-syn and that the interaction between human and rat α-syn may play an important role 
in regulating its aggregation and toxicity (Rochet et al., 2000).  
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• Effect of pS129 on toxicity 
While the effects of phosphorylation at S129 on α-syn aggregation were not identical in the 
different reports and animal models, the same discrepancies were observed for the toxicity 
effects. The co-expression of the GRK6 kinase with A53T α-syn in a rat model was shown to 
exacerbate A53T-induced toxicity while co-expression of GRK6 and the S129A mutant did not 
result in major changes in toxicity relative to the WT protein (Sato et al., 2011). Attenuating or 
blocking phosphorylation at S129 through the induction of phosphatase activity or expression of 
the S129A mutant respectively resulted in opposing effects in mice and rat models. Tg mice 
over-expressing α-syn, with an enhanced PP2A activity, revealed a better motor performance 
and reduced microglial activation, suggesting that phosphorylation at S129 might induce 
neurodegeneration (Lee et al., 2011). However, overexpression of S129A, which cannot be 
phosphorylated, in rat SN resulted in increased loss of DA neurons compared to expression of 
the WT protein (Gorbatyuk et al., 2008, Azeredo da Silveira et al., 2009).  
In invertebrate models, the effect of phosphorylation at S129 on toxicity was not consistent: the 
over-expression of the Drosophila homolog of the kinase GRK2 induced degeneration of 
dopaminergic neurons (Chen and Feany, 2005) while the expression of PLK2 suppressed α-syn 
-induced neuronal loss in C.elegans (Gitler et al., 2009). While both models do not have α-syn 
homologues the discrepancies between the Drosophila and C.elegans models could result from 
the different extent of phosphorylation by the two kinases since PLK2 was shown to 
phosphorylate α-syn more efficiently than GRK2 in vitro and cell-based studies (Mbefo et al., 
2010).  
The use of the phosphomimicking mutant S129D to investigate the effect of constitutive 
phosphorylation in the rat and Drosophila models of PD also yielded contradictory results. 
Over-expression of S129D α-syn resulted in an accelerated loss of dopaminergic neurons 
compared to WT α-syn in fly model (Chen and Feany, 2005), while no additional toxic effect 
was reported for this mutant in the rat model (Gorbatyuk et al., 2008, Azeredo da Silveira et al., 
2009).  
I.4.1.2. Phosphorylation at S87 
Unlike S129 which is highly conserved among species, a serine is present at position 87 of α-
syn in primates whereas in mice, rats and other species, this residue is an asparagine (Figure 
I-20). Recently, our group developed an antibody that is specific for pS87. Using this antibody, 
Paleologou et al. demonstrated the presence pS87 α-syn in LB and showed that the level of 
pS87 is increased in brain samples of AD, MSA and PD in comparison to healthy individuals 
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(Paleologou et al., 2010). In a Tg mouse model of PD, the levels of pS87 were also shown to be 
increased compared to controls (Paleologou et al., 2010). Interestingly, pS87 α-syn seemed to be 
preferentially present in membrane fractions.  
Only CK1/2 (Okochi et al., 2000) and the dual specificity tyrosine-regulated kinase Dyrk1A 
have been shown to phosphorylate α-syn at S87 (Kim et al., 2006). pS87 and CK1 co-localize in 
inclusions in Tg mice and PD brains (Paleologou et al., 2010). No specific phosphatase that 
regulates pS87 dephosphorylation has been reported to date.  
• Effect of pS87 on the conformation and aggregation of α-syn  
S87 is the only phosphorylation site to lie within the NAC region and thus phosphorylation of 
this residue was expected to attenuate the fibrillization of α-syn. Indeed, phosphorylation at S87 
or S?E/D substitution at this residue was shown to inhibit the fibrillization of α-syn in vitro 
(Waxman and Giasson, 2008, Paleologou et al., 2010). This finding was also confirmed in vivo 
where S?E substitution was shown to inhibit α-syn aggregation and to protect against toxicity 
compared to WT and S87A expression that resulted in 28% loss of DA neurons and formed 
proteinase-K-resistant and ThS-positive aggregates (Oueslati et al., 2012).  
I.4.2. Phosphorylation at Tyrosines 
Previous proteomics data on α-syn phosphorylation in LB did not report phosphorylation at 
tyrosine residues (Anderson et al., 2006), as it could not be detected under the experimental 
conditions used at that time. Indeed, the tyrosine phosphorylation/dephosphorlation cycle of 
proteins is a very dynamic process and phosphotyrosine containing proteins have been reported 
to be rare (Yousefi et al., 1994).  
I.4.2.1. Phosphorylation at Y125 
Comparison of the amino acid sequences of α-syn and its homologues revealed that the four 
tyrosine residues are conserved between species (Figure I-20). Among these tyrosine residues, 
three lie in the C-terminal domain (Y125, Y133 and Y136) whereas Y39 is in the N-terminus. 
Ellis et al. were the first to demonstrate that α-syn is phosphorylated at tyrosines in cell-culture 
models (Ellis et al., 2001). Upon treatment with pervanadate, a general phosphatase inhibitor, 
Y125 was identified as the major phosphorylation site (Ellis et al., 2001, Ahn et al., 2002). Y125 
was also the major phosphorylation site using in vitro phosphorylation assays with tyrosine 
kinases (Nakamura et al., 2001, Nakamura et al., 2002, Negro et al., 2002). Chen et al. also 
showed that inhibition of phosphatases with general inhibitors enhances the detection of pY125. 
Up to 30% of total α-syn in Drosophila brain homogenate was reported to be phosphorylated at 
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Y125, suggesting that phosphorylation at this residue occurs at low levels and/or is tightly 
regulated (Chen et al., 2009).   
• pY125 is a pathophysiological marker of PD 
Given that the α-syn PD-linked mutations A30P and A53T do not affect phosphorylation at 
Y125 in cells treated with phosphatase inhibitors (Ellis et al., 2001) as well as upon in vitro 
phosphorylation by the Fyn kinase (Nakamura et al., 2001), this suggests that this 
phosphorylation may not be directly linked to the pathogenesis of familial PD (Ellis et al., 
2001). However, Nakamura et al. reported that phosphorylation of α-syn at Y125 by Src and 
Pyk2/RAFTK kinases does not occur spontaneously but is induced by hyperosmotic-stress 
(Nakamura et al., 2002). Similar observations were reported in rotenone-treated cells where 
pY125 was reported among other modifications, suggesting that this PTM is induced by 
mitochondrial dysfunction (Mirzaei et al., 2006). Interestingly, in the only study from human 
brain samples that seems to stress a physiological role for pY125, the levels of pY125 α-syn 
were shown to decrease with age and with the pathology, suggesting that the loss of pY125 is 
associated with pathogenesis (Chen et al., 2009). 
 
Figure I-22. Kinases implicated in the phosphorylation of α-syn at tyrosines 
 
In vitro and cell culture studies have shown that α-syn is phosphorylated at Y125 by Fyn (Ellis 
et al., 2001, Nakamura et al., 2001), Pyk2/RAFTK (Nakamura et al., 2002), c-Src (Ellis et al., 
2001, Nakamura et al., 2002), and c-Fgr (Negro et al., 2002); and at the three tyrosine residues 
Y125, Y133 and Y136 by Syk (Negro et al., 2002) (Figure I-22). 
Only the Syk kinase was shown to efficiently phosphorylate α-syn at Y125, whereas 
phosphorylation by Fyn and c-Frg is largely substoichiometric, (Negro et al., 2002). 
Nevertheless, although Syk and α-syn have been reported to co-localize in mouse brain sections 
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(Negro et al., 2002), the natural phosphatases involved in regulating α-syn tyrosine 
phosphorylation in vivo remain unknown. 
• Effect of pY125 on the conformation and aggregation of α-syn  
Although the site-specific effect of phosphorylation at each of these tyrosine residues has not 
been fully investigated, inhibition of α-syn oligomerization and inclusion formation has been 
observed under conditions where all three C-terminal tyrosine residues are phosphorylated, i.e. 
pY125/pY133/pY136 (Negro et al., 2002). Partial phosphorylation was not sufficient to inhibit 
α-syn fibrillization (Negro et al., 2002). The combined effect of triple tyrosine phosphorylation 
was also investigated in the fly model (through the expression of Shark kinase, a homolog of 
Syk) and the same inhibitory effect of this modifications on α-syn oligomerization was reported 
(Chen et al., 2009).   
• Effect of pY125 on toxicity  
To determine the functional consequences of Y125 phosphorylation in a Drosophila model, a  
mutant form of α-syn (α-synYF) in which all C-terminal tyrosines was mutated to phenylalanine 
(Y125F/Y133F/Y136F) was generated (Chen et al., 2009). The flies over-expressing this mutant 
exhibited substantial loss of dopaminergic neurons and a reduction in climbing ability compared 
to flies over-expressing WT α-syn. These findings suggest a protective for α-syn 
phosphorylation at its C-terminal tyrosine residues and was confirmed in Tg flies over-
expressing the Shark kinase (the Drosophila homolog of Syk) and α-syn S129D mutants to 
mimic for phosphorylation at this residue: a rescue of the neurotoxicity-induced by the 
phosphomimic was reported. These findings, together with the decrease of the level of pY125 in 
humans with age and pathology progression, confirm a protective role for Y125 
phosphorylation. However, it is important to note that the effect of site-specifically-modified α-
syn at Y125 was not investigated.  
I.4.2.2. Functional roles of phosphorylation  
Although the majority of studies on α-syn phosphorylation have focused on elucidating the 
effects of this modification on α-syn aggregation, pathology and toxicity, increasing evidence 
suggest that PTM, including phosphorylation, may play important roles in regulating α-syn 
physiological and cellular properties by modulating its subcellular localization, its degradation 
and its interaction with other proteins and ligands.  
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• Subcellular localization 
The subcellular localization of proteins is an important determinant of their function and 
dysfunction. Several studies have recently shown that phosphorylation at S129 enhances the 
nuclear localization of α-syn (Wakamatsu et al., 2007, Schell et al., 2009, Mbefo et al., 2010). 
Studies in the A30P mouse model of α-syn revealed the presence of nuclear pS129 only in 
cortical regions of the brain. The nuclear localization of phosphorylated α-syn was absent in 
control littermates and increased with age in Tg mice (Schell et al., 2009). Similar observations 
were made in the A53T Tg mouse model (Wakamatsu et al., 2007). These findings were also 
confirmed in cell culture studies: HEK cells over-expressing α-syn and the kinase GRK5 
showed a nuclear localization for pS129 while the WT α-syn remained predominantly cytosolic 
(Schell et al., 2009, Mbefo et al., 2010). Although the mechanism of α-syn translocation from 
the cytosol to the nucleus, as well as the functional consequences of S129 phosphorylation in the 
nucleus remain unknown, it has been suggested that α-syn may play a role in transcriptional 
regulation in the nucleus through its interaction with histones (section I.3.7), but further studies 
are needed to test this hypothesis.     
• Targeting to the proteasome 
α-syn is degraded both by the proteasomal and lysosomal pathways (Webb et al., 2003). The 
hypothesis that specific PTM of α-syn could result in a preferential degradation was confirmed 
in studies by two independent groups who reported that proteasomal inhibition in cell-culture 
and primary neurons resulted in an increase of phosphorylated α-syn at S129, suggesting that 
phosphorylation at S129 may target α-syn to the proteasome for degradation (Chau et al., 2009, 
Machiya et al., 2010). Interestingly, this degradation was reported to be independent of 
ubiquitination (Machiya et al., 2010).  
• Inhibition of phospholipase D 
Studies by Payton et al. suggested potential functional roles for α-syn phosphorylation at Y125. 
α-syn was previously identified as an inhibitor of phospholipase D isoforms 1 and 2 (PLD) 
(Jenco et al., 1998, Ahn et al., 2002), although this finding was contradicted by another study 
(Rappley et al., 2009). Tyrosine phosphorylation at residue 125 appears to specifically play a 
role in the modulation of the activity of PLD since pY125 α-syn (obtained by treatment of the 
cells with pervanadate) rescued the activity of the enzyme (Ahn et al., 2002, Payton et al., 
2004). PLD is thought to play a role in exocytosis and α-syn could potentially regulate the 
activity of the enzyme via its own phosphorylation.  
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• Protein-protein interactions 
Other potential roles for Y125 phosphorylation may be mediated by phosphorylation-dependent 
protein-protein interactions. Peptide-based proteomic studies have identified several proteins 
from mouse synaptosomes that interact preferentially with a pY125 C-terminal α-syn peptide 
compared to the non-phosphorylated form. The increased interaction between pY125 and 
proteins from the cytoskeleton and clathrin heavy subunits could suggest that phosphorylation at 
Y125 could induce the binding of α-syn to microtubules and play a role in stabilizing synapses. 
The same interacting proteins were reported in pull-down studies using a pS129 α-syn peptide 
(McFarland et al., 2008). Together, these studies point to a potential role for phosphorylation in 
synaptic vesicle trafficking. Interestingly, the pY125 peptide interacted more preferentially with 
CK1 than the corresponding pS129 peptide, despite the fact that CK1 phosphorylates α-syn at 
S129 and not Y125 (Okochi et al., 2000). These findings point to a mechanism of cross-talk 
between the two phosphorylation sites where pY125 could be involved in a cooperative manner 
in the phosphorylation S129.  
• Binding to metal ions 
Phosphorylation at Y125 was shown to increase the binding to bivalent cation such as Cu2+, 
Pb2+ and Fe2+ and to induce the transfer of the binding sites of the metal ions from the N- to the 
C-terminal domain of α-syn to residues close to the phosphorylation sites. Similar findings were 
observed for S129 phosphorylation (Lu et al., 2011). 
I.4.3. Ubiquitination 
The discovery that LB were immunoreactive for both α-syn and ubiquitin suggested that 
ubiquitination of α-syn may play a role in LB formation (Spillantini, Crowther et al. 1998). 
Biochemical analysis of the insoluble fractions of brain samples from PD brains revealed the 
presence of  higher-molecular-weight bands (~ 22-29kD) that were immunoreactive to α-syn 
and ubiquitin, thus providing the first evidence that α-syn in LB is actually ubiquitinated and 
does not simply colocalize with ubiquitin (Hasegawa et al., 2002). 
I.4.3.1. Ubiquitinated α-syn is a pathological hallmark of PD  
The link between ubiquitinated α-syn and PD pathogenesis was provided by studies showing 
that this PTM was only present in samples from PD patients and more specifically in insoluble 
fractions of PD and DLB brain samples but not in controls (Hasegawa et al., 2002, Tofaris et al., 
2003, Anderson et al., 2006). Furthermore, α-syn was shown to be mono-, di- and to a lesser 
extent tri-ubiquitinated (Hasegawa et al., 2002, Sampathu et al., 2003, Tofaris et al., 2003, 
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Anderson et al., 2006). Interestingly, some of the ubiquitinated forms of α-syn were also shown 
to be phosphorylated at S129 (Hasegawa et al., 2002, Tofaris et al., 2003). The sites of 
ubiquitination within α-syn have been identified using mass spectrometry analysis of LB-
derived materials and were identified as K12, K21 and K23 (Anderson et al., 2006). 
 
 
 
Figure I-23. Immunoblots revealing that mono- and di-ubiquitinated α-syn is phosphorylated at S129. 
Immunoblot analysis of PD/DLB brain samples using antibodies for α-syn (LB509), pS129 α-syn and ubiquitin. 
Figure from Hasegawa et al. (Hasegawa et al., 2002) 
 
• E3 ligases and DUBs  
The conjugation of a single ubiquitin moiety or polyubiquitin chains on lysine residue relies on 
the combined enzymatic activity of a E1 ligase (Ubiquitin-activating enzyme), a E2 ligase 
(Ubiquitin-carrier enzyme) and a E3 ligase, that through substrate recognition, determines the 
site of modification (Pickart, 2001, David et al., 2011). Several E3 ligases have been reported to 
ubiquitinate α-syn in vitro and in vivo. α-syn is monoubiquitinated in vitro and in cell-culture 
models by Seven in absentia homologue-1 (SIAH-1) at residues 12, 21, 23 (same residues as in 
the LB) but also at lysines 10, 34, 43, and 96 (Lee et al., 2008b, Rott et al., 2008). Nedd4 
polyubiquitinates α-syn through K63 ubiquitin chains mainly on K12 and K96, and on K23, 45 
and 58 to a lesser extent (Tofaris et al., 2011) (Figure I-24). Other E3 ligases such as TRAF6  
and CHIP also ubiquitinate α-syn (Zucchelli et al., 2010) (Kalia et al., 2011). The USP9X 
enzyme was recently reported to deubiquitinate α-syn (Rott et al., 2011). 
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Figure I-24. Ubiquitination sites in vivo and in vitro 
SIAH-1 and Nedd4 ligases ubiquitinate α-syn in vitro at major sites (thick arrows) and at other sites to a lesser 
extent (dotted arrows). In vivo, α-syn is ubiquitinated at K12, K21 and K23 while in cell-based studies where α-syn 
and ubiquitin were co-expressed, α-syn shows ubiquitination at K6, K10 and K12. In vitro ubiquitination assays 
using rabbit reticulocytes of monomeric or fibrillar α-syn also results in heterogeneous ubiquitination sites.  
 
• Ubiquitinated α-syn and aggregation  
The fact that many α-syn inclusions in PD patients and Tg mice brains are not immunoreactive 
to anti-ubiquitin antibodies suggests that ubiquitination of α-syn is not required for its 
aggregation in vivo and that aggregation of α-syn precedes its ubiquitination (Sampathu et al., 
2003). Consistent with this hypothesis, in vitro ubiquitination experiments conducted with pre-
formed α-syn fibrils resulted in mono- and di-ubiquitinated forms that recapitulated the same 
ubiquitination pattern of α-syn obtained from brain samples, while in vitro ubiquitination of 
monomeric α-syn resulted predominantly in polyubiquitinated species (Sampathu et al., 2003). 
The sites of ubiquitination were furthermore dependent on the aggregation state of the protein. 
Nonaka et al. showed that the sites of ubiquitination of fibrillar α-syn resembled those occurring 
in vivo (Figure I-24) (Nonaka et al., 2005). Initially, in vitro and cell culture studies suggested 
that ubiquitination of α-syn promotes its aggregation. Cell-based studies using over-expressed 
E3 ligase SIAH-1 reported an increase in α-syn aggregation. SIAH-1-ubiquitinated α-syn was 
only present in Triton-insoluble fractions of cell lysates and an increase in inclusion formation 
was reported in these cells (Lee et al., 2008b, Rott et al., 2008). In vitro aggregation assays also 
showed increased fibrillization of α-syn that had been ubiquitinated by SIAH-2 (Rott et al., 
2008). These results would lead to the speculation that α-syn ubiquitination might trigger LB 
formation. 
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• Ubiquitinated α-syn and toxicity  
Very few reports have investigated the relation between ubiquitination of α-syn and cell death. 
In one report, Lee et al. have shown that ubiquitination of α-syn by SIAH-1 enhances apoptotic 
cell death (Lee et al., 2008b). Different findings were reported from yeast models where an 
ortholog of the Nedd4 ligase rescued α-syn-induced toxicity (Tofaris et al., 2011). 
I.4.3.2. Functional role of ubiquitination  
Ubiquitination of proteins represents an important mechanism not only for targeting proteins for 
degradation via the proteasome, but also for regulating protein subcellular localization and 
interaction with other proteins. In the case of α-syn, several studies have shown that the 
ubiquitin-proteasome pathway is not the main pathway involved in regulating the degradation of 
α-syn (Ancolio et al., 2000, Cuervo et al., 2004, Mak et al., 2010). No accumulation of 
ubiquitinated α-syn was observed upon pharmacologically-induced impairment of proteasomal 
function (Rideout and Stefanis, 2002, Tofaris et al., 2003) while earlier reports were able to 
reveal the presence of ubiquitinated α-syn upon proteasomal inhibition (Rideout et al., 2001). 
Co-expression of α-syn and SIAH-1 did not result in an increase of α-syn steady-state levels in 
the presence of MG132, a widely used proteasome inhibitor (Lee et al., 2008b). However, 
incubation of α-syn with SIAH-2 in presence of purified 26S proteasomes resulted in its 
degradation while WT α-syn was not degraded (Rott et al., 2011). Interestingly, two 
independent groups have shown that non-ubiquitinated α-syn can be degraded by the 
proteasome (Bennett et al., 1999, Webb et al., 2003, Machiya et al., 2010). Recently, Goldberg 
and colleagues demonstrated that Nedd4-mediated ubiquitination accelerates the degradation of 
α-syn via the lysosomal-endosomal pathway (Tofaris et al., 2011).  Together, these studies 
suggest that ubiquitination may play a role in regulating the turnover of α-syn, but the extent of 
α-syn clearance and the pathways involved are dictated by the site and pattern of ubiquitination 
as well as the E3 ligase that is used.   
I.4.4. Truncation of α-syn  
I.4.4.1. Truncation of α-syn occurs in healthy and PD individuals  
Western-blot and Mass Spectrometry (MS) analysis of purified LB from patients with 
synucleinopathies revealed the presence of truncated forms of α-syn (Baba et al., 1998, 
Campbell et al., 2001, Liu et al., 2005, Anderson et al., 2006). These species were also observed 
in several Tg mouse models of PD (Giasson et al., 2002, Lee et al., 2002c, Liu et al., 2005). The 
observation that truncation of the C-terminal domain increases α-syn aggregation in vitro 
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(Crowther et al., 1998, Serpell et al., 2000, Murray et al., 2003, Hoyer et al., 2004) led to the 
hypothesis that proteolytic cleavage of α-syn at the C-terminus may be required for or involved 
in the initiation of α-syn aggregation in vivo. This hypothesis was supported by the finding that 
expression of the PD-linked mutations resulted in increased levels of truncated α-syn in SH-
SY5Y cells and in Tg mouse models of PD (Li et al., 2005). However, truncated forms of α-syn 
(of 12, 10 and 8 kD masses) were shown to also exist in samples from healthy individuals (Li et 
al., 2005) with the 12 and 10 kD masses representing around 10-25% of total α-syn levels. The 8 
kD species was however only found in insoluble fractions of mouse and human brains. 
Proteomic studies of α-syn isolated from LB has identified the following proteolytic products of 
α-syn in LB: 1-134, 1-133, 1-126, 1-122, 1-119, 1-115 and 1-96 (Anderson et al., 2006). 
• Proteases involved in the truncation of α-syn  
A number of proteases have been identified to cleave α-syn at its C-terminal domain: Neurosin 
generates a 1-80 residues fragment as a major truncated variant. Three additional minor species 
were observed in these studies: 1-97, 1-114 and 1-121 (Iwata et al., 2003, Kasai et al., 2008), 
Calpain I cleaves monomeric α-syn within the NAC region and fibrillar α-syn after residue 120 
(Mishizen-Eberz et al., 2003, Mishizen-Eberz et al., 2005), whereas Cathepsin D, a lysosomal 
enzyme, cleaves α-syn at its C-terminus (Sevlever et al., 2008). The following α-syn fragments 
were observed upon treatment with matrix metalloproteases:  1-54, 1-57, 1-78 and 1-79 (Sung et 
al., 2005, Levin et al., 2009). The 20S proteasome also cleaves α-syn and generates truncated 
forms, but only when α-syn is in a free, non-vesicle bound state (Liu et al., 2005) (Figure I-25) 
 
Figure I-25. Truncated variants of α-syn generated by proteolysis 
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• Effect of truncations on aggregation and toxicity  
In vitro aggregation assays of α-syn 1-87 (Serpell et al., 2000), 1-110 (Crowther et al., 1998, 
Murray et al., 2003, Liu et al., 2005), 1-108 (Hoyer et al., 2004), 1-120 (Liu et al., 2005) 
(Crowther et al., 1998, Serpell et al., 2000, Murray et al., 2003, Li et al., 2005), 1-123 (Li et al., 
2005), 1-124 (Hoyer et al., 2004) and 1-130 (Crowther et al., 1998, Murray et al., 2003) have 
consistently showed that removal of the C-terminal acidic residues enhances α-syn fibril 
formation and that aggregates formed by truncated variants can seed the aggregation of the full-
length protein (Liu et al., 2005).  
In cell culture studies, overexpression of the truncated variants 1-110 and 1-120 resulted in 
increased vulnerability of cells to oxidative stress compared to the full-length protein, even 
when substoichiometric amounts of truncated variants were present (Liu et al., 2005).  
The effect of α-syn truncation on aggregation and toxicity was also investigated in various 
animal models of synucleinopathies. Drosophila models expressing the truncated 1-87 form 
showed increased accumulation of α-syn into large inclusion bodies and enhanced neurotoxicity 
(Periquet et al., 2007). Tg mice over-expressing the fragment 1-120 in α-syn KO mice showed 
the presence of α-syn-positive inclusions in the SN and olfactory bulb and increased motor 
dysfunction (Tofaris et al., 2006). Finally, Tg mice overexpressing 1-130 α-syn exhibited 
selective DA neuron loss, albeit without cytoplasmic inclusions (Wakamatsu et al., 2008). This 
could be due to the interaction between mouse and human α-syn in this model, which could be 
preventing its fibrillization as suggested by in vitro data (Rochet et al., 2000). Moreover, the 
over-expression of truncated α-syn in animal models reflects neither the physiological nor the 
pathological conditions in PD since only a small fraction of α-syn is truncated in the brain of PD 
patients (Anderson et al., 2006).  
I.4.5. Other PTM: acetylation, nitration, sumoylation 
I.4.5.1.  Acetylation 
α-syn is ubiquitously acetylated at its N-terminal Met residue (Anderson et al., 2006). Recent 
studies from our group and others have shown that N-terminal acetylation α-syn does not 
significantly influence its secondary structure, aggregation propensity or subcellular localization 
as compared to the WT protein (Fauvet et al., 2012a, Kang et al., 2012, Maltsev et al., 2012, 
Trexler and Rhoades, 2012).  
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I.4.5.2. Nitration 
Oxidative stress is one of the major pathways that have been implicated in α-syn-induced 
toxicity and neurodegeneration (section I.3.6.4). Released reactive oxygen and nitrogen species 
modify α-syn to generate species containing 3-nitrotyrosine, a modification that has been 
identified in LB (Giasson et al., 2000). Oxidative stress-induced covalent cross-linking of α-syn 
via o-o′-dityrosine formation was also detected in vitro and shown to contribute to the formation 
of stable α-syn oligomers (Souza et al., 2000a). 
I.4.5.3. Sumoylation 
α-syn has been shown to be sumoylated at lysines 96 and 102. Recent studies suggested that α-
syn sumoylation is induced by proteasomal impairment (Kim et al., 2011, Krumova et al., 
2011). The conjugates responsible for this modification were identified as SUMO1, and to a 
lesser extent SUMO2 (Dorval and Fraser, 2006). Although the consequences of α-syn 
SUMOylation remain unexplored, recent studies suggest that α-syn sumoylation blocks α-syn 
aggregation and that small amounts of the sumoylated proteins (around 10%) are sufficient to 
inhibit aggregation (Krumova et al., 2011). 
 
 
I.5. α-syn studies of Tyr phosphorylation  and ubiquitination: limitations and 
proposed solutions 
I.5.1. Studies of α-syn phosphorylation 
I.5.1.1. Use of phosphomimics 
Previous studies that aimed at investigating the phosphorylation of α-syn at Serine or Tyrosine 
residues relied primarily on the use of natural amino acids that mimic the phosphorylation state 
of these residues. When the identity of the natural kinases is not known, substitution of Serine 
and Threonine by Glutamate or Aspartate is used to mimic the phosphorylated states of both 
residues (pS/pT) in cell culture and in vivo studies (Figure I-26). Whereas the structure and 
charge similarity between pS/pT and E/D allows for mimicking some aspects of 
phosphorylation, there are no natural amino acids that mimic the phosphorylated state of 
tyrosine residues (pY). Therefore, the results from studies where E/D substitution is used to 
mimic tyrosine phosphorylation should be interpreted with caution. 
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Figure I-26. Structure of pSer, pTyr and their phosphomimics : Glu and Asp 
Due to charge similarity (net charge of -1 for E/D and -2 for pS), natural amino acids mimicking phosphorylation at 
serine have been used. 
 
Advantages and limitations of using phosphomimics 
One major advantage of using phosphomimics is their easy generation by site-directed 
mutagenesis. When the phosphomimicking substitutions reproduce key features of true 
phosphorylation, they provide a valuable tool to investigate cross-talk between different PTM 
and between phosphorylation and disease-associated mutations. In addition, the use of S/T ? 
E/D substitution allows for mimicking constitutive phosphorylation. However, it has become 
increasingly clear that phosphomimics do not reproduce all aspects of phosphorylation, as the 
substitution of Ser by Glu or Asp in different proteins and model systems has yielded different 
results. Herein, I will present a brief overview of previous studies that investigated α-syn 
phosphorylation through the use of phosphomimicking substitutions and our current 
understanding of the impact of these substitutions on α-syn aggregation and toxicity in vitro and 
in vivo.  
• Phosphomimics do not fully reproduce phosphorylation 
The first detailed study that compared the structure and aggregation propensity of 
phosphomimics and truly-phosphorylated α-syn at S129 (pS129) was carried out by Paleologou 
et al. (Paleologou et al., 2008). The results from this study demonstrated that the 
phosphomimicking mutations (S129E/D) do not reproduce all aspects of phosphorylation in 
vitro and in cell culture. Indeed, while the secondary structure of WT, S129E/S129D and pS129 
was random-coiled and the binding of these proteins to lipid vesicles was unaffected, differences 
emerged from high-resolution NMR studies that showed the disruption of long-range 
interactions between the N- and C-terminal domains of α-syn. Moreover, a more extended 
conformation for the phosphorylated protein, but not S129E/D, was reported as calculated by its 
hydrodynamic radius (WT: 28.2 Å, S129D: 28.3 Å, S129E: 27.8 Å, pS129: 35.3 Å). In addition, 
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in vitro fibrillization assays revealed a marked difference between the phosphomimics and 
pS129 α-syn: the S129A mutant, which is commonly used to block phosphorylation in vivo, 
aggregated more readily than the WT protein while S129E and S129D exhibited similar 
fibrillization propensities to WT α-syn. On the other hand, natively phosphorylated α-syn at 
S129 completely abolished α-syn aggregation, even in presence of 80% of WT α-syn. 
Interestingly, the effect of α-syn phosphorylation at S87 on its aggregation properties was 
reproduced by S87D or S87E. Both the phosphorylation at S87 and the substitution of S with 
E/D resulted in a marked inhibition of α-syn fibril formation in vitro and in vivo (Paleologou et 
al., 2010, Oueslati et al., 2012). 
The S129A and S129D α-syn mutants have been used in animal models to elucidate the effect of 
phosphorylation at this residue on α-syn aggregation and toxicity. Phosphorylation of α-syn at 
S129 was initially thought to block its aggregation since the overexpression of S129A α-syn in 
Drosophila and rat models resulted in an increased aggregation (Chen and Feany, 2005, 
Azeredo da Silveira et al., 2009). However, it later became clear that the increased aggregation 
propensity of this protein is due to the S?A mutation rather than to the blockade of 
phosphorylation at this residue; (Paleologou et al., 2008). Whether the increased toxicity of this 
mutant, which was reported by two independent studies using the rat model of PD, is also 
caused by enhanced aggregation of this mutant remains to be determined. Nevertheless, the 
increased effect on toxicity that was shown for S129A in the rat model was not reported in 
Drosophila, where S129A was not toxic. On the other hand, expression of the phosphomimic 
S129D in fly models or co-expression of WT α-syn and GRK kinases in rats resulted in the loss 
of DA neurons and increased motor deficits (Chen and Feany, 2005, Sato et al., 2011). This 
discrepancy in terms of the toxicity of these mutants may arise from the fact that the fly, unlike 
the rat, does not express a homolog of α-syn, which could potentially influence the aggregation 
of the human protein. Indeed, in vitro studies have shown that mouse α-syn (one amino acid 
difference with rat α-syn) had a higher fibrillization propensity than human α-syn and that 
mixing both α-syn proteins resulted in the formation of more oligomers and less fibrils (Rochet 
et al., 2000). Bearing in mind recent findings that support the toxic effects of oligomers, the 
interaction between rat and human α-syn could exacerbate α-syn toxicity in rodent models and 
therefore studies using α-syn KO animals are needed to verify this hypothesis. Moreover, to 
investigate the extent of aggregation in the different animal models, different approaches were 
followed such as the use of proteinase K digestion in Drosophila in some studies and Thioflavin 
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S staining of rat brain sections in others, thus making a direct comparative assessment of 
aggregation quite difficult (Chen et al., 2005, Azeredo da Silveira et al., 2009).  
To summarize, phosphomimics exhibit the same fibrillization rate as WT α-syn both in vitro and 
in vivo while pS129 was reported to inhibit α-syn aggregation in vitro and to alter its structure 
and subcellular localization. It is thus difficult to extrapolate the relationship between 
phosphorylation and aggregation in vivo using phosphomimics. Hence, the identification of the 
natural kinases that specifically phosphorylate α-syn at this residue is crucial for accurate 
determination of the effect of this modification on α-syn aggregation and toxicity in animal 
models of synuleinopathies. 
I.5.1.2. Use of kinases 
Several kinases have been reported to phosphorylate α-syn at S129, including CK1 , CK2, 
GRKs and PLKs (sections I.4.1.1and I.4.1.2). However, only CK1 and PLKs phosphorylate α-
syn efficiently in vitro and in cell culture and co-localize with α-syn in DA neurons. While 
PLK2 and PLK3 phosphorylate α-syn specifically at S129, CK1-mediated phosphorylation 
occurs at S129 and S87. Therefore, without the use of mutations that block phosphorylation at 
S87 or S129, only PLK2 or PLK3 can be used today to induce specific and efficient 
phosphorylation of α-syn in vitro and in vivo. Recent studies suggest that expression of PLK2 in 
C.elegans and primary neuron models is neuroprotective (Gitler et al., 2009). Similarly, the 
tyrosine kinase Syk phosphorylates α-syn at the three tyrosines Y125, Y133 and Y136 in vitro. 
Other tyrosine kinases are more specific but much less efficient. Therefore, site-specific 
phosphorylation at tyrosine residues is only possible today by using Syk combined with 
mutation of the remaining tyrosine residues to phenylalanine.  
The use of a specific but non-efficient kinase is possible but one has to always take into 
consideration the level of phosphorylation achieved and the resulting heterogeneity of α-syn 
species when interpreting the results. Therefore, there is an urgent need to identify the natural 
kinases and phosphatases that are responsible for regulating α-syn phosphorylation at different 
residues. These advances will facilitate studies aimed at determining the effects of 
phosphorylation in vivo and validating these kinases as potential targets for the treatment of PD.  
I.5.1.3. Use of nonsense suppression methodology 
An alternative approach for the study of protein phosphorylation is the use of nonsense 
suppression methodology. This methodology was pioneered by P. Schultz’s group and is based 
on the generation of a pair of modified tRNA and aminoacyl-tRNA synthetase that has been 
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evolved to incorporate a modified amino acid at the position of an amber stop codon in the gene 
where the modified amino acid is to be incorporated. To date, more than 50 amino acids have 
been incorporated into proteins, spanning the range of naturals, D-amino acids, phosphorylated, 
and photocaged amino acids (Young and Schultz, 2010). The genetic code was expanded in 
2011 with the addition of phosphoserine (Park et al., 2011). This approach allowed site-specific 
incorporation of two phosphoserine residues in the activated form of human mitogen-activated 
ERK activating kinase 1 (MEK1). However, one major drawback of this approach remains the 
low yields of modified proteins obtained. In the case of MEK1, a yield of 25 micrograms of 
protein per liter of culture medium was reported. Phosphotyrosine residues have not been 
introduced in proteins using this methodology but nonhydrolyzable phosphorylated tyrosine 
analogues were successfully incorporated into the enzyme serotonin N-acetyltransferase (Zheng 
et al., 2005b, Young and Schultz, 2010). Another major limitation of the nonsense suppression 
method is the requirement for large quantities of aminoacylated tRNAs and the restricted 
number of unnatural amino acids that can be co-incorporated in a protein.  
I.5.2. Studies of α-syn ubiquitination 
In comparison to protein phosphorylation, investigating the effect of site-specific ubiquitination 
(mono- and poly-ubiquitination) in vitro is even more challenging, mainly due to the lack of 
methodologies that allow the site-specific introduction of these modifications without the 
introduction of mutations into the protein of interest. Furthermore, no natural amino acid can be 
used as a mimic for ubiquitinated lysines. In LB, α-syn has been shown to be mono-, di-, and 
sometimes triubiquitinated at K12, K21 and K23, raising questions about the nature of the 
molecular mechanisms that regulate this process in vivo. 
I.5.2.1. Methods generating native isopeptide bonds 
• E3 ligases 
The E3 ligases SIAH-1 and SIAH-2 have been shown to monoubiquitinate α-syn at K12, K21 
and K23 but also at other lysines (section I.4.3). Results from two independent groups revealed 
that SIAH-mediated ubiquitination results in an increase of α-syn fibrillization but yielded 
contradictory results on the effect of SIAH-1/2 on α-syn degradation (Lee et al., 2008b, Rott et 
al., 2008, Rott et al., 2011). The authors did not investigate the roles of ubiquitination at each 
lysine residue because of the requirement of multiple single-point mutations in the sequence of 
α-syn (which contains 15 lysine residues) to achieve site-specific ubiquitination. Recently, it 
was reported that Nedd4 polyubiquitinates α-syn mainly at K12 and K96, as well as at other 
lysines; however, the identified sites and the nature of the ubiquitin conjugates are not the same 
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as in the LB (K12, K21 and K23 are ubiquitinated in vivo). The data presented by these studies 
clearly show that only a small percentage of α-syn is ubiquitinated in presence of E3 ligases as 
evidenced by the requirement for immunoprecipitation to detect ubiquitinated forms of α-syn by 
western blotting (Rott et al., 2008, Tofaris et al., 2011). The investigation of the sub-cellular 
localization of ubiquitinated α-syn is impossible for the moment due to the absence of antibodies 
that specifically discriminate ubiquitinated α-syn from the WT protein.  
• Use of rabbit reticulocytes 
To study ubiquitination in vitro and to circumvent the use of E3 ligases, rabbit reticulocyte 
fractions that contain the enzymatic machinery necessary for ubiquitin conjugation are 
commonly used (Hasegawa et al., 2002, Nonaka et al., 2005). While this approach yielded 
mainly mono-and di-ubiquitinated forms of α-syn, similar to what is observed in the human 
brain, the sites of these modifications were not the same and were highly dependent on the 
polymerization state of the protein: when α-syn was monomeric, rabbit reticulocyte-based 
ubiquitination resulted in modification of K21, K23, K32 and K34, while fibrillar α-syn was 
ubiquitinated at K6, K10 and K12 (Nonaka et al., 2005). This methodology is also restricted for 
in vitro studies and cannot be applied for cell-based studies or in vivo.  
I.5.2.2. Non-native isopeptide bonds 
To circumvent the use of enzymatic reactions for the generation of ubiquitinated proteins, 
chemists have developed an array of chemical reactions for the conjugation of ubiquitin to 
proteins through isopeptidic-like bonds. Site-specificity was achieved but non-native isopeptide 
bonds were generated in the ligation reaction: Oxime (Shanmugham et al., 2010), triazole (Yin 
et al., 2000, Rostovtsev et al., 2002, Weikart et al., 2012) and disulfide-based (Chatterjee et al., 
2010, Chen et al., 2010) isopeptide-like bonds allowed the conjugation of a ubiquitin moiety to 
the protein of interest through either irreversible or unstable bonds ( 
Figure I-27). These approaches have been successfully applied to generate monoubiquitinated 
proteins such as histone 2B (H2B) and proliferating cell nuclear antigen (PCNA) as well as di-
ubiquitin chains (section I.5.3.3). Recently, a disulfide-bond strategy was used to generate 
several forms of monoubiquitinated α-syn at different lysine residues and enabled the site-
specific investigation of monoubiquitination on its aggregation propensity (Meier et al., 2012). 
Cysteine mutations were introduced in the sequence of α-syn as substitutions of lysines 6, 10, 
12, 21, 23, 32, 34, 46 and 96. The effect on aggregation was dependent on the site of 
ubiquitination since monoubiquitination at K23 and K10 slightly affected the rate of 
fibrillization but not its extent, while monoubiquitionation at other residues completely inhibited 
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the aggregation (Meier et al., 2012). However, it is important to stress that the use of disulfide 
linkages does not mimic the native state of the protein and may influence its structure. 
Furthermore, the unstable nature of the disulfide bond prevents further use of these 
monoubiquitinated proteins in cellular assays or introducing these proteins into cellular 
environments, where they would be readily reduced back to free proteins through reduction by 
glutathione or other cellular reducing agents.  
 
 
Figure I-27. Different approaches for the generation of isopeptide bonds for ubiquitin conjugation 
Several strategies have been used to generate monoubiquitinated proteins through the ligation of ubiquitin to the 
protein of interest via disulfide, oxime and triazole isopeptide-like bonds. 
 
I.5.3. Protein semisynthesis  
To overcome the limitations associated with the use of phosphomimicking mutations or the 
requirement for efficient and specific kinases to study the structural, functional and pathologic 
consequences of phosphorylation, a phosphorylated serine or tyrosine residue can be site-
specifically incorporated into the protein of interest using different chemical strategies. One 
obvious approach is based on the use of solid-phase peptide synthesis (SPPS), which was 
developed by Merrifield (Merrifield, 1986). This approach allows the incorporation of any 
unnatural amino acids in the sequence of a peptide of around 50-70 residues at maximum (Kent, 
1988). SPPS involves the attachment of the protected C-terminal amino acid on a polymer-based 
resin and the assembly of the subsequent amino acids stepwise from the C-terminus to the N-
terminus. Two types of protecting groups are needed in SPPS: a temporary protecting group of 
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the α-amino group of the residues, such as Fluorenylmethyloxycarbonyl (Fmoc) or tert-
butyloxycarbonyl (Boc) groups that are removed with base or acid treatment respectively, after 
the formation of each peptide bond; and side-chain protecting groups that are removed after 
assembly of the complete peptide chain (Figure I-28). Peptide bond formation is carried out by 
activating the carboxylic acid moiety of the residue to be attached using coupling agents such as 
O-Benzotriazole-N,N,N',N'-tetramethyl-uronium-hexafluoro-phosphate (known as HBTU) in 
presence of HOBt (Hydroxybenzotriazole) to eliminate side-reactions such as racemization at 
the alpha carbon. Cleavage of Fmoc-based peptides is carried out in Trifluoroacetic acid (TFA) 
in the presence of scavengers to trap reactive byproducts. Boc-based peptides are cleaved at low 
temperature with Hydrogen fluoride (HF) or with TFA/TFMSA (trifluoromethanesulfonic acid). 
The peptide is subsequently purified by reversed-phase HPLC and characterized by mass 
spectrometry. Recent advances in chemistry have allowed for efficient coupling conditions, 
minimization of side-reactions and enhanced peptide solubility, all of which have contributed to 
the development of fully-automated machines for the synthesis of peptides.   
 
 
 
Figure I-28. General SPPS scheme 
The last residue in the desired sequence is attached via its C-terminal carboxylic group to a polymer resin. 
Deprotection of the amine and activation of the carboxylic acid of the next residue allows elongation of the peptide 
and formation of a peptide bond. The same cycle is repeated for the remaining residues. Final deprotection allows 
cleaving the peptide from the resin and deprotection of the side-chains. Figure adapted from CEM website 
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I.5.3.1. Native Chemical ligation 
SPPS allows the assembly of peptides on solid support of up to 50-70 amino acids (depending 
on the sequence) (Kent, 1988, Dawson and Kent, 2000). To overcome this limitation, chemical 
ligations method were developed in the early 1990s, which have enabled the preparation of 
proteins and peptides from the ligation of unprotected peptide fragments (Kent, 1988). In 1994, 
Dawson and colleagues reported the ligation of two unprotected peptides to synthesize human 
Interleukin-8 (Dawson et al., 1994). The reaction was termed “Native Chemical Ligation” 
(NCL) and had the following characteristics: it was chemoselective and was performed in 
aqueous solutions at physiological pH, but compared to previous chemical ligation strategies, 
which generated thioesters (Schnolzer and Kent, 1992), thioethers, (Englebretsen et al., 2002), 
oximes (Thumshirn et al., 2003), thiazolidines (Liu and Tam, 1994) and disulfide bonds at the 
ligation sites (Chatterjee et al., 2010), this new reaction allowed for the generation of a native 
peptide bond at the ligation site. The reaction occurs between a peptide bearing a C-terminal 
thioester with a peptide containing an N-terminal cysteine. The first step of the reaction is 
mediated by a reversible thiol-thioester exchange between an electrophilic thioester at the C-
terminus of peptide 1 and the nucleophilic thiol of the cysteine residue at the N-terminus of 
peptide 2 (Figure I-29). This transthioesterification reaction is followed by a spontaneous S-N 
acyl shift to generate an amide bond at the ligation site. The ligation occurs hence at a cysteine 
residue and the presence of other cysteines in the sequence does not interfere since the 
irreversible S-N acyl rearrangement can only occur with an N-terminal cysteine (Hackenberger 
and Schwarzer, 2008).  
 
Figure I-29. Native Chemical Ligation Mechanism. 
 
• Catalytic thiol cofactors 
The nature of the thioester is very important for NCL. Indeed, aryl thioesters are more reactive 
than alkyl thioesters but they are also more prone to hydrolysis. The common procedure that is 
widely followed is based on the preparation of peptide thioesters as alkyl form for better 
handling and storage and the in situ conversion to aryl thioesters during the NCL reaction 
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through the addition of a thiol catalyst. The most common thiol catalysts used to date are 
thiophenol, benzyl mercaptan and 4-mercaptophenylacetic acid (MPAA) (Johnson and Kent, 
2006). The addition of the thiol catalyst also helps to maintain the cysteine at the N-terminus of 
peptide 2 in a reduced state. 
• Ligation at Alanine 
Native chemical ligation requires cysteine residues and lacking such residues in proteins 
requires the introduction of cysteine residues at the ligation site. To circumvent the introduction 
of unnatural cysteine residues in such proteins, Yan and colleagues have developed a 
desulfurization method that allow for the conversion of cysteine residues back to alanine (Yan 
and Danishefsky, 2001), which then enable carrying out ligation reactions at alanine residues, 
which occur more frequently in proteins. Hydrogenolytic desulfurization using Raney nickel 
was also used; however prolonged treatment with Raney nickel was found to result in 
demethylthiolation of methionine residues. A metal-free desulfurization step was developed in 
2007 by Wan and colleagues, which relied on the reaction between tert-butyl mercaptan and 
trialkylphosphite in presence of a radical initiator (Wan and Danishefsky, 2007). This reaction 
accommodates methionine and different cysteine protecting groups such as Acm and Thz. These 
advances expanded the use of NCL to prepare proteins of increasing size and sequence 
complexity.  
• Ligation at other residues 
Chemical advances have allowed synthesizing β-thiol-containing amino acid analogues, which 
in turn have enabled performing NCL at sites other than cysteine and alanine. After 
desulfurization, phenylalanine, leucine, valine, threonine and glutamine can be generated at the 
ligation site (Hackenberger and Schwarzer, 2008, Butterfield et al., 2012a) (Figure I-30).  
 
  
 67 
  
 
 
Figure I-30. Desulfurization allows performing ligations at Ala, Phe, Thr, Leu, Val and Gln 
  
• Synthesis of peptide thioesters by SPPS 
Peptide thioesters can be prepared using Fmoc and Boc-based SPPS (Hackenberger and 
Schwarzer, 2008). For the purpose of this thesis, I will only describe thioester formation on 
Fmoc-based peptides. The thioester is usually introduced at the C-terminus of the protected 
peptide after cleavage from a 2-chlorotrityl resin under mild acidic conditions. The carboxylic 
group at the C-terminus is activated by a strong coupling reagent such as PyBOP, which is then 
attacked by a thiol to form a thioester. A final deprotection step releases the side-chain 
protections. However, using this method, there is a high risk of epimerization at the C-terminal 
residue (Hackenberger and Schwarzer, 2008) (Figure I-31.A).  
Another Fmoc-based strategy relies on the in-situ synthesis of the thioester. The peptide is 
assembled on a resin containing a protected thiol group on β-mercapto-α-hydroxypropionic 
acid. After cleavage from the resin and deprotection of the thiol, an intramolecular O-S acyl 
shift generates the thioester (Botti et al., 2004, Hackenberger and Schwarzer, 2008) (Figure 
I-31.B).  
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Figure I-31. Generation of peptide thioesters 
  
Thioester formation using an N-acyl urea-based C-terminal group has been reported recently 
(Blanco-Canosa and Dawson, 2008). A 3,4-diaminobenzoic acid group (Dbz) is added onto a 
Rink amide MBHA resin before the coupling of the first residue. After peptide assembly, the C-
terminus is activated through acylation with p-nitrophenylchloroformate followed by the 
addition of a base to promote the intramolecular attack of the anilide to form the resin-bound N-
benzimidazolinone (Nbz). The peptide is subsequently cleaved in TFA. The Nbz group is a good 
leaving group which can be used in place of a thioester during NCL, however it is not as stable 
as alkyl thioesters, therefore thiolysis of the Nbz group is often used to store the peptides as 
alkyl thioesters (Figure I-31.C). 
I.5.3.2. Expressed protein ligation 
To date, a large number of proteins of various sizes (up to 300 amino acids) have been prepared 
using NCL (Hackenberger and Schwarzer, 2008, Kumar et al., 2011). Catalytically active 
enzymes and membrane proteins have also been successfully generated (Hackenberger and 
Schwarzer, 2008). However, despite major advances in ligation reaction methodologies, the size 
limitation in SPPS and the requirement of multiple NCL reactions to prepare large proteins 
resulted in low yields and thus limited the utility of NCL to mostly small proteins. To overcome 
these limitations, two independent groups developed a strategy that combines the 
chemoselective ligation of NCL with the possibility to produce longer protein fragments via 
recombinant expression of proteins in E. coli (Evans et al., 1998, Muir et al., 1998). The 
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Expressed Protein Ligation approach (EPL) is based on the reaction between a protein fragment 
containing a thioester and another fragment harboring a cysteine at its N-terminus. Overcoming 
the size restriction in NCL through the development of EPL allowed the introduction of PTMs, 
fluorescent probes, unnatural amino acids, and stable isotopes in proteins (Muir, 2003a). Ion 
channels and membrane proteins were successfully produced using semisynthesis (Valiyaveetil 
et al., 2002, Olschewski and Becker, 2008) and the reaction could also take place in living cells 
(Giriat and Muir, 2003). 
Depending on the position of the modification, two strategies are to be followed: if the modified 
amino acid is in the N-terminal part of the protein, a peptide thioester, containing the modified 
amino acid, will be produced by SPPS and ligated to a protein fragment expressed in E. coli 
with an N-terminal cysteine (Figure I-32). If the modification is in the C-terminal domain, a 
protein thioester is produced in bacteria using intein-mediated splicing (Figure I-33) and the C-
terminal fragment containing the modified residue is prepared by SPPS (with an N-terminal 
cysteine) (Figure I-32). 
Although a wide variety of proteins can be prepared by semisynthesis, practical considerations 
have to be considered before designing an EPL strategy (Szewczuk et al., 2009): i) the modified 
amino acid to be introduced in the protein needs to be positioned within 50 amino acids from the 
N- or C-terminus of the protein of interest due to the size limitation imposed by SPPS, ii) the 
folding and the solubility of the truncated protein segments – to be expressed in fusion with the 
intein or with an N-terminal cysteine – might be different from the full-length protein and iii) 
the ligation site has to be wisely chosen so as not to disturb the native sequence of the protein 
and not to disrupt the kinetics of the NCL reaction. Indeed, the identity and steric hindrance 
induced by the amino acid that is adjacent to the ligation site influences the ligation kinetics 
(Hackenberger and Schwarzer, 2008).  
 
Figure I-32. Strategies for the semisynthesis of proteins: N- and C-terminal modifications 
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• Generation of protein thioesters 
Synthetic peptide thioesters or peptides containing an N-terminal cysteine are readily prepared 
by SPPS and the generation of recombinant protein fragments with an N-terminal cysteine 
residue relies on cloning and molecular biology (Figure I-32). The missing piece of the puzzle 
was the generation of recombinant protein thioesters. The answer came from nature itself and 
protein engineering approaches that allowed using protein splicing for EPL.  
In 1990, it was observed that the open-reading frame for the gene of Saccharomyces cerevisiae 
vacuolar ATPase (Sce VMA) was twice as large as the actual encoded protein and that 454 
amino acids that were derived from the translation of the protein had no similarity to vacuolar 
ATPases (Noren et al., 2000). Compared to RNA splicing that removes introns from the coding 
sequence, protein splicing involves the removal of intein sequences from a protein precursor. 
Inteins should be seen as around 100 amino acid enzymes that break two peptide bonds and 
ligate the two excised exteins. Over 300 inteins have been identified with low sequence 
similarity, however the key residues in the splicing event, which are situated at the junction 
between the intein and the extein, are conserved (Saleh and Perler, 2006).  
• Mechanism of protein splicing 
The sequence of the majority of inteins begins with a Cys or Ser residue and ends with an Asn 
while the first residue of the C-extein is Cys, Ser or Thr. The first step in intein-mediated protein 
splicing is an N-S or an N-O acyl shift of Cys/Ser1 of the intein (Figure I-33). To overcome the 
high energy-demanding rearrangement of the peptide bond to an ester or thioester bond, a 
conformational change was reported in inteins that pushed the equilibrium toward the thioester 
bond (Klabunde et al., 1998, Romanelli et al., 2004). In addition to the strained geometry, 
deprotonation of the nucleophilic thiol or hydroxyl of Cys/Ser1 is required as well as the 
protonation of the leaving amino group. A basic residue was identified in proximity of Cys1 that 
fulfills this role (Saleh and Perler, 2006).  
The second step of the process is a transthioesterification that involves the nucleophilic attack of 
the thiol or hydroxyl group of the first residue of the C-extein (Cys/Ser/Thr) termed +1 on the 
thioester at the junction between the N-extein and the intein. In this step, the N-extein is brought 
to the C-extein through the Cys/Ser +1. A conformational change of the intein as well as the low 
pKa of Cys+1 (estimated to be around 5.8) were suggested to favor the nucleophilic attack 
(Saleh and Perler, 2006). 
The third step involves the cyclization of the last residue of the intein (Asn) to release the intein 
with a succinimide C-terminus. In the last step, the amide bond is restored with a Cys or Ser 
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between the N-extein and the C-extein after a S-N or O-N acyl shift (Noren et al., 2000, Muir, 
2003a, Saleh and Perler, 2006).  
• Intein engineering for EPL 
Mutation of the last residue of the intein (Asn) to Ala promotes only the first step of the protein 
splicing and blocks the succinimide formation. Addition of thiols such as DTT or MESNa to the 
mutated intein results in the thiolysis of the thioester bond that was formed in the first step of the 
protein splicing, and the release of the N-extein as a thioester. Commercially available vectors 
from New England Biolabs contain the modified mini-inteins Saccharomyces cerevisiae 
vacuolar ATPase (Sce VMA1) and the Mycobacterium xenopi DNA Gyrase A (Mxe GyrA) in 
fusion with chitin-binding domain for purification purpose (Muir, 2003a). 
 
Figure I-33. Mechanism of intein splicing 
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Figure I-34. Production of protein thioesters using modified inteins 
 
• Generation of proteins with an N-terminal Cys 
Recombinant proteins with an N-terminal cysteine residue can be prepared using different 
approaches with typically high yields. The most straightforward approach is the introduction of 
a Cys codon after the initiating ATG codon in the gene of the protein of interest. The initiating 
Met will be cleaved by endogenous methionine aminopeptidases during translation, releasing a 
Cys at the N-terminus (Muir, 2003a). However, the activity of the enzymes depends on the 
identity and bulkiness of the amino acid that is adjacent to the initiating Met residue (Hirel et al., 
1989). To overcome this limitation, a protease recognition sequence can be added upstream of 
the Cys residue. Factor Xa and Tobacco Etch Virus (TEV) recognition sequences have been 
used to generate a free Cys after incubation with the protease (Muir, 2003a). In a recent study, 
Bartke and colleagues elegantly designed a plasmid that expressed their protein of interest with 
the modified TEV recognition under the control of the T7 promoter, along with the gene 
encoding the TEV protease under the control of an AraC promoter. Coexpression of the TEV-
cleavable truncated protein with TEV protease in E. coli leads to processing into a truncated 
histone in vivo (Bartke et al., 2010). To improve the solubility of the protein fragment, some 
reports have relied on the fusion with the SUMO tag (11kD). To demonstrate the feasibility of 
this approach, fragments of a membrane protein have been prepared with the SUMO tag 
upstream of the Cys residue and subsequent incubation with SUMO protease released the free 
Cys (Komarov et al., 2009).  
An alternative approach to generate proteins with an N-terminal Cys residue is based on the 
fusion to an intein that is engineered to undergo cleavage at its C-terminus as a result of a pH or 
temperature change. Plasmids encoding the intein Methanobacterium thermoautotrophicum 
(Mth) RIR1 or Mxe GyrA or Ssp DnaB are commercially available from New England Biolabs 
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and allow releasing the N-terminal Cys of a protein of interest without the use of a protease 
(Evans et al., 1999, Muir, 2003a).  
 
Figure I-35. Different approaches to generate protein fragments with N-terminal Cys. 
  
I.5.3.3. Applications of protein semisynthesis for the generation of ubiquitinated proteins 
A large panel of natural modifications (phosphorylation, acetylation, oxidation, D-amino acids) 
and unnatural modifications (photocleavable groups, non-hydrolyzable phosphonates, 
fluorescent probes, cross-linking groups) were readily incorporated into proteins via 
semisynthesis (Muir, 2003a). However, other naturally-occurring modifications such as 
glycosylation and ubiquitination present additional challenges for protein semisynthesis. Indeed, 
ubiquitination requires the conjugation of a 75-residue protein residues via an isopeptide bond; 
and different types of sugar moieties of varying complexity can be added onto the side-chains of 
asparagine (N-glycosylation) or serine/threonine (O-glycosylation). In the case of 
ubiquitination, since the isopeptide bond could not be readily produced via standard EPL, 
different approaches were followed to generate ubiquitinated proteins with an unstable or 
irreversible isopeptide bond (Spasser and Brik, 2012).  
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Figure I-36. Chemical approaches to generate monoubiquitinated proteins via isopeptide-like bonds 
A: dichloroacetone-based approach (Yin et al., 2000) ,B: disulfide-based approach (Chatterjee et al., 2010, Chen et 
al., 2010, Meier et al., 2012), C: oxime-based approach (Shanmugham et al., 2010) , D and E: oxime-based 
approach (Eger et al., 2010, Weikart and Mootz, 2010, Weikart et al., 2012). Figure adapted from Spasser and Brik 
(Spasser and Brik, 2012). 
 
• Dichloroacetone-based isopeptide bond 
This approach is based on the cross-linking of two cysteine residues with dichloroacteone and 
was used for the generation of diubiquitin chains with K63, K48, K29 and K11 isopeptidic 
linkage (Yin et al., 2000). The lysines residues to be ubiquitinated in one ubiquitin were 
replaced by Cys while the C-terminal Gly residue of the other ubiquitin was also mutated to 
Cys. Addition of dichloroacetone resulted in the formation of ubiquitin dimers that were able to 
selectively inhibit the activity of DUB (Figure I-36.A) 
• Disulfide-based isopeptide bond 
Monoubiquitinated Histone 2B (H2B) at K120 was prepared through a disulfide-bond linkage. 
H2B was expressed in E.coli with a Lys ? Cys mutation at residue 120 (Chatterjee et al., 2010). 
Ubiquitin was expressed in fusion with an intein and addition of cysteamine yielded the 
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generation of ubiquitin with a C-terminal aminoethanethiol linker. Subsequent activation of 
H2B with a more reactive thiol (2,2′-dithiobis(5-nitropyridine) (DTNP)) in presence of the C-
terminally activated ubiquitin resulted in the generation of ubiquitinated H2B (Chatterjee et al., 
2010). Independently, Chen et al. described the generation of monoubiquitinated proliferating 
cell nuclear antigen (PCNA) using the same strategy (Chen et al., 2010). This approach allowed 
to generate milligram quantities of ubiquitinated proteins with good yields (80%) and to perform 
various structural studies (Chatterjee et al., 2010) or protein-protein interaction assays (Chen et 
al., 2010). The methodology can be easily extended to other proteins through the introduction of 
cysteines by single-point mutagenesis (Figure I-36.B) and was recently applied to the study of 
site-specific impact of monoubiquitination of α-syn on its fibrillization rate (Meier et al., 2012).  
• Oxime-based isopeptide bond 
The oxime-based approach relies on the condensation of an aldehyde-containing peptide with a 
peptide harboring an aminooxy group. The methodology was used to prepare peptide fragments 
derived from the diubiquitin chain (K63 and K48-linked) (Shanmugham et al., 2010). Using 
SPPS, a ubiquitin peptide where lysines were modified by aminoxyacetyl-l-diaminopropionic 
acid was prepared. Since the isopeptide bond between the two ubiquitin fragments could not be 
hydrolyzed by deubiquitinating enzymes, they were used as probes to investigate the specificity 
of the enzymes toward the substrate and it was revealed that the peptide sequence flanking the 
isopeptide bond is important for the recognition and the selectivity (Figure I-36.C).   
• Click chemistry-based isopeptide bond 
Click-chemistry allows the cycloaddition of azide-containing peptide onto an alkyne-containing 
peptide to produce a triazole at the ligation site (Rostovtsev et al., 2002). In a study by Weikart 
and colleagues, recombinant SUMO2 (a ubiquitin-like protein) and Ubc9 (an E2 ligase) were 
functionalized respectively with an alkyl and azide group. SUMO2 (with a deletion of the 
diglycine motif at the C-terminus) was fused to an intein and subsequently released as a 
thioester with MESNa. Reaction with propargylamine introduced the alkyne moiety while 
alkylation of the side chain of a cysteine residue in the substrate to be modified with 
iodoacetamide ethyl azide introduced the azide group (Figure I-36.D). The same group reported 
later the preparation of diubiquitin chains through click-chemistry and nonsense suppression 
methodology: p-azidophenylalanine (AzF) is incorporated in place of lysine residues, while 
SUMO2 is prepared as discussed earlier. By using this approach, conjugation of SUMO2 to the 
enzyme Ubc9 was reported (Weikart et al., 2012). 
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Other groups have also used click-chemistry, in addition to the nonsense suppression 
methodology, to generate diubiquitin chains where the azide function was introduced via the 
methionine analogue azidohomoalanine (Aha) and the alkyne function via a pyrrolysine 
analogue, the propargyl-protected lysine derivative Plk (Eger et al., 2010). The methionine 
analogue Aha was introduced after substituting the codon for the C-terminal Gly by a Met 
codon. Pyrrolysine analogues were incorporated at lysine sites through the amber stop codon 
UAG via a pyrrolysyl-tRNA synthetase/tRNA CUA pair (Eger et al., 2010). All Lys-linked 
diubiquitin chains were prepared and were shown to be recognized by other E3 ligases and 
subsequently polyubiquitinated (Figure I-36.E).  
• Expressed protein ligation 
McGinty and colleagues pioneered the generation of site-specifically ubiquitinated proteins with 
a native isopeptide bond using a semisynthetic approach (McGinty et al., 2008). 
Monoubiquitinated H2B at K120 was prepared via two EPL reactions: for the first ligation, 
fragment 117-125 of H2B with a photocleavable protecting auxiliary of the N-terminal Cys 
residue and another photocleavable auxiliary that was masking the amino group of the Lys 
residue at position 120 was prepared by SPPS. Ubiquitin thioester produced by thiolysis of an 
intein fusion was added to the synthetic peptide to yield a protected ubiquitinated H2B 
fragment. Upon photoirradiation, the thiol group at position 117 was released and a NCL 
reaction was carried out with the N-terminal fragment of H2B thioester (produced by intein-
mediated splicing) spanning residues 1-116 (McGinty et al., 2008) (Figure I-37). 
 
 
 
Figure I-37. Generation of monoubiquitinated H2B via a native isopeptide bond 
Figure from Ginty et al. (McGinty et al., 2008) 
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The monoubiquitinated histone H2B was able to induce the methylation of Histone 3 in the 
nucleosome and provided a proof of histone PTM cross-talk in vitro. The EPL reactions that 
resulted in the first report of a monoubiquitinated protein relied on slow ligations that take up to 
5-7 days and low yields reported (20%) (McGinty et al., 2008), rendering this methodology less 
amenable for the study of other proteins.  
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I.6. Objective of the PhD study  
One of the major research interests in the Lashuel laboratory is to elucidate the effect of PTM in 
regulating α-syn’s function in health and disease. Prior to 2008, phosphomimicking substitutions 
of S129 and S87 were routinely used in transgenic animals and cell-culture without prior 
investigation of the effect of these mutations on the structure of the protein; and it took a study 
conducted in our laboratory in 2008 to demonstrate that the phosphomimics do not reproduce all 
aspects of phosphorylation (Paleologou et al., 2008). Serine substitution by glutamate was 
shown to mimic the effect of phosphorylation at S87 on α-syn’s aggregation, but pS87 and S87E 
exhibited different membrane binding properties, whereas the S129E/D mutants did not 
reproduce the effect of phosphorylation on the structure, aggregation and subcellular 
localization of α-syn (Paleologou et al., 2008, Paleologou et al., 2010).  
At the beginning of this PhD study, the majority of PTM in α-syn were shown to localize in the 
N-terminal (ubiquitination) and the C-terminal domain of the protein (phosphorylation, 
truncation and nitration). The primary focus of my PhD project focused on investigating the 
effect of α-syn’s phosphorylation at Y125 and monoubiquitination at K6. Given that the kinases 
that phosphorylate α-syn at Tyr residues are either non-specific or inefficient and that the E3 
ligases that are responsible for the conjugation of ubiquitin to α-syn result in a mixture of the 
non-ubiquitinated form of α-syn along with mono- and di-ubiquitination on several sites, we 
decided to pursue the development of two semisynthetic approaches: one strategy to allow the 
introduction of modifications in the N-terminal domain of α-syn and which was further 
optimized to introduce any unnatural amino acid within the first 29 residues and another strategy 
for the introduction of modifications in the C-terminal region of α-syn (in the last 40 residues). 
The first strategy allowed the production of pY125 α-syn and the second one generated 
monoubiquitinated α-syn at K6 in milligram quantities (in collaboration with the group of Prof. 
Ashraf Brik). With these homogeneously modified proteins in hand, we were able to investigate 
the effect of these modifications on the structure, aggregation, subcellular localization and 
protein-protein interactions of α-syn. These studies have provided novel insight into the role of 
these PTM in the mechanism of α-syn fibril formation, and the tools generated are proven to be 
very valuable in studies aimed at identifying novel therapeutic targets and development of 
diagnostic tools based on quantitative assessment of the levels of these modifications in 
Cerebrospinal Fluid and blood. Further optimization of this methodology along with the 
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development of effective means to introduce the proteins in cells and animal models would pave 
the way for novel approaches to investigate α-syn’s biology and pathogenesis.   
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II. Chapter 1: Elucidating the role of C-terminal post-translational 
modifications using protein semisynthesis strategies: α-synuclein 
phosphorylation at tyrosine 125 
 
This chapter is part of a published article in the Journal of the American Chemistry Society 
2012, 134 (11), pp 5196–5210 (DOI: 10.1021/ja210866)j with the following authors: 
Hejjaoui M.1*, Butterfield S. 1*, Fauvet B. 1, Vercruysse F. 1, Cui J. 2, Dikiy I. 3, Prudent M. 1, 
Olschewski D. 1, Zhang Y. 2, Eliezer D. 3, Lashuel H.A. 1  
* these authors contributed equally 
Affiliations:  
1. Laboratory of Molecular and Chemical Biology of Neurodegeneration, Brain Mind Institute, 
Ecole Polytechnique Fédérale de Lausanne (EPFL), CH-1015 Lausanne, Switzerland. 
2. Laboratory of Neurobiology and State Key Laboratory of Biomembrane and Membrane 
Biotechnology, College of Life Sciences, Peking University, Beijing, China 
3. Department of Biochemistry and Program in Structural Biology, Weill Cornell Medical 
College, New York, New York 10021, United States 
 
II.2. Abstract 
Despite increasing evidence that supports the role of different post-translational modifications 
(PTM) in modulating α-synuclein (α-syn) aggregation and toxicity, relatively little is known 
about the functional consequences of each modification and whether or not these modifications 
are regulated by each other. This lack of knowledge arises primarily from the current lack of 
tools and methodologies for the site-specific introduction of PTM in α-syn. More specifically, 
the kinases that mediate selective and efficient phosphorylation of C-terminal tyrosine residues 
of α-syn remain to be identified. Unlike phospho-serine and phospho-threonine residues, which 
in some cases can be mimicked by serine/threonine ? glutamate or aspartate substitutions, there 
are no natural amino acids that can mimic phospho-tyrosine. To address these challenges, we 
developed a general and efficient semisynthetic strategy that enables the site-specific 
introduction of single or multiple PTM and the preparation of homogeneously C-terminal 
modified forms of α-syn in milligram quantities. These advances have allowed us to investigate, 
for the first time, the effects of selective phosphorylation at Y125 on the structure, aggregation, 
membrane binding and subcellular localization of α-syn. The development of semisynthetic 
methods for the site-specific introduction of single or PTM represents an important advance 
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toward determining the roles of such modifications in α-syn structure, aggregation and functions 
in health and disease. 
 
II.3. Introduction 
α-synuclein (α-syn) aggregation and fibrillogenesis in the brain are the hallmark of Parkinson’s 
disease (PD) and have been linked to the pathogenesis of several neurodegenerative diseases 
that are collectively referred to as “synucleinopathies” (Trojanowski and Lee, 2003). PD is 
characterized by the formation of intraneuronal inclusions termed Lewy bodies (LB), which are 
composed primarily of insoluble fibrillar and aggregated forms of α-syn (Spillantini et al., 1997, 
Dawson, 2000). Although three mutations in the α-syn gene A30P (Kruger et al., 1998), A53T 
(Polymeropoulos et al., 1997), and E46K (Zarranz et al., 2004)) have been linked to early-onset 
forms of the disease, they account for only 1% of all PD cases. Therefore, a better understanding 
of the molecular determinants that govern the structural, aggregation and functional properties 
of α-syn is crucial to elucidating its role in the pathogenesis of sporadic and inherited forms of 
PD.   
The primary sequence of α-syn can be divided into three domains, which are: 1) The N-terminal 
domain which contains the sites of three disease-associated mutations and the imperfect 6 
repeats of a conserved sequence (KTKEGV) that play an important role in regulating α-syn 
secretion (Desplats et al., 2009), internalization (Emmanouilidou et al., 2010, Jang et al., 2010) 
and binding to membranes; 2) The central fragment, also known as the NAC - non amyloid 
component - (residues 61-95) region, is highly hydrophobic and is essential for α-syn 
oligomerization and fibrillogenesis (Del Mar et al., 2005); 3) The C-terminal region comprising 
residues 96-140. This region is highly disordered and negatively charged (10 glutamate and 5 
aspartate residues). The C-terminal region has been proposed to play a role in regulating α-syn 
transport to the nucleus and has been shown to mediate α-syn interactions with other proteins 
(Jensen et al., 1999, Giasson BI, 2003, Goers J, 2003, Cherny et al., 2004), metal ions (Paik et 
al., 1999, Brown, 2007) and natural ligands (e.g. dopamine and polyamines) (Goers et al., 
2003b). The majority of α-syn PTM (truncation, phosphorylation, methionine oxidation, and 
nitration) occurs within the C-terminal region. The clustering of PTM in this functional domain 
of the protein suggests that these modifications may be involved in the regulation of α-syn’s 
function in health and disease. This hypothesis is further supported by the fact that the majority 
of these post-translational modification sites are highly conserved across different species.  
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Furthermore, the close proximity of these different modifications suggests that they may act in 
concert, and cross-talk between these modifications may constitute an additional molecular 
switch for regulating the dynamics of α-syn function and aggregation (Figure II-1).  Previously, 
our group identified the polo-like kinases, PLK2 and PLK3, which phosphorylate α-syn 
efficiently in vitro and are major contributors to α-syn phosphorylation in vivo (Mbefo et al., 
Inglis et al., 2009). However, the kinases that carry out selective and efficient phosphorylation 
of the other known and putative phosphorylation sites (S87, Y125, Y133, and Y136) remain to 
be identified.  
Protein semisynthesis (Muir et al., 1998, Muir, 2003b, Hackenberger and Schwarzer, 2008, 
Berrade and Camarero, 2009, Chiang et al., 2009, Komarov et al., 2009, Broncel et al., 2012b, 
Spasser and Brik, 2012), which combines the powers of recombinant protein expression, peptide 
chemical synthesis and native chemical ligation (NCL) has successfully been used to study post-
translational modifications on a variety of proteins  (Muir, 2003b, Szewczuk et al., 2009) and 
offers means of generating site-specifically modified forms of α-syn (Hejjaoui et al., 2011, 
Butterfield et al., 2012b) (Figure II-2). 
 
Figure II-1. The clustering of C-terminal post-translational modifications of α-syn 
A: Schematic depiction of the sequence of α-syn with its 3 domains. The putative and identified sites of C-terminal 
phosphorylation are indicated with arrows. B: Sequence alignment of the sequences of the C-terminal domain of α-
syn from 5 different species. The conserved positions of the phosphorylation sites are highlighted in red. 
 
To address the aforementioned challenges and to facilitate the investigation of the structural and 
functional consequences of specific C-terminal PTM of α-syn, we developed a general and 
efficient semisynthetic strategy that permits the site-specific introduction of single or multiple 
PTM. Despite mounting evidence supporting the role of C-terminal phosphorylation in 
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modulating α-syn aggregation and toxicity, relatively little is known about the functional 
consequences of tyrosine phosphorylation and whether or not tyrosine and serine 
phosphorylation in this region are regulated by each other (Chen et al., 2009). This is partly due 
to the lack of tools and methodologies for the site-specific introduction of single or multiple 
PTM in α-syn. This strategy also enables the preparation of milligram quantities of 
homogeneous forms of α-syn modified at the C-terminus that are sufficient for carrying out 
detailed biochemical, biophysical and cellular studies. We used this strategy to produce α-syn 
phosphorylated at tyrosine 125 (pY125 α-syn). We choose to investigate Y125 phosphorylation 
for the following reasons: 1) the levels of pY125 α-syn have been reported to decrease with age 
(Chen et al., 2009); 2) studies by Feany and colleagues suggest that phosphorylation at Y125 
acts as a counter-regulator of pS129-induced toxicity in the fly model of PD (Chen et al., 2009), 
and provide evidence for a potential cross-talk between these two modifications; 3) because 
there are no effective mutagenesis-based strategies for mimicking tyrosine phosphorylation and 
thus very little is known about the structural and functional consequences of selective 
phosphorylation of α-syn at Y125. 
 
Figure II-2. Mechanism of Native Chemical Ligation 
Top: A peptide thioester and a peptide fragment bearing an N-terminal Cys undergo a thioester exchange followed 
by an S to N acyl migration to create an amide bond between two unprotected peptides in aqueous solution.  
Bottom: Semisynthetic strategy to generate derivatives of α-syn site-specifically phosphorylated within the C-
terminal region. The protein thioester α-syn(1-106)SR generated by recombinant protein expression is ligated by 
NCL to the synthetic C-terminal fragment α-syn(A107C-140) bearing the desired phosphorylated side chain.  A 
final desulfurization step restores the native Ala-107. 
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More specifically, we determined the effect of phosphorylation at Y125 on the structure, fibril 
formation, and phospholipid membrane association-induced conformational shifts in vitro. In 
addition, we further probed cross-talk between phosphorylation at S129, Y125, and S87 residues 
by determining the relative activity of each phosphorylated form of α-syn as a substrate for the 
kinases that phosphorylate α-syn at other residues within the C-terminus. We also assessed, for 
the first time, the subcellular localization of pY125 α-syn in mammalian cells and rat 
hippocampal neurons.  Our work demonstrates the power and potential of applying chemical 
approaches to elucidate the role of C-terminal PTM in regulating α-syn function in health and 
disease.  
 
II.4. Material and Methods 
II.4.1. Materials 
9-Fluorenylmethoxycarbonyl (Fmoc)-amino acids, t-butyloxycarbonyl (Boc)-amino acids, 2 - 
(1H - benzotriazole - 1 - yl) - 1,1,3,3 - tetramethyluronium hexafluorophosphate  (HBTU), were 
purchased from Novabiochem or Anaspec.  The side-chain functionalities of the Fmoc-amino 
acids were chemically protected as shown in parentheses: Asp(OtBu), Glu(OtBu), Lys(Boc), 
Thr(tBu), Ser(tBu), Tyr(tBu), Gln(Trt), and Asn(Trt).  Phosphorylated Tyr residues were 
purchased from Novabiochem or Anaspec as protected Fmoc-Tyr[PO(OBzl)]-OH building 
blocks.  All unlisted amino acids were not protected.  The Boc-amino acid was Boc-Cys(Trt). 
N,N-diisopropylethylamine (DIPEA), trifluoroacetic acid (TFA), triisopropylsilane (TIPS), 
sodium 2-mercaptoethanesulfonate (MESNa), ammonium iodide, 1,2-ethanedithiol (EDT), 2-
methyl-2-propanethiol (tert-butyl mercaptan, tBuSH) dimethylsulfide, guanidine hydrochloride 
(GuHCl) and tris(2-carboxyethyl)-phosphine hydrochloride (TCEP) were purchased from 
Sigma-Aldrich.  Piperidine and diethyl ether were purchased from Acros. 2-2’-Azobis[2-(2-
imidazolin-2-yl)propane] dihydrochloride (VA-044) was purchased from Wako. The solvents N-
methylpyrrolidone (NMP), dichloromethane, and HPLC-grade acetonitrile were purchased from 
VWR.   
II.4.2. General Solid Phase Peptide Synthesis and Purification 
Solid phase peptide synthesis was performed on an automated CS 336X peptide synthesizer 
from CS Bio using standard Fmoc protocols including the in situ neutralization protocol 
described by Alewood et al. (Alewood et al., 1997). A preloaded Fmoc-Ala Wang resin was 
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used. Syntheses were carried out on a 0.2 mmol scale and coupling steps were performed with 5 
eq. Fmoc-amino acid, 5 eq. HBTU/HOBt, and 5 eq. DIPEA in NMP. The N-terminal Cys 
residues were attached with Boc protecting groups on their N-terminus. Fmoc-group 
deprotections were carried out with 20% piperidine in DMF. Peptide side chain deprotections, 
removal of N-terminal Boc group and cleavage from the resin was performed by treatment with 
81.5:5:3:5:2.5:2:1.5 of TFA:water:phenol:thioanisole:EDT:Me2S:NH4I for 4 hours on a rotating 
wheel to generate peptides with a C-terminal acid functionality. The crude product was 
subsequently precipitated three times with a ten-fold excess volume of cold diethyl ether, 
dissolved in water and lyophilized. Peptides were then purified by reversed-phase HPLC 
(Waters 600 system) using a Cosmosil C18 preparative column (20x250 mm, 5µm particles, 
300Å pores) with a linear gradient of 20-70% B over 30 minutes (solvent A was water/0.1% 
TFA and solvent B was acetonitrile/0.1% TFA). Peptide elution was monitored by UV 
absorbance at 214 nm and 280 nm. Peptide masses were confirmed by MALDI-TOF-MS and 
ESI-MS analysis. Peptide purity was confirmed by re-injection on an analytical RP-HPLC 
column (Cosmosil C18, 4.6x250 mm, 5µm particles, 300Å pores). 
II.4.3. Expression and Purification of Recombinant α-Syn(1-106)SR 
C-terminally truncated human α-synuclein was initially cloned into the pT7-7 vector in fusion 
with the GyrA Mini-Intein from Mycobacterium Xenopii and a chitin binding domain (CBD) 
using the following primers: Forward: 5’-GGG CAA GAA TGA AGA AGG ATG CCG AAG 
AGC AGG AAT TCT G-3’ and reverse: 5’-CAG AAT TCC TGC TCT TCG GCA TCC TTC 
TTC ATT CTT GCC C-3’.  The α-syn fragment (1-106) was isolated by NdeI and SapI digest. 
The intein was isolated from the pTXB1 vector (New England Biolabs) by SapI and BamHI 
digest. Both fragments were ligated into pT7-7 digested by NdeI and BamHI to generate the 
plasmid pT7-7 α-syn-Mxe-CBD. To insert a polyhistidine tag at the C-terminus of the intein 
instead of CBD , an EcoRI site was introduced using site-directed mutagenesis using the 
following primers: Forward: 5’ CTG GCC TCA CCG GTC TGG AAT TCG GCC TCA CGA 
CAA ATC 3’ and reverse 5’ GAT TTG TCG TGA GGC CGA ATT CCA GAC CGG TGA 
GGC CAG 3’. An oligonucleotide containing six histidines and two stop codons with the 
digested recognition sequences of EcoRI and BamHI sites was ordered:  Forward 5’AA TTC 
CAC CAC CAC CAC CAC CAC TGA TAA G 3’ and reverse 5’ GA TCC TTA TCA GTG 
GTG GTG GTG GTG GTG G 3’. The annealed oligonucleotides were ligated into the plasmid 
pT7-7 α-syn-Mxe-CBD digested with EcoRI and BamHI. Expression was carried out in E.coli 
BL21(DE3). Protein expression was induced with 0.5 mM isopropyl-β-D-thiogalactopyranoside 
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(IPTG) and by growing the cells for 4h at 37°C. The cells were harvested by centrifugation and 
lysed by ultra-sonication in 40 mM Tris-acetate, 5 mM EDTA pH 8,3. The supernatant was 
separated from the cell debris by centrifugation (23, 000 x g, 30 min, 4°C). 4 equivalents of 
MgCl2 were added prior to the loading on the Ni-NTA column. The soluble fraction was loaded 
on a HisPrep FF 16/60 (Amersham) pre-equilibrated with 50 mM HEPES pH 7.5. A washing 
step of 50 mM HEPES 25 mM imidazole, pH 7.5 for 5 column volumes was included to remove 
non-specific binding. The protein α-syn-Mxe-His(6) was eluted with a step elution of 50 mM 
HEPES, 350 mM Imidazole pH 7.5. The splicing reaction was carried out directly in the eluate 
from the Ni-NTA column for 12 h under agitation at RT in presence of 0.25 M MESNa. The 
splicing efficiency was around 90% (by SDS-PAGE analysis, data not shown). The sample was 
subsequently purified by reverse-phase HPLC using a preparative C4 column (VYDAC, 20x250 
mm,5µm particles, 300Å pores) with a linear gradient of 20-70% B in 30 min at a flowrate of 10 
ml/min (solvent A was water/0.1% TFA and solvent B was acetonitrile/0.1% TFA). The pure 
protein thioester was obtained in a yield of 10 mg per liter of BL21 (DE3) expression medium. 
II.4.4. Expression and purification of 15N labeled proteins 
α-syn A107C: The α-syn mutant A107C was generated using single-point mutagenesis with the 
following primer pairs to generate the plasmid pT7-7 α-syn A107C: forward primer 5’ GCA 
AGA ATG AAG AAG GAT GCC CAC AGG AAG GAA TTC TG 3’ and reverse primer 5’ 
CAG AAT TCC TTC CTG TGG GCA TCC TTC TTC ATT CTT GC 3’. BL21 (DE3) cells 
were transformed with the plasmid and grown in M9 minimal media with 15N labeled 
ammonium chloride. Protein expression was induced by the addition of 1 mM IPTG for 4 h at 
37°C. After harvesting the cells by centrifugation at 6000 x g for 15 min, the cell pellet was 
resuspended in 40 mM Tris-acetate and 5mM EDTA (pH 8.3) and lysed by ultra-sonication. The 
insoluble material was removed by centrifugation at 23,000 x g for 40 min at 4°C. The 
supernatant was boiled for 15 min in a water bath at 100°C followed by centrifugation at 23,000 
x g for 40 min, which precipitates most cellular proteins but not α-syn A107C. The final 
supernatant was filtered through a PVDF membrane with 0.22 μm pores. Anion-exchange 
chromatography was performed on a Pharmacia AKTA FPLC system using a 20 mL HiPrep 
16/10 Q FF column (Amersham). The protein was eluted with a linear gradient of 0 to 1 M NaCl 
(the protein elutes at approximately 300 mM NaCl ) and subsequently purified on a Superdex 
200 26/60 size-exclusion chromatography column (Amersham) using a mobile phase of buffer 
containing 50 mM Tris, 150 mM NaCl,  pH 7.5. The purified protein was dialyzed extensively 
against de-ionized water and lyophilized and stored at -20°C until used. From 1 L of expression 
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medium, the average yield of lyophilized material was 30 mg. To remove the glutathatione 
disulfide adduct, the lyophilized powder was dissolved in a buffer containing 50 mM Tris 
150mM NaCl (pH 7.5), with 30eq of TCEP and the solution was incubated for 10 min at RT. 
The protein was subsequently purified on a C4 preparative column (Vydac) with a linear 
gradient of 20-70% B in solvent A over 30 min at a flow rate of 10 mL/min (solvent A was 
water/0.1% TFA and solvent B was acetonitrile/0.1% TFA). The 15N labeled protein was 
obtained in a final yield of 10 mg per liter of bacterial expression.  
α-syn (1-106)SR: The expression of 15N labeled α-syn(1-106) SR was carried out in a similar 
manner as for the non-labeled protein with an overall yield of pure protein of ~3.5 mg per liter. 
II.4.5. Semisynthesis and desulfurization of α-syn phosphorylated at Tyr 125 
The semisynthesis of α-syn site-specifically phosphorylated within the C-terminus (residues 
107-140) involved an NCL reaction between recombinant α-syn(1-106)SR and synthetic 
peptides α-syn (A107C-140) phosphorylated at Tyr-125 or the WT peptide. NCL reactions were 
carried out in 6 M GuHCl, 200 mM sodium phosphate buffer, pH 7.0 using 1.5 mM of α-syn(1-
106)SR and 2 molar excess of C-terminal peptide A107C-140 pY125 or A107C-140 WT 
peptide in the presence of 30 eq. TCEP in a volume of 1 mL at 37°C with shaking at 1000 rpm. 
Three ligation reactions were carried out in parallel. To monitor the NCL reactions, aliquots of 
the reaction mixture (4μl) were removed and quenched with 38 μl of water containing 0.1% 
TFA and subsequently analyzed by SDS-PAGE (15% polyacrylamide) and MALDI-TOF-MS.  
RP-HPLC was not used due to the co-elution of α-syn(1-106)SR and the ligated product under 
all conditions tested in our laboratory. Based on SDS-PAGE analysis, the desired ligated 
product was produced within 1-2 hrs.   
Free radical-based desulfurization of the semi-synthetic α-syn mutant was carried out as 
previously described by Danishefsky and colleagues (Wan and Danishefsky, 2007). In our case, 
the ligation and the desulfurization were carried out in one-pot. 1mL of a solution of 1 M of 
TCEP (in 6 M GuHCl, 200 mM sodium phosphate pH 7.0) was added to the ligation reaction. 
160 μl of 2-methyl-2-propanethiol and 100 μl of a 0.1 M solution of 2-2’-Azobis[2-(2-
imidazolin-2-yl)propane] dihydrochloride (VA-044) free radical initiator (in 6 M GuHCl, 200 
mM sodium phosphate pH 7.0) were added under argon. The reaction was incubated at 37°C 
with agitation at 1000 rpm in a ventilated fume hood for 3.5 h. The progress of desulfurization 
was followed by MALDI-TOF-MS.   
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II.4.6. Purification of the semisynthetic pY125 α-syn 
Prior to purification, the ligated desulfurized products from the 3 ligation/desulfurization 
reactions (that were carried out in parallel) were desalted through a 5mL HiTrap desalting 
column (Amersham) with 20 mM sodium dihydrogen citrate pH 4.0 as the mobile phase. The 
fractions containing the protein were subsequently pooled and manually injected on a 5 mL 
cation-exchange column HiTrap SP HP (Amersham). We took advantage of the charge 
difference between the full-length protein, the fragment α-syn(1-106)OH (hydrolyzed thioester) 
and the C-terminal 107-140 peptide for a single-column purification. At pH 4.0, the peptide is 
negatively charged (net charge: -2) and will not bind to the column while the full-length protein 
and the fragment (1-106) are positively charged and hence will bind to the column. At pH 5.0, 
the charge of the full-length protein is -1 and the fragment (1-106) has a charge of 6 and can be 
subsequently separated using a gradient of salt. We initially allow the peptide to pass in the flow 
through by washing the column after injection with 10 column volumes (CV) of 20 mM sodium 
citrate pH 4 then with a linear gradient of NaCl from 0 to 100% B (where A is a solution of 20 
mM sodium citrate pH 4, B the same solution supplemented with 0,5 M NaCl) over 4 CV on a 
Akta Purifier system. To elute bound proteins, we applied a linear gradient of NaCl from 0 to 
70% B (where A is B is a solution of 20 mM sodium citrate pH 5 and B is the same solution 
supplemented with 0,25 M NaCl) over 30 CV at a flow of 1 mL/min. The full-length protein 
elutes around 20% B and the fragment (1-106) around 30% B. The fractions containing the 
protein were extensively dialyzed against de-ionized water and lyophilized. The final yield of 
pure lyophilized protein is around 19% (9 mg).  
II.4.7. Preparation and purification of pS129 and pS87 α-syn 
Recombinant WT α-syn (3 mg per reaction, 10 µM) was phosphorylated at S129 in vitro by 
PLK3 (10 µg per reaction, 4.8 µg/mL) at 30°C in 20 mM HEPES (pH 7.4), 10 mM MgCl2, 2 
mM DTT, and 1 mM ATP. The phosphorylated protein was purified by reversed-phase HPLC 
using a semipreparative C8 column (InertSil 7.6 x 250 mm, 5 µm particles, 300Å pores). The 
proteins were eluted with a linear gradient from 20% to 40% of solvent B in solvent A over 40 
min at a flowrate of 5 mL/min (solvent A was water/0.1% TFA and solvent B was 
acetonitrile/0.1% TFA). The collected fractions were pooled according to purity assessed by 
ESI-MS and MALDI-TOF-MS. After purification, pS129 α-syn was lyophilized and stored at -
20°C until use. pS87 α-syn was prepared as previously described (Paleologou et al., 2010) .  
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II.4.8. Preparation of α-syn S129A, S129E and Y125F 
The expression and purification of α-syn S129A, S129E and Y125F were performed as 
described (II.4.4) (Paleologou et al., 2008). 
II.4.9. Circular dichroism measurements  
Protein samples (10 μM) in pH 7.5 buffer containing 50 mM Tris buffer and 150 mM NaCl 
were analyzed at 25°C using a Jasco J-815 CD spectrometer. An average of 10 spectra was 
collected in the range of 195-250 nm using a 0.1 mm path length quartz cuvette. Data points 
were acquired every 0.2 nm in the continuous scanning mode at a speed of 50 nm/min with a 
digital integration time of 2 s, and a bandwidth of 1 nm. Processed spectra were obtained by 
subtracting the baseline signal due to the buffer and cell contribution from the protein spectra 
and a final smoothing was applied (Savitzky-Golay filter; convolution width of 25 data points). 
II.4.10. In vitro Phosphorylation assay 
pY125 α-syn (6 μM) was incubated in 50 mM Tris pH 7.5, 10 mM DTT, 1 mM ATP, 1 mM 
MgCl2 in presence of 0,42 μg (1μL) of PLK3 (Invitrogen) in a total volume of 50 μL. For the 
phosphorylation by CK1, 6 μM of protein were incubated in CK1 buffer 1X supplemented with 
1 mM ATP and 1000 units of CK1 (1 μL) in a final volume of 50 μL. The reaction was allowed 
to proceed for 12 h at 30°C with no agitation. The extent of phosphorylation was monitored by 
MALDI-TOF-MS and western-blotting using pS87, pS129 and pY125-specific antibodies.  
For phosphorylation by tyrosine kinases, WT α-syn, -pS87, and -pS129 were incubated at a 
concentration of 3 µM in a final volume of 30 µL with the appropriate tyrosine kinase. Kinases 
were added at a final concentration of 50 nM. The reaction buffers were the following: Syk / 
Lyn: 50 mM Tris and 5 mM MnCl2 (50μL); Fyn / Src: 20 mM Tris and 5 mM MnCl2 (pH 7.4); 
Fgr: 50 mM Tris and 5 mM MgCl2 (pH 7.5). The reactions were started by the addition of 
freshly prepared ATP (1 mM), and incubated for 14 h at 30 °C before analysis. 
II.4.11. NMR spectroscopy  
Work carried out by Igor Diky (Prof. David Eliezer’s group) 
NMR studies were performed as previously described (Paleologou et al., 2008). Briefly, 
lyophilized 15N-labeled α-syn was dissolved in sample buffer (100 mM NaCl, 10 mM Na2HPO4, 
in 90% H2O, 10%, D2O at pH 7.4 to a concentration of 0.1-0.3 mM. For spectra in the presence 
of SDS, the sample buffer also contained 40 mM SDS. All 1H, 15N HSQC spectra were collected 
at 10 °C in the absence of SDS and at 40 °C in the presence of SDS on either a Varian INOVA 
600 MHz spectrometer (Weill Cornell Medical College) or a Bruker Avance 800 MHz 
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spectrometer (New York Structural Biology Center) equipped with cryogenic probes. NMR data 
were processed by NMRPipe (Delaglio et al., 1995) and analyzed in NMRViewJ (Johnson, 
2004) . Spectra were referenced indirectly to sodium 2,2-dimethyl-2-silapentane-5-sulfonate and 
ammonia using the known chemical shift of water. Assignments for the spectra of mutant and 
phosphorylated α-syn at Y125 were estimated by transferring each previously assigned cross-
peak in the HSQC spectrum of WT α-syn to the closest unassigned cross-peak in each spectrum. 
Normalized per residue, the chemical shift change was calculated as Δδ = √(ΔδH12 + ΔδN152/25) 
/2). For PRE experiments, α-syn was dissolved in sample buffer without SDS, a 10-fold excess 
of MTSL spin-label was added and the resulting solution was incubated for 30 minutes. A 
buffer-exchange column was used to remove unbound spin-label and the sample was divided 
into diamagnetic and paramagnetic samples. DTT (final concentration 2 mM) was added to the 
diamagnetic sample to reduce off the spin-label. Matched two-dimensional HSQC spectra were 
collected on the two samples, and the ratio of the intensity of each cross-peak was determined. 
II.4.12. In vitro fibrillization assay 
pY125 α-syn and WT α-syn were incubated at 15 μM in a volume of 450 µL under constant 
agitation at 1200 rpm for 48h or 7 days at 37°C. ThT fluorescence reading was carried out with 
a ThT concentration of 10 μM and a protein concentration of 1.5 μM in a volume of 70 μL in a 
pH 8.5 buffer containing 50 mM Glycine. A TECAN spectrometer was used to measure ThT 
fluorescence at an excitation wavelength of 450 nm and an emission wavelength of 485 nm. 
Aliquots taken at 0, 24 and 48 h were measured in triplicates. Values were expressed as the ThT 
fluorescence of three measurements (mean ± S.D.). 
II.4.13. Transmission electron microscopy (TEM) 
7 μL of proteins were deposited on Formvar-coated 200 mesh copper grids (Electron 
Microscopy Sciences). Grids were washed with two drops of double-distilled H2O and stained 
with two drops of freshly prepared 2% (w/v) uranyl acetate (Electron Microscopy Sciences) and 
then vacuum dried from the edge of the grids. Specimens were viewed on a Philips CIME 12 
electron microscope, operated at 80 kV.  Digitized photographs were recorded with a CCD 
camera (Digital Camera Morada by Soft Imaging System, 4008 X 2672 pixels). 
II.4.14. Western-blot analysis 
Protein samples were separated at 80 V on 15% polyacrylamide 1 mm-thick gels over 1-2 h.  
The proteins were transferred onto nitrocellulose membranes (Omnilab SA) using a semi-dry 
transfer system (Bio-Rad) under constant current (~200 mA per membrane) and the membranes 
  
 92 
  
were blocked for 1 h at room temperature with Odyssey blocking buffer (Li-COR Biosciences) 
diluted three-fold in PBS buffer. The membranes were probed with the relevant primary 
antibodies: mouse anti-α-syn (1:1000 dilution, BD Transduction Laboratories), rabbit anti-α-syn 
ab51252 (1:1000 dilution, Abcam), rabbit anti-α-syn SA3400 (1:1000 dilution, Biomol)  mouse 
monoclonal anti-phosphorylated α-Syn at Tyr-125 (1:1000 dilution; BD Transduction 
Laboratories), homemade rabbit anti-pY125 α-syn (1:1000); mouse monoclonal anti-pS129 α-
syn (dilution 1:5000; Wako), rabbit anti-pS87 α-syn (1:200 dilution,(Mbefo et al., 2010)) 
overnight at 4°C. After three washes with PBS buffer containing 0.1% (v/v) Tween 20 (Fluka), 
the membrane was incubated with secondary goat anti-mouse or anti-rabbit antibodies 
conjugated to Alexa 680 (dilution 1:5000; Invitrogen). The membranes were then washed three 
times with PBS buffer containing 0.01% (v/v) Tween 20 and once with PBS buffer and scanned 
on a LiCOR scanner at 700 nm. 
II.4.15. pY125 α-syn dephosphorylation assay 
HeLa cells were grown to 90% confluency in a 10cm Petri dish and lysed by occasional 
vortexing on ice over 30 min in 600 μL of lysis buffer (50 mM tris pH 7.4, 150 mM NaCl, 5% 
glycerol, 25 mM sucrose, 1% NP-40, and 0.25% sodium deoxycholate with 100 mM PMSF and 
protease inhibitor cocktail from Sigma). The lysate was clarified by centrifugation at 20800 g 
for 30 min at 4°C.  Incubation of pY125 α-syn (1.2 μg in 100 μL) with HeLa lysate was carried 
out for 0, 30 min and 1 h at 37°C. The reaction was quenched by the addition of Laemmli 
sample buffer. For inhibition by sodium orthovanadate, different concentrations of the activated 
inhibitor (0.1, 1 and 10 mM) were incubated with samples of lysate containing 1.2 μg of pY125 
α-syn for 2 h. Lysate from each incubation (300 ng) was loaded onto a SDS-PAGE gel and 
analyzed by Western-Blot with antibodies against WT α-syn and pY125 α-syn . 
II.4.16. Cell culture and transient transfection 
Human embryonic kidney cells (HEK 293T) and HeLa cells were grown in Dulbecco’s modified 
Eagle’s medium (Invitrogen) supplemented with 10% fetal bovine serum and 5% 
penicillin/streptomycin in a humidified incubator with 5% CO2 at 37 °C. For HEK 293T cells, 
transient transfection was performed in 6-well plates at a cell confluence of 70–80%, using a 
standard calcium phosphate (CaPO4) transfection protocol. For HeLa cells, transient transfection 
using LipofectamineTM 2000 (Invitrogen) was performed according to the manufacturer’s 
instructions. The total amount of plasmid used in the transfection was 2 μg/well for 6-well-
plates and 0.8 μg/well for 24-well plates. 
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II.4.17. Detection of pY125 α-syn in HEK 298T and HeLa cells 
HeLa and HEK 293T cells were grown in 6-well-plates and transfected with the plasmid pAAV 
α-syn WT and pAAV α-syn Y125F. The cells were treated with pervanadate (100 μM sodium 
orthovanadate and 4 mM H2O2) 24 h post-transfection for 5, 10 and 20 min, as reported 
previously (Ellis et al., 2001). The medium containing the inhibitor was removed, and the cells 
were subsequently harvested by pipetting in PBS or by scraping. The cells were pelleted by 
centrifugation at 100 g for 3 min, lysed by the addition of 100 μL of Laemmli buffer and boiled 
at 95°C for 30 min. 30 µL of sample was loaded on SDS-PAGE and analyzed by Western-Blot 
with antibodies for WT α-syn and pY125 α-syn 
II.4.18. Subcellular fractionation 
HEK 293 cells were grown in 6-well-plates, transfected with the plasmid pAAV WT α-syn and 
treated with pervanadate (100 μM sodium orthovanadate and 4 mM H2O2) 24h post-
transfection. Subcellular fractionation was carried out using the kit from Calbiochem according 
to the manufacturer’s instructions and as previously described (Mbefo et al., 2010). Pervanadate 
(100 μM sodium orthovanadate and 4 mM H2O2) was also added during the extraction steps.  
II.4.19. Primary neuronal cultures  
Work carried out by Jia Cui (Prof. Yan Zhang’s group) 
Rat primary neurons were cultured from newborn Sprague Dawley (SD) rat hippocampus, 
following the regulations of Peking University Animal Care and Use Committee. In brief, rat 
hippocampal tissues were dissociated with 0.25% trypsin (Invitrogen), which was then 
inactivated by 10% decomplemented fetal bovine serum (FBS, HyClone). The mixture was 
triturated through a pipette to produce a homogenous mixture. After filtering the mixture 
through 0,7 μm sterilized filters, the flow-through was centrifuged. The pellet was then washed 
once with PBS followed by one wash with Dulbecco's Modified Eagle Medium (DMEM) in 
Earle’s balanced salt solution containing 0.225% sodium bicarbonate, 1 mM sodium pyruvate, 2 
mM L-glutamine, 0.1% dextrose and antibiotic Pen-Strep with 5% FBS (all from Invitrogen). 
Cells were then plated on poly-L-lysine (Sigma) coated plates or on glass coverslips at a density 
of 1x106 cells/ml. Neurons were incubated at 37°C in DMEM without phenol red with 5% FBS 
and 5% circulating CO2. Cytarabine was added to culture media 24 hours after plating to a final 
concentration of 10 μM to inhibit cell growth. The culture medium was changed every 48 hours. 
Cells were used for experiments at day 7 of culture. 
  
 94 
  
II.4.20. Subcellular localization of pY125 α-syn in HeLa cells  
HeLa cells were seeded on coverslips (100 000 cells in a 24-well-plate) pre-coated for 30 min at 
RT with Poly-L-lysine. The cells were transfected with the plasmid pAAV α-syn WT (0.8 µg ) 
and subsequently treated with pervanadate prepared as described above  for 30 min 24 h post-
transfection. The cells were subsequently fixed in 4% paraformaldehyde in PBS for 30 min, 
washed three times in PBS, blocked for 1 h with 3% BSA, 0.1% Triton X-100 in PBS and 
incubated overnight at 4°C with a cocktail of primary antibodies (mouse α-syn pY125, BD 
Pharmingen, 558246, 1:1000; rabbit α-syn, ab51252, Abcam, 1: 1000) in 1% BSA, 0.1% Triton 
X-100 in PBS. The cells were then washed three times with 1% BSA, 0.1% Triton X-100 in 
PBS and incubated for 1 h at RT with a cocktail of secondary antibodies (goat anti-mouse 
coupled to Alexa Fluor 568, Molecular Probes Inc., 1:1000; goat anti-rabbit coupled to Alexa 
Fluor 488, Molecular Probes Inc., 1:1000). After three washes in PBS, coverslips were counter-
stained with 4,6-diamidino-2-phenylindole (DAPI, 1:5000), washed 3 times with PBS and 
mounted on glass slides with Vectashield mounting medium (Vector). Cells were imaged using 
a Zeiss LSM700 confocal microscope. 
II.4.21. Microinjection and immunocytochemistry  
Work carried out by Jia Cui (Prof. Yan Zhang’s group) 
Thin-walled Borosilicate glass capillaries (outer diameter=1.0 mm, inner diameter=0.5 mm) 
with a microfilament (MTW100F-4, World Precision Instrument) were pulled with a 
Flaming/Brown Micropipette Puller (P-97, Sutter) to obtain injection needles with a tip diameter 
of approximately 0.5 μm. Microinjections into the cytosol of each were performed cell using an 
Eppendorf Microinjector FemtoJet and Eppendorf Micromanipulator (Eppendorf). Neurons 
were injected with 25 fl/shot at an injection pressure of 100 hPa, a compensation pressure of 50 
hPa, and an injection time of 0.1 s. pY125 α-syn was diluted for a final concentration of 1 μM in  
phosphate-buffered saline (PBS, 0.14 M NaCl, 0.003 M KCl, 0.01 M Na2HPO4, 0.002 M 
KH2PO4, pH7.2). The solutions were injected with 100 μg/ml dextran Texas Red (DTR, MW: 
3000, Molecular Probes) as a fluorescent marker or with Fast Green as a visible marker to 
enable the identification of injected cells. The injected cells were treated either with control 
DMEM medium or with pervanadate (100 μM orthovanadate and 4 mM H2O2) for 30 min. For 
immunocytochemistry, cells were fixed, permeabilized and blocked with 10% donkey serum at 
room temperature followed by incubation with anti-α-synuclein antibody (mouse α-syn pY125, 
BD Pharmingen, 558246, 1:1000; rabbit α-syn, ab51252, Abcam, 1: 1000) at 4°C for 24 h. Cy2 
or Cy3-conjugated donkey anti-rabbit antibody was used as the secondary antibody. Nuclei were 
  
 95 
  
subsequently stained by Hoechst 33258 (1 μg/ml, Sigma) for 15 minutes in the dark. The 
coverslips were mounted on glass slides with ImmunonTM mounting medium (Shandon) and 
imaged by fluorescence microscopy (Olympus BH2-RFCA, Olympus) with a digital camera 
(Olympus DP70 Digital Microscope Camera, Olympus).  
II.4.22. Isolation, Expression and Purification of NbSyn87 
Work carried out by Farah El Tuk and Tim Guilliams (Prof. Christopher Dobson’s group) 
The antibody fragment, NbSyn87, was isolated and identified by the Dobson group using phage 
display selection following the immunization of a llama with α-syn, according to previously 
published protocol (Decanniere et al., 1999, Conrath et al., 2001). The expression and 
purification of NbSyn87 was performed as described in Guilliams et al. 2012. 
II.4.23. Isothermal Titration Calorimetry 
Work carried out by Tim Guilliams (Prof. Christopher Dobson’s group) 
Calorimetric data were recorded using an iTC200 calorimeter (MicroCal, LLC, Northampton, 
MA, USA). A solution of 40 μl of NbSyn87 at a concentration of 150 μM was titrated in 2 μl 
aliquots with a 150 s intervals into the calorimetric cell containing a standard volume (203 μl) of 
10 μM monomeric α-syn in solution. Experiments were performed at 25 °C in 10 mM phosphate 
and 150 mM sodium chloride at a pH of 7.4. The thermodynamic analysis was performed using 
the Microcal analysis software (Origin 7.0) using a simple 1:1 bimolecular binding model. 
 
II.5. RESULTS 
The semisynthesis of α-syn site-specifically phosphorylated within the C-terminus (residues 
107-140) involved an NCL reaction between the recombinant thioester α-syn(1-106)SR and the 
synthetic peptide α-syn (A107C-140) phosphorylated at Tyr-125 or the corresponding 
nonphosphorylated peptide. Because the primary sequence of α-syn does not contain any 
cysteine residues, we mutated alanine residue 107 to a cysteine to allow the NCL reaction to 
occur with the juxtaposed residue at position 106 being an unhindered residue (Gly). 
II.5.1. Generation of semisynthetic pY125 α-syn 
Recombinant α-syn(1-106)SR was expressed in E.coli utilizing the intein approach, which 
exploits the mechanism of intein self-splicing to generate recombinant proteins with a C-
terminal thioester (Figure II-3.A) (Muir et al., 1998). In the case of natural intein splicing, a 
series of transthioesterification and succinimide formation events that involve an arginine 
  
 96 
  
residue at the C-terminus of the intein mediates the splicing of the intein and the linkage of the 
N-extein and the C-extein by an amide bond (Evans and Xu, 1999). Briefly, truncated α-syn(1-
106) was expressed in fusion with the GyrA mini-intein (Mxe GyrA) which contained a C-
terminal hexahistidine purification tag to facilitate purification from bacterial lysate.  
 
Figure II-3. Semisynthesis and characterization of phosphorylated α-syn derivatives 
A: Expressed Protein Ligation (EPL) approach to generate WT α-syn and pY125 α-syn. The α-syn(1-106)SR 
fragment was generated using intein-mediated thioester formation. MALDI-TOF analyses of 1) α-syn(1-106)SR 
(expected mass: 10744 Da [M+H]); The synthetic peptides α-syn (A107C-140) and α-syn(A107C-140)_pY125 
were generated by Fmoc-based SPPS. MALDI-TOF analyses of 2) α-syn(A107C-140)_pY125 (expected mass: 
3970 Da [M+H]);. Full-length semisynthetic α-synA107C and α-synA107C_pY125 were generated by a NCL step 
between α-syn(1-106)SR and synthetic peptide α-syn(A107C-140)_pY125 or α-syn(A107C-140). Radical 
desulfurization of the purified ligation product generated pY125 α-syn and α-syn WT. The final purification step 
involved a cation-exchange chromatographic step. B: MALDI-TOF analyses of 3) α-synA107C_pY125 (expected 
mass: 14573 Da [M+H]); and 4) pY125 α-syn (expected mass: 14541 Da ([M+H])). C: Coomassie blue stained 
SDS-PAGE analysis of the NCL reaction to generate pY125 α-syn. Lane 1, 2, 3, and 4 represent α-syn(1-106)SR; 
ligation reaction after 45 min, 90 min, and 140 min, respectively. 
 
Initially, we used the chitin binding domain from the commercially available IMPACT system 
(New England Biolabs) as a purification tag for the attachment of the fusion protein to the chitin 
beads followed by splicing on the column with 0.25 M MESNa and subsequent purification of 
the thioester by reversed-phase HPLC. We then added a C-terminal histidine tag on the intein to 
facilitate the purification of the protein from larger volumes of E.coli lysates .The purification 
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procedure was therefore modified and cell lysates were passed through a Ni-NTA column to 
immobilize the fusion protein and remove undesired proteins (Figure II-3.A). The α-syn(1-
106)SR was released by thiolysis with an excess of MESNa. The protein thioester was then 
purified by RP-HPLC and characterized by MALDI-TOF mass spectrometry and RP-HPLC 
(Figure II-3.A and Figure S II-3).  The peptide fragments α-syn (A107C-140) pY125 and α-syn 
(A107C-140) WT, each with an N-terminal cysteine, were generated by stepwise SPPS (Figure 
S II-1 and Figure S II-2). 
The expressed fragment α-syn(1-106)SR was then subjected to two separate NCL reactions 
under denaturing conditions with 2 molar excess synthetic C-terminal peptides α-syn (A107C-
140) pY125 and α-syn (A107C-140) (Figure II-3.A), generating two variants of full length α-syn 
A107C selectively phosphorylated at Tyr-125 (pY125 α-syn) and the wild-type (WT) protein, 
respectively. Hydrolyzed α-syn(1-106)-OH was generated as a minor side product, even when 
the NCL reaction was carried out at lower pH values. Due to the co-elution of α-syn(1-106)OH 
and the full-length protein by reverse phase HPLC under all conditions tested in our laboratory, 
we could not quantitatively assess the yield at each step of the semisynthesis. The final yield of 
the purified protein is 19%. (Figure II-3.C and Figure S II-5). Radical-initiated desulfurization 
of Cys-107 in the ligated proteins re-established the native Ala-107 residue in the 
phosphorylated variant of α-syn and its WT counterpart with minimal loss of starting material. 
A loss of 32 mass units from each protein was observed by MALDI-TOF-MS in each protein, 
consistent with the loss of a sulfur atom (Figure II-3.B, Figure S II-6 and Figure S II-8). 
Separation of the ligated fragment from the hydrolyzed thioester and excess C-terminal peptide 
was initially achieved by using a combination of different purification methods, including RP-
HPLC, anion-exchange, liquid isoelectric focusing and size exclusion chromatography. Only a 
combination of two or more of these techniques resulted in pure semi-synthetic proteins. 
However, this approach resulted in very low final yield. Later, the ligation products were 
purified using cation-exchange chromatography, which permitted single-step chromatographic 
separation of the full-length fragment, the hydrolyzed thioester, the C-terminal peptide and other 
contaminants (Figure S II-9, Figure S II-10 and Figure S II-11). Using optimized NCL, 
desulfurization and purification conditions, we obtained milligram quantities of the purified 
ligated proteins. In the case of α-syn phosphorylated at Y125, MALDI-TOF analysis of the 
purified products demonstrated a major peak with m/z = 14545 corresponding to the desired 
[M+H+] ions (Figure II-4.A and Figure S II-6 andFigure S II-8). Western-blot analysis using 
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anti-α-syn and anti-pY125 α-syn antibodies further confirmed the identity and purity of the 
semisynthetic WT α-syn and pY125 α-syn proteins (Figure II-4.B). 
II.5.2. Semisynthetic pY125 α-syn adopts an α-helical structure upon binding to 
membrane 
The secondary structure of the semisynthetic pY125 α-syn was investigated using circular 
dichroism in solution (50 mM Tris buffer and 150 mM NaCl, pH 7.5,) and in the presence of 
POPG vesicles (with a lipid:protein mass ratio of  20:1). As shown in Figure II-4.C, pY125 α-
syn exhibits a virtually identical CD spectrum to that of the WT recombinant α-syn in solution 
(random coil) and adopts an α-helical structure upon binding to the lipid vesicles.  
 
Figure II-4. Biochemical and biophysical characterization of semisynthetic WT and pY125 α-syn.  
A: SDS-PAGE, RP-HPLC and MALDI-TOF analyses of the pure semisynthetic pY125 α-syn. MALDI analysis 
pY125 α-syn (expected mass: 14541 Da ([M+H]), a sinapinic matrix adduct is also observed as well as the double-
charged peak. B: Western blot analyses of WT and pY125 α-syn confirmed that the phosphorylated semisynthetic 
protein could be detected by the anti-phosphorylated α-syn primary antibody, as well as by a non-phospho-specific 
antibody C: Circular dichroism spectra of pY125 α-syn in the absence (circles) and presence (triangles) of POPG 
vesicles. Open and closed symbols indicate WT recombinant α-syn and pY125 α-syn, respectively.  
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II.5.3. Phosphorylation at Y125 does not alter the structure of monomeric α-syn 
To determine the effect of Y125 phosphorylation on the structural properties of monomeric α-
syn, 15N labeled A107C α-syn and A107C/pY125 α-syn were generated for solution NMR 
studies (Figure S II-12 and Figure S II-13).  The NMR spectra of the free proteins were 
essentially identical and similar to the equivalent spectrum of the WT protein (not shown), 
indicating that both A107C and A107C/pY125 α-syn remain in the highly disordered ensemble 
characteristic of this protein (Eliezer et al., 2001). 
 
Figure II-5. NMR characterization of free and micelle-bound WT and pY125 α-syn.  
A: Paramagnetic relaxation enhancement profiles for A107C (upper panel) and A107C/pY125 (lower panel) α-syn, 
derived from the intensity ratios of equivalent resonances between 1H, 15N HSQC spectra collected with and 
without an attached spin-label.  A ratio of 1 indicates no PRE effect, while smaller ratios indicated a PRE effect, 
resulting from the proximity of the corresponding residue to the site of spin-label attachment. B: Overlaid 1H, 15N 
HSQC spectra of SDS micelle bound WT (black) and A107C/pY125 (red) α-syn (upper panel) and plots of the 
normalized chemical shift changes between the two spectra as a function of residue number (lower panel).  The 
solid line in panel B is a three-residue average.  Note that each red peak corresponds closely to a black peak, 
indicating that the structures of the two variants are highly similar in the micelle-bound state.  Black peaks without 
corresponding red peaks arise from residues 108 and beyond, where the semisynthetic A107C/pY125 protein is not 
15N-labeled and therefore does not give rise to signals in this spectrum. 
 
To assess the potential influence of phosphorylation on the transient long-range structure of the 
protein, we collected paramagnetic relaxation data for phosphorylated and unphosphorylated α-
syn modified at Cys 107 by the spin label MTSL. The paramagnetic spin label increases the 
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relaxation rate and thus broadens the resonance of any residue within ~20 Å. Intramolecular 
contacts can thus be discerned by measuring the intensity ratio of resonances in a 
paramagnetically-labeled sample to the equivalent resonances in a diamagnetic control.  
Plots of the intensity ratio as a function of residue number for A107C and A107C/pY125 α-syn, 
shown in Figure II-5.A reveal two interesting results.  First, even in the unphosphorylated 
sample, there is little indication of the previously reported long-range contacts between the C- 
and N-terminal regions of the protein (Paleologou et al., 2008). This observation is surprising, 
but suggests that position 107 may not be highly sensitive to these contacts. However, there is a 
significant difference in the data between the phosphorylated and unphosphorylated proteins in 
the regions proximal to the labeling site.  Residues close to the labeling site are broadened 
because they are covalently constrained to close proximity with the spin label, resulting in a well 
(or minimum) around position 107.   
It has been argued that the breadth of this well reflects the local compactness of the protein.  
Despite the fact that only residues prior to the position 107 in A107C/pY125 α-syn are 15N 
labeled give rise to data, it is evident that the well around position 107 is narrower for the 
phosphorylated protein.  This result indicates that in the phosphorylated protein, the C-terminal 
region samples a more expanded ensemble of conformations. 
Because the PRE data could not be used to monitor changes in long-range contacts due to 
phosphorylation at position 125, we also measured and compared the hydrodynamic radii of the 
phosphorylated and unphosphorylated proteins using pulsed field gradient NMR methods. The 
hydrodynamic radius of A107C/pY125 α-syn was found to be identical, within experimental 
error, to that of both A107C and WT α-syn, indicating that no significant overall compaction or 
expansion of the monomer occurs upon Y125 phosphorylation. These observations contrast with 
observations made in the case of S129 phosphorylation, where a significant degree of expansion 
occurs (Paleologou et al., 2008). 
We also examined the potential effects of phosphorylation at Y125 on the micelle-bound form 
of the protein; this form is thought to closely resemble one of several membrane-bound forms of 
the protein. We observed a high degree of overlap between the 1H,15N-HSQC spectra of WT 
A107C/pY125 α-syn in the presence of SDS micelles (Figure II-5.B), indicating that no gross 
structural changes in the protein occur upon phosphorylation at Y125. To more closely assess 
the effects of Y125 phosphorylation, we plotted the chemical shift changes between the two 
spectra as a function of residue number (Figure II-5.B). The results show that while the changes 
are generally small (on the order of 0.01 ppm), they are larger than those we observed for pS129 
(Paleologou et al., 2008). Furthermore, these changes appear to be slightly greater in regions 
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corresponding to the center of each of the two previously characterized helices of the micelle-
bound form of the protein (Bisaglia et al., 2005).   
II.5.4. Phosphorylation at Y125 does not affect the fibrillization of α-syn 
Previously, work from our group and others (Paleologou et al., 2008, Levitan et al., 2011) has 
shown that phosphorylation at S129 inhibits the fibrillization of α-syn in vitro. To determine 
whether phosphorylation at Y125 influences the aggregation properties of α-syn, we optimized 
conditions for α-syn fibril formation at low protein concentrations (15 µM) and compared the 
extent and kinetics of fibrillization of semisynthetic pY125 α-syn to those of the semisynthetic 
WT α-syn and recombinant WT proteins. Each protein was incubated with agitation at 37°C and 
the extent of fibrillization was assessed by ThT fluorescence and TEM after 72 h of agitation. 
As evidenced by the increase in ThT signal shown in Figure II-6, WT and pY125 α-syn forms 
mature fibrils after 24 h of incubation. Next, we assessed the amount of monomeric protein 
using a filtration assay and used TEM to characterize the structural properties of the aggregates 
formed by each protein. On the structural level, both WT and pY125 α-syn formed mature 
fibrillar structures (Figure II-6.C and Figure S II-14). 
 
Figure II-6. Fibrillization of pY125 α-syn.  
A: ThT fluorescence of recombinant WT and pY125 α-syn monitored over 48 h. B: SDS-PAGE analysis of the 
remaining WT and pY125 α-syn monomers prior to and after aggregation for 72 h and filtration through a 100 kD 
membrane. C: TEM images of WT and pY125 α-syn after 7 days of aggregation. The scale bar represents 500 nm. 
The images are representative of 5 independent experiments. The scale bar represents 500 nm. 
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After filtration of the samples through a 100 kDa membrane filter, the amount of monomeric α-
syn was assessed by SDS-PAGE analysis. No significant amounts of monomers were detected 
for WT and pY125 α-syn after 7 days (Figure II-6.B). Together, these data suggest that 
phosphorylation at Y125 does not alter the aggregation of α-syn. 
II.5.5. pY125 α-syn is dephosphorylated within minutes in vitro and in vivo 
To investigate the subcellular localization in vivo, pY125 α-syn was microinjected into 
hippocampal primary neurons at a concentration of 1 μM. Because microinjected pY125 α-syn 
might be rapidly dephosphorylated, we fixed the neurons either immediately or 30 min after 
microinjection and probed for pY125 α-syn and total α-syn using the appropriate antibodies. 
Interestingly, in the injected cells, the signal for pY125 α-syn dramatically decreased within 30 
min compared to the signal for WT α-syn (data not shown).  
 
Figure II-7. Dephosphorylation and detection of pY125 α-syn in cells  
A: Confocal images of HeLa cells transfected with WT α-syn plasmid and treated or not with pervanadate for 
30min. The scale bar represents 20 μm. Subsequently, the cells were fixed and stained with the indicated antibodies 
(respectively rabbit anti-α-syn from Abcam ab51252 and mouse anti-pY125 α-syn from BD Pharmingen). B: 
Detection of pY125 α-syn in primary neurons. Confocal images of rat hippocampal neurons microinjected with 1 
μM pY125 α-syn (25 fl/injection) together with the visible marker dye Faster Green (100 μg/ml) to identify the 
injected cells, the cells were treated with medium containing pervanadate for 30 min. Subsequently, the cells were 
fixed and stained with the indicated antibodies (respectively rabbit anti-α-syn from Abcam ab51252 and mouse 
anti-pY125 α-syn from BD Pharmingen). C: Immunoblots of HEK and HeLa cell lysates untreated or treated with 
pervanadate for 0, 5, 10 and 20min. The membranes were probed with total α-syn and pY125-specific antibodies 
(respectively rabbit anti-α-syn ab51252 from Abcam and mouse anti-pY125 α-syn from BD Pharmingen) D: 
Immunoblots of pY125 α-syn dephosphorylated from HeLa cell lysate. Membranes were probed with total α-syn 
and pY125-specific antibodies. The dephosphorylation was inhibited using different concentrations of sodium 
orthovanadate. E: Immuboblots of the subcellular fractionation of HEK cells over-expressing WT α-syn and treated 
with pervanadate for 20 min. Markers for cytoplasmic, membrane and nuclear fraction were used to assess for the 
purity of each fractions (Hsp90α, calnexin and PARP-1). 
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To confirm these observations and to test for rapid dephosphorylation in vitro, a HeLa cell 
lysate was spiked with pY125 α-syn and incubated for 0, 30 and 60 min. A loss of signal from 
the phosphorylated protein but not from the total α-syn protein was observed, indicating that 
pY125 α-syn is completely dephosphorylated by endogenous phosphatases within 30 min of 
incubation (Figure II-7.D). These results indicate tight regulation of the phosphorylation state of 
α-syn at Y125 by endogenous tyrosine phosphatases. In these experiments, dephosphorylation 
was effectively inhibited using sodium orthovanadate, a general tyrosine-phosphatase inhibitor. 
II.5.6. pY125 α-syn is localized into the cytoplasm in HeLa cells and primary neurons  
Previous attempts to characterize the possible effect of Y125 phosphorylation on the subcellular 
localization of α-syn were unsuccessful, in part due to lack of pY125-specific antibodies that are 
suitable for immunocytochemistry (Chen et al., 2009). In an attempt to overcome this limitation, 
we generated an antibody specific for pY125 α-syn and used it to immunolocalize of pY125 α-
syn in HeLa cells and rat hippocampal neurons. The pattern of pY125 α-syn immunoreactivity 
produced by this antibody was compared with the pattern obtained using a commercially 
available antibody from BD Pharmingen. 
For these experiments, we first identified conditions that prevent rapid dephosphorylation of 
pY125 α-syn. Previous reports indicated that pY125 α-syn is detectable in HEK293 cells that 
overexpress WT α-syn upon treatment with pervanadate (Ellis et al., 2001, Ahn et al., 2002). We 
validated these findings and found by Western-blot analysis of lysates from HEK293 and HeLa 
cells overexpressing human WT  α-syn, that treatment with pervanadate results in the 
upregulation of pY125 α-syn in these cells (Figure II-7.C). 
In cells over-expressing WT α-syn, but not the mutant Y125F α-syn, we observed a significant 
increase in the level of pY125 α-syn when the duration of treatment with pervanadate was 
increased. Non-specific bands of higher molecular weight were also detected with both the 
commercial (BD Pharmingen) and homemade anti pY125 α-syn antibodies after pervanadate 
treatment (Figure S II-15).  This precludes the use of these antibodies to accurately assess in 
more details the subcellular localization of pY125 α-syn in specific cellular organelles. We were 
able to partially circumvent this problem by studying the subcellular localization of pY125 α-
syn in HeLa cells overexpressing α-syn (Figure II-7.A). Quantification of the average 
fluorescence intensity of 65 cells (data not shown) treated with pervanadate showed that the 
increasing levels of cytosolic pY125 α-syn correlated well with increasing α-syn levels, and 
indicated a predominantly cytosolic localization of pY125 α-syn. We did not observe pY125 α-
syn immunoreactivity in the nucleus nor was any cytosolic increase in pY125 α-syn 
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immunoreactivity observed in HeLa cells over-expressing the mutant Y125F α-syn (Figure S 
II-16). When semisynthetic pY125 α-syn was microinjected into rat hippocampal neurons at a 
concentration of 1 μM, it showed a cytoplasmic distribution similar to the distribution of WT α-
syn immunoreactivity in HeLa cells (Figure II-7.B). To more accurately assess the subcellular 
localization of pY125, we preformed subcellular fractionation studies on HEK 293T cells 
overexpressing -synuclein in the presence and absence of pervanadate. Using this approach, we 
can demonstrate conclusively that pY125 localizes mainly in the cytosolic fraction and to a 
small extent in the membrane fraction, consistent with the results from immunocytochemistry 
(Figure II-7.E).  
II.5.7. Phosphorylation at Y125 does not block the phosphorylation at S129 and S87 in 
vitro and vice-versa 
The proximity of the three C-terminal tyrosine residues in α-syn suggests the possibility that the 
phosphorylation of one of these residues may trigger or modulate the extent of phosphorylation 
at the other residues. In a recent study, Y125 phosphorylation was suggested to protect against 
α-syn toxicity (Chen et al., 2009). Using a transgenic Drosophila model overexpressing the 
S129D phosphomimetic mutant of human α-syn in retinal and dopaminergic neurons, Chen et 
al. demonstrated that co-expression of Shark, a Drosophila homolog of the human tyrosine 
kinase Syk, which was previously reported to efficiently (although non-specifically) 
phosphorylate α-syn at Y125 (Negro et al., 2002), significantly alleviates neurodegeneration due 
to S129D α-syn expression. To investigate potential cross-talk between Y125 and S129 
phosphorylation sites, pY125 α-syn was incubated with PLK3, CK1 kinases, which are known 
to phosphorylate α-syn specifically and efficiently at S129 (PLK3) or at S87 and S129 (CK1). 
Phosphorylation at Y125, S129 and S87 was detected using the appropriate phosphospecific 
antibodies and confirmed by MALDI-TOF MS (Figure II-8.A-B).  
These results indicated that phosphorylation of α-syn at Y125 does not prevent recognition of 
the protein by PLK3 or CK1, affect the subsequent phosphorylation of pY125 α-syn at S129 and 
S87, or prevent recognition of the double-phosphorylated species (pY125/pS87 and 
pY125/pS129) by the appropriate antibodies. To determine whether phosphorylation at Y125 
influences S129 phosphorylation by endogenous kinases, we assessed the levels of pS129 in 
HeLa and HEK293 cells before and after treatment with pervanadate. Despite the significant 
increase in pY125 α-syn levels observed upon treatment with pervanadate, we did not observe 
any significant changes in pS129 levels (Figure II-9).  
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A recent study by Chen and colleagues suggested that phosphorylation at S129 does not affect 
the tyrosine phosphorylation of α-syn (Chen et al., 2009). However, these results were based on 
expression of a phosphomimetic mutant (S129D) that does not reproduce all aspects of 
phosphorylation at this site (Paleologou et al., 2008). Therefore, we sought to determine whether 
prior phosphorylation at S129 effects further phosphorylation at Y125 by the non-receptor 
tyrosine kinases Syk and members of the Src family (Lyn, Fyn, c-Fgr and c-Src), which have 
been previously shown to phosphorylate tyrosine residues in the C-terminus of α-syn.  
 
Figure II-8. Phosphorylation of pY125 and pS129 α-syn.  
A: Immunoblots of pY125 α-syn phosphorylated by CK1 and PLK3. Membranes were probed using pS129, pY125, 
and α-syn antibodies. B: MALDI-TOF-MS analysis of the phosphorylation reaction after 12h. C: Immunoblots of 
pS129 α-syn phosphorylated by Syk, Lyn, Fyn, c-Src, and c-Fgr. Membranes were probed for pY125, pS129, and 
α-syn immunoreactivity. D: MALDI-TOF analysis of pS129 α-syn phosphorylated by (a) Syk, (b) Lyn, (c) Fyn, (d) 
c-Src, (e) and c-Fgr (f) after 14h of reaction. In all MALDI-TOF-MS spectra, the symbol ‘n’ indicates the peak 
corresponding to the starting material, the numbers above the other peaks correspond to the number of 
phosphorylation events, which were each detected by a +80 Da mass shift. The symbol ‘*’ indicates a sinapinic 
acid matrix adduct. 
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Figure II-9. Phosphorylation of pY125 α-syn and pS129 α-syn.  
Immunoblots of HeLa cells over-expressing WT α-syn and treated with pervanadate for 0, 5, 10 and 20min. 
Membranes were probed with pS129 and pY125 α-syn and WT α-syn antibodies. 
 
The protein was first quantitatively phosphorylated using PLK3, purified by reversed-phase 
HPLC and incubated at 3 µM for 14 h at 30°C in the presence of 100 nM of each individual 
tyrosine kinase. Western blot and MALDI-TOF-MS analyses (Figure II-8.C-D), showed the 
same efficiency and site-specificity of phosphorylation by these kinases as reported in previous 
in vitro studies. Of these kinases, Syk is by far the most efficient at phosphorylating α-syn with 
a reported Kcat/Km of around 30, it also phosphorylated multiple tyrosines within the C-terminal 
region of α-syn (Ellis et al., 2001, Negro et al., 2002). We consistently observed 
phosphorylation at Y125 and at two other sites by MALDI-TOF MS (Figure II-8.D (b)). The 
other kinases were more specific but lacked efficiency. For example, the Kcat/Km for Lyn is 
around 0.5. Most importantly, we observed that S129 phosphorylation did not block the activity 
of any of the tyrosine kinases. As a control, WT α-syn was incubated under the same conditions, 
a similar phosphorylation pattern was obtained (data not shown). Western-blot-based detection 
of Y125 phosphorylation appeared to be more sensitive than MALDI-TOF-MS because pY125 
α-syn could be detected in all of the enzymatic reactions (Figure II-8.C). Together, these data 
suggest that S129 phosphorylation of α-syn does not interfere with further modifications of the 
protein by tyrosine kinases.  Moreover, because the consensus recognition sequences of tyrosine 
kinases such as Syk includes acidic residues (Brunati et al., 1995), pS129 might act to stabilize 
the electrostatic interactions between the kinases and α-syn. 
We performed a similar experiment aimed at determining whether phosphorylation at S87, 
another disease-related phosphorylation site within α-syn that was recently identified by our 
group (Paleologou et al., 2010), influence the recognition and processing of α-syn by the soluble 
tyrosine kinases mentioned above. We observed that phosphorylation of α-syn at S87 does not 
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significantly influence the protein’s activity as a substrate for the non-receptor tyrosine kinases 
Syk, Fyn, Ly, c-Fgr, and c-Src or the site-specificity of its phosphorylation by these enzymes 
(Figure S II-17). 
II.5.8. Phosphorylation at Y125 disrupts the binding of nanobody Nb87 to α-syn C-
terminus 
Phosphorylation of α-syn at Y125 has been previously shown to affect α-syn protein-protein 
interactions as described in reports using C-terminal fragments of α-syn (McFarland et al., 
2008). We sought to probe the effect of phosphorylation at S129 and Y125 on the interaction of 
full-length α-syn with proteins or peptides that are known to bind tightly to α-syn via specific 
interactions involving the C-terminal region of the protein. After careful review of the literature, 
we decided to focus on Nanobodies, which are single antibody variable domains obtained by 
immunization of camels (Dumoulin et al., 2003, Vincke et al., 2009, De Genst et al., 2010) . 
More specifically, we took advantage of the use of Nanobody Nb87 that was previously 
identified by the Dobson group using phage-display and was shown to bind with high affinity 
(Kd in the range of nM) to α-syn (De Genst et al., 2010)(Guilliams et al, 2012). NMR studies 
have shown that Nb87 binds sites comprising α-syn C-terminal residues 118-132 (Guilliams et 
al, 2012). To assess the influence of α-syn phosphorylation at S129 and Y125, we generated the 
corresponding forms of the protein either via in vitro phosphorylation of WT α-syn with PLK3 
(pS129) or by semisynthesis (pY125) and evaluated their binding to Nb87 using Isothermal 
Titration Calorimetry technique (in collaboration with the Dobson group). Given the common 
use of phosphomimics, we also sought to compare the binding of pS129 and S129E to Nb87. 
S129A and Y125F were also included as controls.  
Phosphorylation of α-syn at Y125 and the mutation of Tyr125 to Phe resulted in 638-fold and 
23-fold lower affinity to Nb87 respectively compared to the WT protein (Figure II-10.C and 
Figure II-11.A). These results suggest that the epitope of α-syn recognized by Nb87 is most 
likely situated around residue 125 and that phosphorylation of α-syn at Y125 strongly impaired 
α-syn-Nb87 interactions. Aside from the disruption of the binding to Nb87, phosphorylation at 
Y125 also induced higher enthalpy of binding (5-fold higher), compared to WT and Y125F α-
syn (Figure II-11.A), which suggests a binding event that has an entropic contribution.   
We were also able to assess for the first time, the effect of site-specific phosphorylation of full-
length α-syn on its interactions with proteins. Phosphorylation at S129 did not affect 
significantly the binding to Nb87 and even showed a slight increase of binding affinity in 
respect to WT or S129A α-syn (Kd = 10nM) (Figure II-10. D,E,F and Figure II-11. B). 
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However, some differences emerged in the case of the phosphomimic: the binding of S129E to 
Nb87 was 4 fold weaker than pS129 (Figure II-10. D,E,F and Figure II-11. B), consistent with 
previous results from our lab highlighting major differences between phosphomimics S129E 
and S129D and phosphorylated α-syn pS129 on the structure and fibrillization rate of α-syn 
(Paleologou et al., 2008). The binding enthalpies were similar though for all α-syn constructs 
(Figure II-11.B). These results demonstrate that the phosphomimics are not suitable for 
investigating α-syn phosphorylation-dependent protein-protein interactions.  
 
Figure II-10. Raw ITC thermograms of Nb87 binding to α-syn variants  
Raw ITC thermograms of Nb87 binding to WT (A), Y125F (B), pY125 (C), pS129 (D), S129E (E), S129A (F) α-
syn. Data were recorded in PBS at 25°C.  
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Figure II-11. Dissociation constants and binding enthalpies of Nb87 binding to α-syn variants 
Dissociation constants and binding enthalpies of α-syn-Nb87 binding were calculated for WT, Y125F and pY125 α-
syn (A) and WT, pS129, S129E and S129A α-syn (B) 
 
II.6. Discussion 
Recent studies indicate that α-syn phosphorylation at serine residues S87 and S129 can 
dramatically influence α-syn structure (Paleologou et al., 2008, Paleologou et al., 2010), turn-
over (Chau et al., 2009), membrane binding (Paleologou et al., 2008, Paleologou et al., 2010), 
aggregation (Paleologou et al., 2008, Paleologou et al., 2010) and protein-protein interactions 
(McFarland et al., 2008). Notably, phosphorylations at S87 and S129 have emerged as a 
defining hallmark of PD and other synucleinopathies (Fujiwara et al., 2002, Anderson et al., 
2006). The use of phosphomimetic mutations (S?E/D) combined with the identification of 
kinases that specifically phosphorylate α-syn in vitro and in vivo has facilitated detailed studies 
that aimed at investigating the structural and functional consequences of phosphorylation of the 
protein at these residues in vitro and in vivo (Okochi et al., 2000, Pronin et al., 2000, Chen and 
Feany, 2005, Gorbatyuk et al., 2008, Azeredo da Silveira et al., 2009, Chen et al., 2009, Inglis et 
al., 2009, Mbefo et al., 2010). In addition to serine residues, α-syn has also been shown to 
undergo phosphorylation at its C-terminal tyrosine residues Y125, Y133, Y136 in vitro, with a 
preference for Y125 as the major phosphorylation site (Ellis et al., 2001, Nakamura et al., 2001, 
Ahn et al., 2002, Negro et al., 2002). However, only phosphorylation at Y125 has been detected 
in vivo (Chen et al., 2009). 
  
 110 
  
Several kinases have been reported to phosphorylate tyrosine residues in the C-terminus of α-
syn. However, all known kinases are either inefficient or lack specificity to phosphorylate α-syn 
at specific tyrosine residues in its C-terminus. The tyrosine kinase Syk phosphorylates α-syn at 
multiple tyrosine residues (Y125, Y133 and Y136) (Negro et al., 2002). In contrast, Fyn, Lyn, c-
Fgr and c-Src phosphorylate α-syn specifically at Y125, but these kinases are less efficient 
(Negro et al., 2002). The lack of specificity and efficiency of tyrosine phosphorylation of α-syn 
has hampered efforts to obtain homogenous preparations of phosphorylated α-syn and to 
elucidate the structural and functional consequences of phosphorylation at Y125. Unlike 
phospho-serine and phospho-threonine, which in some cases can be mimicked by serine ? 
glutamate or aspartate substitutions, there are no natural amino acids that can mimic phospho-
tyrosine. Inspired by the pioneering work of Muir and Cole on the use of expressed protein 
ligation to study the effect of site-specific phosphorylation and other post-translational 
modifications (Muir et al., 1998), we developed, for the first time, an efficient semisynthetic 
approach based on a one-pot native chemical ligation and desulfurization followed by a single 
chromatographic purification step for the production of pY125 α-syn. This strategy enabled us 
to obtain preparations of α-syn protein site-specifically modified at single or multiple residues 
within the C-terminal region comprising residues 107-140, the region that contains the majority 
of the reported PTM of the protein. Using this approach, we were able to obtain milligram 
quantities of semisynthetic WT and pY125 α-syn and to carry out detailed studies aimed at 
elucidating the effect of this modification on the structure, membrane binding, aggregation and 
subcellular localization of α-syn.  
The results presented here demonstrate that phosphorylation at Y125 does not significantly alter 
the structure of monomeric α-syn in solution (Figure II-4.B and Figure II-5). Although the 
hydrodynamic radius of pY125 α-syn is virtually identical to that of the WT protein, the 
paramagnetic relaxation data presented here indicate that the C-terminal region of pY125 α-syn 
samples a more expanded ensemble of conformations than in the WT protein. Interestingly, 
these observations contrast with the case of S129 phosphorylation, where a significant degree of 
expansion occurs (Paleologou et al., 2008). Phosphorylation at Y125 did not interfere with the 
ability of α-syn to form an α-helical structure upon binding to synthetic phosphatidylglycerol 
(POPG) or SDS micelles as assessed by CD spectroscopy. These results are consistent with 
previous observations regarding pS129 and with the fact that both S129 and Y125 lie outside the 
region involved in α-syn binding to membranes. However, the 1H,15N-HSQC spectra of the 
protein reveal small structural changes that are larger than those observed for the case of pS129 
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(Paleologou et al., 2008). Furthermore, the structural changes in the protein that result from 
Y125 phosphorylation appear to be slightly greater in regions corresponding to the centers of 
each of the two previously characterized helices of the micelle-bound form of the protein 
(Bussell and Eliezer, 2003).  Thus, while phosphorylation at Y125 does not result in large-scale 
structural changes in the micelle-bound form of the protein, it may cause slight rearrangements 
of the two micelle-bound helices. Such small changes may be consistent with results that 
indicate that modifications occuring in the C-terminal tail of the protein can influence the N-
terminal lipid-binding domain (Sevcsik et al., 2011).  
Previous studies by Negro et al. showed that co-incubation of α-syn with Syk kinase inhibits α-
syn aggregation in vitro (Negro et al., 2002). Co-expression of Syk and α-syn was also reported 
to inhibit α-syn oligomerization and inclusion formation in cell culture (Negro et al., 2002) and 
in Drosophila expressing Shark, the fly homolog of Syk (Chen et al., 2009). However, it is 
difficult to discern the relative contribution of phosphorylation at Y125 in these studies, because 
the Syk kinase phosphorylates all three C-terminal tyrosine residues (Y125, Y133 and Y136) to 
different extents. In subsequent studies by Negro and colleagues, it was reported that the 
addition of other tyrosine kinases (Lyn and c-Fgr) did not influence the aggregation of α-syn in 
vitro (Negro et al., 2002). However, the significantly reduced efficiency of these kinases for the 
phosphorylation of α-syn makes it difficult to draw any conclusions regarding the effect of 
phosphorylation at Y125 on α-syn aggregation and fibrillization. In this work, the availability of 
semisynthetic pY125 α-syn allowed us to address this question directly for the first time. WT α-
syn and semisynthetic pY125 α-syn exhibited similar aggregation properties as discerned by 
TEM and ThT fluorescence, demonstrating that pY125 α-syn behaves similarly to the 
recombinant protein produced in E. coli, unlike phosphorylation at S129, which inhibits α-syn 
fibrillization. Interestingly, pY125 α-syn exhibited similar aggregation properties as WT α-syn, 
consistent with the NMR results demonstrating that phosphorylation at Y125 induces only 
subtle structural changes on monomeric α-syn.  
The availability of semisynthetic pY125 α-syn provided unique opportunities to assess the 
subcellular localization of pY125 α-syn and to explore the potential cross-talk between 
phosphorylation at S129 and Y125. Recent studies by Chen et al. suggested that Y125 
phosphorylation may protect against α-syn toxicity by decreasing α-syn phosphorylation at S129 
(Chen et al., 2009). To investigate possible cross-talk between phosphorylation at S129 and 
Y125, we combined semisynthetic approaches and enzymatic phosphorylation assays. 
Employing optimized procedures for the in vitro phosphorylation of α-syn, we used 
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semisynthetic pY125 α-syn to examine the effect of phosphorylation at Y125 on S129 
phosphorylation by subjecting pY125 α-syn to phosphorylation by kinases that phosphorylate α-
syn efficiently at S129 (PLK3) and/or S87 and S129 (CK1) (Paleologou et al., 2008, Mbefo et 
al., 2010). To determine whether phosphorylation at S129 influence Y125 phosphorylation, we 
prepared pS129 α-syn by in vitro phosphorylation with PLK3 (Mbefo et al., 2010) and 
examined the extent of Y125 phosphorylation (pS129/pY125) by the tyrosine kinases Fyn, Lyn, 
Src, c-Fgr and Syk (Ellis et al., 2001, Nakamura et al., 2001, Ahn et al., 2002, Negro et al., 
2002). Our results demonstrate that phosphorylation at Y125 does not attenuate α-syn 
phosphorylation at S129 or S87 in vitro and vice-versa. These findings are consistent with the 
results of studies from Feany and colleagues in Drosophila suggesting that S129 
phosphorylation of α-syn does not influence Y125 phosphorylation. The levels of pY125 α-syn 
were similar in flies overexpressing WT, S129A or S129D, suggesting that S129 
phosphorylation does not influence phosphorylation at Y125. This study confirms these findings 
in mammalian cells (HeLa and HEK 293T), where no changes in pS129 levels were observed 
after treatment with phosphatase inhibitors that significantly enhance pY125 α-syn levels. 
The lack of significant interest in phosphorylation of α-syn at Y125, compared to 
phosphorylation at S87 and S129 can be attributed to difficulties in detecting significant levels 
of pY125 α-syn in human brain tissues and lack of evidence for a direct correlation between 
pY125 α-syn levels and disease progression. Proteomic and mass spectrometry analyses of α-
syn from Lewy bodies failed to detect phosphorylation at Y125 (Anderson et al., 2006). The 
rapid dephosphorylation of α-syn in post-mortem tissues may explain the limited success of 
previous studies in detecting pY125 α-syn in human brains and by biochemical analysis of 
brain-derived materials using mass spectrometry. Due to the dynamic regulation of tyrosine 
phosphorylation in vivo, detection of α-syn phosphorylation at Y125 appears to be dependent on 
the use of tyrosine phosphatase inhibitors or on the time elapsed prior to post-mortem analyses. 
Recently, Y125 phosphorylation was shown to occur both in human and Drosophila brains and 
pY125 α-syn levels was reported to decrease with aging and in PD brains, suggesting a possible 
protective role for this modification (Chen et al., 2009). Interestingly, in the presence of 
phosphatase inhibitors, 30% of α-syn in Drosophila appears to be phosphorylated at Y125 
supporting the role of Y125 phosphorylation in modulating α-syn properties. In this study, we 
showed that upon addition of pY125 α-syn to cell lysates or microinjection into primary 
neurons, pY125 α-syn is almost completely dephosphorylated within 5 min. This effect is 
blocked in the presence of pervanadate. These results are consistent with a very rapid 
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dephosphorylation of α-syn both in vitro and in vivo. Phosphorylation at Y125 appears to be 
tightly regulated such that the levels of pY125 α-syn are maintained at very low levels but 
increases significantly in cell culture, primary neurons, and brain tissues, upon treatment with 
the phosphatase inhibitor pervanadate (Ellis et al., 2001, Ahn et al., 2002, Chen et al., 2009). 
Together, these studies demonstrate that α-syn undergoes phosphorylation at Y125 in vivo and 
suggest that experiments aimed at evaluating and correlating specific PTM with disease 
progression must take into account the stability and dynamics of these modifications, and that 
the protocols used for the analysis and preparations of samples must be modified accordingly.  
Nakamura et al reported that the levels of pY125 α-syn increases by approximately 15 fold 
within the first few minutes in response to hyperosmotic stress, but then declines rapidly after 10 
min. These observations indicate the existence of efficient dephosphorylation mechanisms that 
regulate pY125 α-syn levels (Nakamura et al., 2002). However, the identities of the 
phosphatases responsible for regulating pY125 α-syn phosphorylation remain unknown. The 
availability of semisynthetic pY125 α-syn as a substrate should facilitate the development of 
assays to screen focused libraries of tyrosine phosphatase inhibitors and identify natural 
phosphatases that are involved in regulating Y125 phosphorylation in vivo. To prevent the rapid 
dephosphorylation of pY125 α-syn, we will replace phosphotyrosine by nonhydrolyzable 
phosphonate analogues (Berkowitz et al., 1996, Desmarais et al., 1999) that , once incorporated 
into α-syn, will render it resistant to phosphatase activity (Zheng et al., 2005a). Cole and 
colleagues have successfully introduced non-hydrolyzable tyrosine analogues into proteins 
using expressed protein ligation strategies and demonstrated their utility to investigate the role 
tyrosine phosphorylation in regulating the activity of different tyrosine phosphatases and their 
interaction with other proteins (Lu et al., 2003, Zheng et al., 2003, Shen et al., 2005, Zheng et 
al., 2005a, Schwarzer et al., 2006, Szewczuk et al., 2009). 
Whether phosphorylation at Y125 plays an important role in regulating α-syn aggregation and 
toxicity in vivo remains unknown. This question can only be answered by experimental 
conditions that permit site-specific regulation of phosphorylation at Y125 in vivo. To determine 
the functional consequences of Y125 phosphorylation, Feany and colleagues overexpressed WT 
α-syn, and mutant (α-syn YF) in which all C-terminal tyrosines were mutated to phenylalanine 
(Y125F/Y133F/Y136F) and compared the effects of the mutations on α-syn aggregation, 
toxicity, and locomotor deficit in flies. The mutant (α-syn YF) exhibited enhanced toxicity and 
caused a significant reduction in climbing ability compared to flies overexpressing the WT 
  
 114 
  
protein. Additionally, overexpression of the Shark kinase, the Drosophila homolog of Syk, 
increased the levels of pY125, decreased oligomer formation and rescued the neurotoxicity of 
WT α-syn and the more toxic S129 phosphomimetic S129D. It is important to note that in both 
approaches, the three tyrosines were either mutated or phosphorylated to different extent, 
making it difficult to decipher the effects of selective modification at Y125. Identification and 
expression of the kinases that allow selective modification of pY125 and/or coexpression of 
such kinases with Y133F/Y136F is crucial for gaining insight into the role of Y125 
phosphorylation in regulating α-syn aggregation and toxicity in vivo. The availability of 
semisynthetic pY125 α-syn and our improved understanding of the dynamics of Y125 
phosphorylation should aid in the development of assays to identify the natural kinases and 
phosphatases involved in the regulation of Y125 phosphorylation and will facilitate a 
quantitative evaluation of the extent of pY125 α-syn during disease progression.  
The role of phosphorylation in regulating α-syn interactions with other proteins and ligands 
remains unexplored. Recently McFarland et al. attempted to address this knowledge gap using 
C-terminal-derived α-syn peptides (WT and phosphorylated at S129 and Y125) to 
immunoprecipitate interactants from mouse brain synaptosomes (McFarland et al., 2008). 
Phosphorylation at S129 and Y125 reduced the affinity of α-syn peptides to proteins of the 
mitochondrial electron transport complex and preferentially directed the interaction toward 
proteins involved in the cytoskeletal architecture and the endocytosis pathway. Kinases were 
also identified among the interactants of phosphorylated peptides (McFarland et al., 2008). 
Furthermore, phosphorylation of α-syn has major impacts on its binding to metal. The binding 
of α-syn to bivalent cations (Cu2+, Pb2+ and Fe2+) was reported to be increased in presence of C-
terminal peptides phosphorylated at S129 or Y125 (Lu et al., 2011). Phosphorylation also 
affected the repartition of the binding sites with a clear preference toward the C-terminal domain 
(Lu et al., 2011). Although these studies provided important insights into the potential role of 
phosphorylation in regulating α-syn’s interactions with proteins and metal ions, they were based 
on C-terminal peptide fragments which are likely to eliminate potential candidates that would 
require the binding to N-terminal and NAC region of α-syn. Therefore, the extent to which these 
studies reflect the impact of phosphorylation on the interaction of the full-length protein remains 
unknown.  
We probed here, for the first time, the effect of full-length pS129 and pY125 α-syn on its 
interactions with other proteins. When comparing the affinity of the different phosphorylation 
variants of α-syn on the binding to nanobody Nb87, it was revealed that pS129 had a slightly 
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stronger affinity to Nb87 while pY125 exhibited a 638-fold lower affinity. Phosphorylation of 
α-syn has been shown to play a major role in aggregation, with phosphorylation of S87 and/or 
S129 inhibiting its fibrillization (Paleologou et al., 2008) while phosphorylation of Y125 has no 
effect on α-syn aggregation. In addition, our binding studies confirm previous findings from our 
lab that suggested that phosphomimics do not reproduce all structural aspects of α-syn 
phosphorylation (Paleologou et al., 2008). We report here that the effect of mimicking 
phosphoserine by a glutamate also influences protein-protein interaction since the binding 
affinity of pS129 and S129E to Nb87 was not identical. We show for the first time that 
phosphorylation of a single residue of α-syn is able to disrupt strong interactions, with definitely 
strong implications for the complex of proteins interacting with α-syn in vivo and the cellular 
mechanism that are modulated as a direct consequence.   
 
 
II.7. Conclusions 
We recently reported a semisynthetic approach that enabled site-specific modification of the N-
terminus of α-syn and used this approach to prepare and characterize an α-syn form that is 
mono-ubiquitinated at Lysine 6 (Hejjaoui et al., 2011). In this study, we describe a general and 
efficient semisynthetic strategy that enables the site-specific introduction of single or multiple 
PTM of α-syn and the preparation of homogeneously modified forms of α-syn at its C-terminus 
in milligram quantities. These two approaches make it possible to prepare all the known disease-
associated PTM of α-syn, except pS87, and to study potential cross-talk between these 
modifications. These advances have allowed us to investigate for the first time the effect of 
selective phosphorylation at Y125 α-syn on the structure, aggregation, membrane binding, 
subcellular localization of the protein and protein-protein interaction. In addition, these advances 
provide unique opportunities to investigate PTM-dependent protein-protein interactions 
involving α-syn and to study the cross-talk between different PTM. Furthermore, the availability 
of these proteins is crucial for advancing current research programs with the following aims: 1) 
characterization of PTM in humans and in animal models of PD; 2) development of biomarkers 
and target identification and 3) development of sensitive assays for the detection and 
quantitative assessment of specific PTM in vivo and in biological fluids. Therefore, the 
development of these semisynthetic strategies represents an important advance toward 
unraveling the roles of PTM in determining α-syn structure, aggregation and functions in health 
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and disease. We hope that this work will encourage other research groups to pursue similar 
approaches to elucidate the role of PTM in regulating the function of other proteins, particularly 
proteins linked to neurodegenerative diseases.  
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II.8. Supporting information 
II.8.1. Synthesis and characterization of α-syn C-terminal peptides 
Peptide: α-Syn(A107C-140) 
sequence: CPQEGILEDMPVDPDNEAYEMPSEEGYQDYEPEA 
synthetic specifications: couplings used HBTU; double couplings performed  at Cys107, 
Glu109, Met-116, Asp-119, and Met-127 
yield: 25% 
expected mass: 3886 Da 
 
 
Figure S II-1. Analysis of peptide α-syn A107C-140 
a) MALDI-TOF analysis (observed mass=3885.85Da) and b) RP-HPLC analysis of purified α-syn A107C-140 on a 
C18 analytical column (CosmoSil Protein-R, 4.6x250 mm, 5µm particle size) with a linear gradient of 0 to 80%B 
over 30min (A: water/0.1%TFA and B: acetonitrile/0.1% TFA).  
 
Peptide: α-syn(A107C-140)_pY125 
sequence: CPQEGILEDMPVDPDNEA-pY-EMPSEEGYQDYEPEA 
synthetic specifications: see above 
yield: 25% 
expected mass: 3969 Da 
 
 
 
Figure S II-2. Analysis of peptide α-syn A107C-140_pY125 
a) MALDI-TOF analysis (observed mass= 3968 Da). b) RP-HPLC analysis of purified α-syn A107C-140_pY125 
on a C18 analytical column (CosmoSil Protein-R, 4.6x250 mm, 5µm particle size) with a linear gradient of 0 to 
80%B over 30min (A: water/0.1%TFA and B: acetonitrile/0.1% TFA). 
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II.8.2. Generation of 15N-labeled α-syn(1-106)SR and non-labeled α-syn(1-106)SR 
 
Non-labeled α-syn(1-106)SR 
 
Figure S II-3. Analysis of α-syn(1-106)SR 
a) MALDI-TOF analysis (observed mass= 10739). The mass 5367 corresponds to the double-charged. b) RP-HPLC 
analysis of purified α-syn(1-106)SR on a C4 analytical column (CosmoSil 5C4) with a linear gradient of 0 to 80%B 
over 15min (A: water/0.1%TFA and B: acetonitrile/0.1% TFA). 
 
15N labeled α-syn (1-106)SR  
 
Figure S II-4. Analysis of 15N α-syn(1-106)SR 
a) MALDI-TOF analysis (observed mass= 10870). The mass 5434 corresponds to the double-charged. b) RP-HPLC 
analysis of purified α-syn(1-106)SR 15N labeled on a C4 analytical column with a linear gradient of 0 to 80%B over 
30min (A: water/0.1%TFA and B: acetonitrile/0.1% TFA) 
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II.8.3. Semisynthesis and purification of WT α-syn and pY125 α-syn 
 
α-SynA107C wild-type 
 
Figure S II-5. SDS-PAGE analysis of the ligation reaction 
SDS-PAGE analysis of native chemical ligation reaction between α-syn(1-106)SR and α-syn(A107C-140). 
 
 
 
 
Figure S II-6. Analysis of semi-synthetic WT α-syn 
a) MALDI-TOF analysis of the desulfurized product (expected mass: 14461). The mass of 14676 corresponds to a 
sinapinic matrix adduct and the mass of 7233 to the double-charged. b) RP-HPLC of semi-synthetic WT α-syn on 
an analytical C18 with a linear gradient of 0 to 80%B over 30min (A: water/0.1%TFA and B: acetonitrile/0.1% 
TFA). 
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α-synA107C_pY125 
 
Figure S II-7. SDS-PAGE reaction of the ligation reaction 
SDS-PAGE analysis of native chemical ligation reaction between α-syn(1-106)SR and α-syn(A107C-140_pY125). 
Note: the ligation corresponding to the gel was done with two molar excess of α-syn(1-106)SR.  
 
 
Figure S II-8. Analysis of of semi-synthetic pY125 α-syn 
a) MALDI-TOF analysis of the desulfurized product (expected mass: 14541). The mass of 14744 corresponds to a 
sinapinic matrix adduct and the mass of 7220 to the double-charged. b) RP-HPLC of semi-synthetic pY125 α-syn 
on an analytical C18 with a linear gradient of 0 to 80%B over 30min (A: water/0.1%TFA and B: acetonitrile/0.1% 
TFA). 
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General scheme of ligation and purification 
 
 
 
Figure S II-9. Scheme of the main step for the generation of pY125 α-syn 
Scheme of the main steps for the generation of pY125 α-syn: ligation, desulfurization and purification by 
chromatographic methods.   
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Figure S II-10. Scheme of the cation-exchange chromatography purification of pY125 α-syn.  
 
 
Figure S II-11. SDS-PAGE of the fractions of the cation exchange column 
A: SDS-PAGE analysis of the fractions containing pY125 α-syn (eluting from the cation exchange column at pH 
5). B: SDS-PAGE analysis of the pure lyophilized pY125 α-syn.  
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II.8.4. Generation of α-syn A107C N15 labeled and Semisynthesis of α-syn A107C_pY125 
N15 labeled 
 
α-synA107C 15N labeled 
 
Figure S II-12. Analysis of 15N labeled α-syn A107C 
a) MALDI-TOF analysis of the protein (expected mass: 14659). The mass of 14866 corresponds to a sinapinic 
matrix adduct and the mass of 7329 to the double-charged. b) RP-HPLC of 15N labeled α-syn A107C on an 
analytical Protein-R C18 column with a linear gradient of 0 to 80%B over 30min (A: water/0.1%TFA and B: 
acetonitrile/0.1% TFA). 
 
 
α-synA107C_pY125 15N labeled 
 
 
Figure S II-13. Analysis of semi-synthetic pY125 α-syn 15N labeled 
a) MALDI-TOF analysis of the ligated product (expected mass: 14701). The mass of 14913 corresponds to a 
sinapinic matrix adduct and the mass of 7350 to the double-charged. b) RP-HPLC of semi-synthetic pY125 α-syn 
15N labeled on an analytical Protein-R C18 column with a linear gradient of 0 to 80%B over 30min (A: 
water/0.1%TFA and B: acetonitrile/0.1% TFA).  
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II.8.5. TEM images of recombinant and semisynthetic WT α-syn 
 
 
 
 
Figure S II-14. TEM images of semisynthetic and WT α-syn 
TEM images of recombinant WT and semisynthetic α-syn incubated for 7 days on a rotating wheel at 37°C. The 
images are representative of 3 independent experiments. The scale bars represent 200nm. 
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II.8.6. Analysis of HEK and HeLa cells and mouse neurons treated with pervanadate: 
detection of non-specific bands 
 
 
Figure S II-15. Detection of non-specific bands using pY125 antibodies 
A. Immunoblots of HEK293 (left) and HeLa (right) cells over-expressing WT α-syn and treated with pervanadate 
for 5, 10 and 20min. Membranes were probed with WT α-syn (Biomol SA3400) and pY125 antibodies (BD 
Pharmigen). B. Immunoblots of mouse α-syn KO primary neurons treated with pervanadate for 30min. Membranes 
were probed with WT α-syn (BD transduction laboratory) and pY125 antibodies (BD Pharmigen). 
 
 
 
Figure S II-16. Detection of non-specific signal by immunocytochemistry 
Confocal images of HeLa cells over-expressing WT or Y125F α-syn and treated with pervanadate for 30min. The 
cells were fixed and stained with anti-pY125 antibody (BD pharmigen) and anti-α-syn (abcam). 
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II.8.7. Cross-talk between α-syn phosphorylation at S87 and Y125: in vitro 
phosphorylation assay 
 
 
 
Figure S II-17. Immunoblots of pY125 α-syn phosphorylated using CK1 and PLK3 
A: Immunoblots of pY125 α-syn phosphorylated using CK1 and PLK3. Membranes were probed using pS87, 
pY125, and α-syn antibodies. B: Immunoblots of pS87 α-syn phosphorylated using Syk, Lyn, Fyn, c-Src, and c-Fgr. 
Membranes were probed for pY125, pS87, and α-syn immunoreactivity. D: MALDI-TOF analysis of pS87 α-syn 
(a) phosphorylated by Syk (b), Lyn (c), Fyn (d), c-Src (e), and c-Fgr (f) after 14h of reaction. In all MALDI-TOF-
MS spectra, the symbol ‘n’ indicates the starting material peak, while the numbers above other peaks correspond to 
the number of phosphorylation events, each detected by a +80 Da mass shift. The symbol ‘*’ indicates a sinapinic 
acid matrix adduct.  
 
Supporting information for the figure S17: 
To obtain site-specific phosphorylation at S87, S129A α-syn was incubated with CKI until phosphorylation at S87 
was complete, then pS87 α-syn was purified by reversed-phase HPLC, and incubated with the tyrosine kinases in 
the same conditions as in the experiment with pS129 α-syn. Using first the mutant S129A α-syn, we showed that 
the S129A mutation itself did not influence phosphorylation at Y125 (not shown). Using the purified pS87 α-syn, 
we observed that the behavior of pS87 α-syn is similar to that of pS129 α-syn and WT α-syn: phosphorylation at 
Y125 by Syk is very efficient as judged by Western Blot (Figure S II-17.B) but again not specific as shown by 
MALDI-TOF MS (Figure S II-17. C (b)). We noted, however, that pS87 α-syn might be more efficiently 
phosphorylated at Y125 by Fyn than pS129 α-syn, since a single phosphorylation event could be seen with pS87 α-
syn but not pS129 α-syn. However, Western-Blot data does not support a large effect. 
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III. Chapter 3- Towards elucidating the role of ubiquitination in the 
pathogenesis of Parkinson’s disease using semisynthetic 
ubiquitinated α-synuclein 
 
This chapter is part of a published article in Angewandte Chemie International Edition 2011 
10;50(2):405-9 with the following authors: 
Hejjaoui M.*1, Haj-Yahya M.* 2, Kumar K.S. 2, Brik A. 2, Lashuel H.A. 1 
* these authors contributed equally 
Affiliations: 
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III.2. Abstract 
Herein we report, for the first time, the semisynthesis and characterization of site-specific (K6) 
mono-ubiquitinated form of α-syn. These advances allowed us to investigate the effect of 
ubiquitination on the membrane binding, oligomerization and fibrillogenesis. The ability to site-
specifically introduce ubiquitin modifications into α-syn represents a major advance towards 
elucidating the role of ubiquitination in regulating α-syn’s function(s) in health and disease. 
 
III.3. Introduction 
Ubiquitination of lysine residues has emerged as an important mechanism for regulating a 
variety of cellular processes such as cell signaling pathways, DNA repair and protein 
degradation by the 26S proteasome (Pickart and Fushman, 2004, Ikeda and Dikic, 2008). Until 
recently, studies aiming at deciphering the effect of ubiquitination on protein function have 
relied primarily on biochemical approaches to reconstitute the ubiquitinated protein in vitro. As 
a result, the progress in the field has been very much dependent on the discovery of the E2-E3 
enzymatic machinery that is highly specific to the protein of interest (Pickart, 2001). The lack of 
effective and general method that allows site-specific incorporation of ubiquitin (Ub) or 
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polyubiquitin chains has hampered efforts to elucidate the molecular and structural basis 
underlying the effects of ubiquitination on regulating protein function. Several groups have 
recently reported elegant chemical methods to facilitate site-specific peptide and protein 
ubiquitination. Several of these methods are based on the attachment of ubiquitin through non-
native isopeptide bonds to generate enzymatically stable Ub conjugates of peptides or 
recombinant proteins (Yin et al., 2000, Li et al., 2009, Chatterjee et al., Chen et al., 2010, 
Shanmugham et al., 2010, Weikart and Mootz, 2010). Site-specific ubiquitination of peptides 
and proteins via formation of native isopeptide bond is now possible thanks to the work of Muir, 
Liu and our group (Chatterjee et al., 2007, McGinty et al., 2008, Ajish Kumar et al., 2009, Yang 
et al., 2009). 
We recently developed a highly efficient and chemoselective method to facilitate site-specific 
ubiquitination of peptides and proteins (Ajish Kumar et al., 2009). Our approach utilizes δ-
mercaptolysine residue to mediate transthioesterification with ubiquitin thioester, followed by S-
N acyl transfer to form the native isopeptide bond between ubiquitin and lysine residues. The 
thiol handle of δ-mercaptolysine is then desulfurized to furnish the desired native isopeptide 
linkage without altering the native sequence of the target peptides/proteins. To facilitate the use 
of this unique residue in Fmoc-, Boc-SPPS and in sequential ligation, δ-mercaptolysine with 
different protecting groups was also synthesized (Haj-Yahya et al., 2010). Using these 
(advanced) synthetic tools, herein we describe, for the first time, an efficient strategy for the 
semisynthesis and characterization of monoubiquitinated α-synuclein at Lys6 (T7-Ub-α-
syn(K6)).   
α-synuclein (α-syn) is a natively unfolded 140 amino acid presynaptic protein that is implicated 
in the pathogenesis of Parkinson’s disease (PD) and related neurodegenerative diseases that are 
collectively termed, “synucleopathies” (Spillantini et al., 1998a, Gai et al., 1999, Campbell et 
al., 2001). The pathology of PD is characterized by the loss of dopaminergic neurons and the 
presence of intracellular inclusions, known as Lewy Bodies (LB), composed primarily of α-syn 
(Spillantini et al., 1998a). Several posttranslational modifications, including phosphorylation, C-
terminal truncations and ubiquitination, have been shown to be closely associated with PD 
pathology and were identified in α-syn within LB isolated from PD brains (Hasegawa et al., 
2002, Sampathu et al., 2003, Tofaris et al., 2003, Anderson JP, 2006). Understanding the role of 
these modifications in regulating α-syn aggregation, LB formation and toxicity is crucial to 
understanding the biology of α-syn, elucidating its role in the pathogenesis of PD, and may lead 
to the identification of novel therapeutic targets to treat the disease.    
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The majority of α-syn species found in Lewy bodies are mono- or diubiquitinated at multiple 
lysine residues (Hasegawa et al., 2002, Sampathu et al., 2003, Anderson JP, 2006). Directed 
site-specific ubiquitination of α-syn at a single or multiple lysine residues has not been possible. 
For example, the co-expression of α-syn with ubiquitin ligases results in predominantly mono 
and di-ubiquitination at multiple sites (Lee et al., 2008b, Rott et al., 2008). Similarly, 
ubiquitination of recombinant monomeric or fibrillar α-syn using rabbit reticulocytes fraction II 
or rat-brain extracts revealed that ubiquitination occurs at multiple, but distinct lysine residues 
(Nonaka et al., 2005), thus precluding the possibility of investigating the effect of ubiquitination 
at specific lysine residues. To address this problem, we developed a semisynthetic strategy, 
combining Cys- and δ-mercaptolysine based native chemical ligation methods (NCL) (Dawson 
et al., 1994) which allows for site specific incorporation of ubiquitin and preparation of highly 
homogenous monoubiquitinated α-syn forms.  
 
III.4. Material and Methods 
III.4.1. Synthesis of α-syn (1-18)(K6mK)- thioester (1) 
Work carried out by Mahmood Haj-Yahya (Prof. Ashraf Brik’s group) 
α-syn (1-18)(K6mK)- thioester was prepared by solid phase peptide synthesis (SPPS) on 
MBHA resin (0.59 mmol/g) following the in situ neutralization protocol for Boc chemistry 
developed by Kent and coworkers.  
III.4.2. Cleavage and deprotection 
Work carried out by Mahmood Haj-Yahya (Prof. Ashraf Brik’s group) 
To the dried resin (250 mg) in a round bottom flask equipped with stirring bar, 750 μL of 
thioanisole/EDT (2:1) was added. The reaction mixture was cooled to 0 ºC, using ice bath, 
followed by the addition of TFA (5 mL) and stirred for 5-10 min. To this solution, TFMSA (500 
μL) was added slowly with constant stirring. The reaction was allowed to reach room 
temperature (RT) over 40 min and stirred for an additional 45 min. Resin was removed by 
filtration and washed with TFA. To precipitate the peptide, the combined filtrate was added 
drop-wise to 10-fold volume of cold ether, centrifugation, decanting of ether, followed by 
dissolving the residue in acetonitrile-water. RP-HPLC purification was carried out on C18-
column (Jupiter 5 micron, 300A, 250 x 21.2 mm) using 10-60% B over 30 min afforded the 
corresponding peptide 1 in ~10% yield. 
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III.4.3. Generation of α-syn N-terminal cysteine (2) 
Starting with a plasmid encoding for α-syn Δ2-17 A18C, we performed single-point 
mutagenesis to generate the N-terminal truncated fragment with alanine at position 19 mutated 
to cysteine (α-syn Δ2-18 A19C). The following primers were used: forward 5’ GAG ATA TAC 
ATA TGT GTG AGA AAA CCA AAC AGG 3’OH and reverse 5’ CCT GTT TGG TTT TCT 
CAC ACA TAT GTA TAT CTC 3’OH. For protein expression, E.coli BL21 DE3 cells were 
transformed with the plasmid and grown in LB medium until OD600 = 0.6. Protein expression 
was induced by adding 1 mM isopropyl-β-d-thiogalactopyranoside (IPTG) and the culture was 
incubated for 4 h at 37°C. After harvesting the cells, by centrifugation at 6000 g for 15 min, the 
pellet was resuspended in 40 mM Tris-acetate and 5mM EDTA pH 8.3 and lysed by ultra-
sonication. The insoluble material was removed by centrifugation at 23000 g for 40min at 4°C. 
The supernatant was boiled for 15min followed by centrifugation at 23000 g for 40min and the 
final supernatant was filtered through a PVDF membrane with a 0.22 μm cut-off. Anion-
exchange chromatography was performed on a Pharmacia AKTA FPLC system using a 25 mL 
High-TrapQ column (Amersham). The protein was eluted with a NaCl gradient (the protein 
elutes at around 300mM NaCl) and subsequently purified on a Superdex 200 26/60 size-
exclusion chromatography column (Amersham) using 50 mM Tris 150mM NaCl pH 7.5 as the 
mobile phase. The purified protein was dialyzed extensively against di-ionized water and then 
lyophilized and stored at -20°C until use. From two liters expression, the average yield of pure 
lyophilised material is 25 mg. The purity and identity of the protein was assessed by SDS-PAGE 
and MALDI-TOF analyses. The mass obtained had +26Da and +70Da thiazolidine adducts as 
previously reported by other groups (Gentle et al., 2004, Chiang et al., 2009). 
III.4.4. Deprotection of thiazolidine 
Work carried out by Mahmood Haj-Yahya (Prof. Ashraf Brik’s group) 
The expressed fragment A19C-140 (50mg, 3.94 mmol) was dissolved in 1 ml Gn.HCl (pH=7.2) 
followed by the addition of methoxylamine (1ml, 0.4 M) containing 30 eq of TCEP. The 
reaction was kept for 3.5 h at 37 C in which HPLC and mass spectrometry analysis indicated 
complete removal of the thiazolidine adducts. 
III.4.5. Ligation of peptide thioester (1) and α-syn19-140(A19C) (2) 
Work carried out by Mahmood Haj-Yahya (Prof. Ashraf Brik’s group) 
Peptide thioester, 1 (2.4 mg, 1.00  mmol) and 2, (10.5 mg, 8.3 x 10-4 mmol) were dissolved in 
400 μL of 6 M guanidine•HCl, 200mM phosphate buffer, pH 7. To this solution 8 μL each of 
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benzylmercaptan (2% v/v) and thiophenol (2% v/v) were added and incubated for 24 h at 37 ºC. 
The progress of reaction was monitored by RP-HPLC using an analytical C4 column (C-4, 300 
A, 5 micron, 150 x 4.6 mm) and a gradient of 5-60 %B over 30 min. Preparative HPLC was 
carried out on semiprepartive column (Jupiter 5 micron, 300A, 250x 10 mm) using a gradient of 
5-60% B over 30 min to afford 5.2 mg of pure ligation product 3.  
Acm removal: The purified peptide 3 (5.2 mg, 3.56 x 10-4 mmol) was dissolved in 15% acetic 
acid (648 µL) under nitrogen, and Hg(OAc)2 (3.4 mg, 0.01 mmol, 30 eq.) was added and kept at 
RT for 3 h. DTT (6.6 mg, 0.04 mmol, 120 eq.) was added and the reaction was left for another 
12 h. The reaction mixture was filtered and purified over a semi-prep HPLC column (C4, 300A, 
10 micron, 250 x 10 mm) using a gradient of 5-60% B over 30 min to give 3.5 mg of peptide 4. 
III.4.6. Generation of T7 ubiquitin thioester (5) 
The T7-tagged ubiquitin was amplified by PCR using the following primers: forward 5’GGC 
AGC CAT ATG GCT AGC ATG AC 3’OH and reverse 5’ CCG CAT CGC TCT TCG GCA 
GCC GCC GCC ACG CAG 3’OH. After digestion with NdeI and LguI (Promega and 
Fermentas), it was ligated into a similarly digested pT7-7 vector containing the mini intein Mxe 
GryA followed by a chitin-binding domain. The resulting plasmid encoding T7-Ub fused to its 
C-terminus to the intein was verified by DNA sequencing. For protein expression, E.coli BL21 
DE3 cells were transformed with the plasmid and grown in LB medium until OD = 0.6, before 
induction with with 0.5 mM IPTG for 4 h at 37°C. After harvesting the cells by centrifugation at 
6000 g for 15 min, the pelett was resuspended in 40 mM Tris-acetate 5 mM EDTA (pH 8.3) 
lysis buffer and the cells were lysed by ultra-sonication (5 cycles of 1 min non-stop pulse at 
13W and 30s rest). The insoluble material was removed by centrifugation at 23000g for 40min 
at 4°C followed by filtration through a PVDF membrane with a 0.22μm cut-off (Millipore). 
Initially, chitin beads (NEB) were used for affinity purification of the fusion proteins. However, 
we later observed that a two-step chromatographic purification protocol gave higher purity and 
yield of T7-Ub-SR. In this protocol, the supernatant was applied first to a 25 mL High-TrapQ 
anion-exchange column (Amersham) and separation was performed on a Pharmacia AKTA 
FPLC system. The protein eluted with a NaCl gradient (the protein elutes at around 200mM 
NaCl) and subsequently purified on a Superdex 200 26/60 size-exclusion chromatography 
column using 50mM Tris 150mM NaCl pH 7.5 as the mobile phase. The fractions containing 
the proteins were pooled and splicing was induced by addition of 2-mercaptoethanesulfonic acid 
(Sigma) at a final concentration of 0.5M and incubation for 12 h at room temperature. The 
splicing efficiency was determined as 60%. T7-Ub-SR was further purified by reverse phase 
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HPLC using a C4 column (Vydac) and eluted using a linear gradient of acetonitrile/0,1% TFA 
in water/0.1% TFA. The fractions containing the thioester were pooled, evaporated and 
lyophilised and kept at -20°C until used. The protein purity was assessed by analytical reverse 
phase HPLC and mass spectrometry. From 2 liters expression pelett, the average yield of 
lyophilised pure product was 6 mg. 
III.4.7. Ligation of peptide (4) with ubiquitin thioester (5) 
Work carried out by Mahmood Haj-Yahya (Prof. Ashraf Brik’s group) 
Purified peptides, 4 (3.5 mg, 2.41 x 10-4 mmol) and 5 (3.2 mg, 3.13 x 10-4 mmol), were 
dissolved in 130 μL of 6 M guanidine•HCl, 200 mM phosphate buffer pH ~7. To this solution 2 
μL each of benzyl mercaptan and thiophenol were added and incubated for 13 h at 37 ºC. The 
progress of the reaction was monitored by HPLC using an analytical C4 column and a gradient 
of 5-60% B over 30 min. The product was purified using semi-prep HPLC column (C4, 300A, 
10 micron, 250 x 10 mm) and a gradient of 5-60% B over 30 min to give 3.2 mg of pure ligation 
product 6.  
III.4.8. Procedure for desulfurization of ubiquitylated αsyn(1-140) (6) 
Work carried out by Mahmood Haj-Yahya (Prof. Ashraf Brik’s group) 
To a solution of peptide 6 (3.2 mg, 1.30 x 10-4 mmol, 1.30 mM) in 100 μL 6 M guanidine•HCl, 
200 mM phosphate buffer pH 7.9, 0.5 M TCEP (26.67 mg, 0.10 mmol) in the same buffer and 
20 μL of t-BuSH was added. To this reaction mixture, 10 μL of 0.1 M radical initiator VA-044 
in the same buffer was added and incubated at 37 ºC for 3 h. The progress of the reaction was 
was monitored by HPLC using an analytical C4 and a gradient of 5-60% B over 30 min. The 
product was purified using semi-prep HPLC column (C4, 300A, 10 micron, 250 x 10 mm) and a 
gradient of 5-60% B over 30 min to give 2.5 mg of pure desulfurized monoubiquitinated α-syn, 
7. 
III.4.9. Final purification by liquid-based isoelectric focusing 
The final product after desulfurization contained some unmodified full-length α-syn which 
appears to co-elute with T7-Ub-α-syn. The best separation of T7-Ub-α-syn from WT α-syn was 
achieved using a micro-rotofor system (Biorad), which allows for liquid-based isoelectric 
focusing of protein mixtures. T7-Ub-α-syn (125μg) was dissolved in 8M urea, 4% glycerol, 2% 
ampholytes pH range 4-6 for a total volume of 2,5mL. Constant power of 1 Watt was applied 
and the purification was allowed to proceed until voltage remained constant (~ 2h and 30min). 
The different fractions were analyzed by SDS-PAGE electrophoresis and the fraction containing 
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pure T7-Ub-α-syn was extensively dialyzed against 50mM Tris 150mM NaCl pH 7.5 and 
concentrated through a 30kD cut-off membrane (Amicon). 
III.4.10. SDS-PAGE and Western-Blot analysis 
Proteins were solubilized in 50 mM Tris 150 mM NaCl, pH 7.5. Gels were prepared using 
standard Laemmli techniques and stained with Coomassie Blue stain or with Silver staining 
(Invitrogen). For Western blot analysis, the proteins were transferred to a nitrocellulose 
membrane (Omnilab). The membranes were blocked for 15 min at RT under constant rocking 
using Odyssey blocking buffer (Li-COR Biosciences) and diluted 1:3 in phosphate-buffered 
saline (PBS). For revelation of T7-Ub-α-syn by anti-Ub antibodies, membranes were boiled in 
PBS prior to blocking and the primary antibody was incubated at RT overnight. Membranes 
incubated with anti-α-syn and anti-T7 antibodies were incubated with the following primary 
antibodies at 4 °C with constant rocking overnight: mouse anti-α-syn (1:1000 dilution; BD 
Transduction Laboratories), mouse anti-T7 (1:15000 dilution; Novagen), mouse anti-pS129 α-
syn (1:5000 dilution; Wako), rabbit anti-pS87 α-syn (1:200 dilution,(Paleologou et al., 2010)), 
mouse anti-ubiquitin (1:250 dilution; Zymed) and rabbit anti-ubiquitin (1:500 dilution; Dako). 
Membranes were washed three times with PBS-T (PBS containing 0.01% Tween), followed by 
incubation with secondary antibodies goat anti-mouse and anti-rabbit IgM conjugated to Alexa 
680 (Invitrogen). Finally, membranes were washed three times with PBS-T and once with PBS 
and scanned in a Li-COR scanner (Li-COR Biosciences).  
III.4.11. Ubiquitin hydrolysis assay 
15 μM of T7-Ub-α-syn was incubated with UCH-L3 (BostonBiochem) and the de-ubiquitination 
reaction was carried out as previously described (McGinty et al., 2009). The T7-Ub-α-syn 
contained small amount of WT α-syn which served as a reference for the formation of WT α-
syn after UCH-L3 mediated hydrolysis of T7-Ub-α-syn. Briefly, UCH-L3 was diluted to 10 μM 
in 50 mM Tris 150 mM NaCl 15 mM DTT pH 7.5 and allowed to be reduced for 15min at RT. 
From the reduced UCH-L3, 5 μL were taken into 20μL of T7-Ub-α-syn in a 37°C water bath. 
Aliquots of 5μL were taken after 2 and 10min and the reaction was quenched by addition of 5μL 
Laemmli buffer 2X. The amount of enzyme used was doubled after 10min. Aliquots were taken 
after 30 and 60min. The reaction was monitored by the appearance of WT α-syn and T7-Ub 
using SDS-PAGE electrophoresis.  
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III.4.12. In vitro phosphorylation assay 
A mixture of WT α-syn and T7-Ub-α-syn (28μM) was incubated with 10mM DTT, 1mM 
MgCl2 and 1mM ATP in 49μL of 50mM Tris pH 7.5. G-protein-coupled-receptor kinase 5 
GRK5 (1μL, 0,38μg, Invitrogen) and Polo-like kinase 3 PLK3 (1μL, 0,42μg, Invitrogen) were 
added to the sample. For phosphorylation with Casein kinase 1 CK1, 28μM of proteins were 
mixed with CK1 buffer (NEB), 1mM ATP in 49uL of Tris 50mM pH 7.5. 1000 units (1μL) of 
CK1 (NEB) were added to the sample. The reaction mixtures were incubated overnight at 30°C 
and the extent of phosphorylation was monitored by western-blotting using anti-pS129 and anti-
pS87 antibodies. 
III.4.13. Lipid binding assay 
1-Palmitoyl-2-oleoyl-sn-glycero-3-[phospho-rac-(1-glycerol)] sodium salt POPG (Avanti Polar 
Lipids) was purchased as a chloroform solution, and the solvent was removed by evaporation 
and lyophilization. The phospholipid was resuspended to a final concentration of 10 mg/ml in a 
solution of 50 mm HEPES 150 mm NaCl pH 7.5. To form large unilamellar vesicles, 10 cycles 
of freezing in dry ice and thawing in a 37 °C water bath were carried out. Small unilamellar 
vesicles were prepared by extrusion through a 100-nm polycarbonate membrane (Avestin) 
according to the manufacturer's instructions. The vesicles were stored at 4 °C and used within 5 
days. For lipid binding assay, 15μM of protein (WT α-syn and T7-Ub-α-syn) were incubated 
with freshly prepared POPG vesicles at a 1/10 mass ratio in 50mM Tris 150mM NaCl, pH 7.5. 
The extent of membrane binding of the proteins was analyzed by monitoring the extent of α-
helical structure in membrane-bound proteins using CD spectroscopy. 
III.4.14. Circular Dichroism (CD) Measurements 
CD spectra were obtained on a Jasco J-815 CD spectrometer using protein concentrations of 
15μM. Bovine ubiquitin was purchased from Sigma. Spectra were recorded in 0.1 cm cells from 
250 to 195 nm with a step size of 0.2 nm, a bandwidth of 1 nm, and a response time of 8s. For 
all spectra, an average of ten scans was obtained and the CD spectrum of the buffer (50mM Tris 
150 mM NaCl pH 7.5) was recorded and subtracted from the protein spectra. 
III.4.15. In vitro aggregation studies 
Protein samples (14μM in 450μL) were incubated at 37°C with constant rotation for 10 days. 
The extent of fibril formation was assessed using the Thioflavin T (ThT) fluorescence assay 
after 5, 7, and 10 days of incubation. Readings were carried out with a ThT concentration of 5 
  
 135 
  
μM and a protein concentration of 1.4 μM in 70 μl of 50 mM glycine (pH 8.5) and fluorescence 
measurements were recorded on an “Analyst AD” spectrometer (Bucher Biotec) at an excitation 
wavelength of 450 nm and an emission wavelength of 485 nm. All samples were analyzed in 
triplicate and corrected for the fluorescence level of freshly solubilized α-syn. Values are 
expressed as the ThT fluorescence of three measurements (means ± S.D.). 
III.4.16. Transmission Electron Microscopy (TEM) 
7μL of proteins were deposited on Formvar-coated 200 mesh copper grids (Electron Microscopy 
Sciences). Grids were washed with two drops of double-distilled H2O and stained with 2 drops 
of freshly prepared 2% (w/v) uranyl acetate (Electron Microscopy Sciences) followed by 
vacuum drying from the edge of the grids. Specimens were viewed on a Philips CIME 12 
electron microscope, operated at 80 kV and digitized photographs were recorded with a CCD 
camera (Digital Camera Morada (Soft Imaging System) 4008 X 2672 pixel). 
 
III.5. Results and discussion 
III.5.1. Generation of monoubiquitinated α-syn at K6 (T7-Ub-α-syn (K6)) 
We focused our efforts on monoubiquitinated α-syn at K6 (T7-Ub-α-syn(K6)) because in vitro ubiquitination 
of fibrillar α-syn was shown to occur primarily at K6, K10 and K12 (Nonaka et al., 2005). However, our 
approach can be applied to prepare monoubiquitinated α-syn involving any lysine residues within the N-
terminal region 1-18 and can be modified to allow ubiquitination at other lysine residues. The semisynthetic 
strategy of T7-Ub-α-syn(K6) is based on expressed protein ligation ( 
Figure III-1). Our design is based on linking two fragments using native chemical ligation 
(NCL): a recombinantly expressed α-syn fragment comprising residues 19-140 bearing an N-
terminal Cys α-Syn(19-140) and a synthetic peptide thioester comprising the N-terminal 
residues 1-18 bearing δ-mercaptolysine, α-Syn(1-18)-SR, in which K6 is replaced with the 
acetamidomethyl (Acm) protected δ-mercaptolysine (Haj-Yahya et al., 2010). Notably, the 
sequence of α-syn lacks Cys residues. Therefore, the ligation site was selected at Ala19, which 
is temporarily replaced with Cys to allow NCL and the assembly of full length α-syn. 
Conversion of Cys19 to Ala19 and removal of the thiol handle of the δ-mercaptolysine is 
simultaneously achieved under desulfurization conditions to afford the native 
monoubiquitinated protein T7-Ub-α-syn(K6) (Yan and Dawson, 2001). With this design in 
mind, the C-terminal fragment with an N-terminal free cysteine α-syn(19-140) was expressed in 
E. Coli (Figure S III-1). The α-syn(1-18)-SR peptide was prepared using solid phase peptide 
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synthesis (SPPS) according to the in situ neutralization protocol for Boc-chemistry (Schnolzer et 
al., 1992), wherein the Acm-protected δ-mercaptolysine was coupled instead of K6. 
Having both fragments in hand, we then turned our attention to the ligation and ubiquitination 
steps. The NCL of α-syn(19-140) and the synthetic α-Syn(1-18)-SR peptide thioester was 
carried out under denaturing conditions (i.e. 6 M GuHCl, 200 mM phosphate buffer, pH 7) and 
in the presence of 2% v/v thiophenol/benzylmercaptan. The backbone ligation reaction was 
followed by RP-HPLC and mass spectrometry, both of which indicated a nearly complete 
ligation after 24 h, and gave the desired product in 43% isolated yield. Following the ligation 
step, the Acm protecting group was removed quantitatively by incubation with Hg(OAc)2 in 
15% acetic acid for 3 h, followed by treatment with DTT for an additional 12 h. 
 
 
 
Figure III-1.Schematic depiction of the semisynthetic strategy for the ubiquitination of α-syn at K6. 
 Next, we focused on the ubiquitination between the T7-Ub-SR and full length α-Syn(1-140) 
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presenting the free δ-mercaptolysine. Using the above described ligation conditions, a complete 
ligation of both proteins was observed after 12 h and gave the ubiquitinated product in 54% 
isolated yield ( 
Figure S III-3). Finally, the isolated product was subjected to the metal free desulfurization 
conditions for 3 h to give the native monoubiquitinated α-Syn T7-Ub-α-syn(K6) in 78 % 
isolated yield (Figure III-2) (Wan and Danishefsky, 2007). SDS-PAGE analysis of T7-Ub-α-
syn(K6) revealed a slow migrating band at ~ 26 kDa, consistent with the mass spectrometry data 
and conjugation of one molecule of ubiquitin (Figure III-3.A). Western-blot analysis of this 
sample showed that this band is detectable using anti-T7, anti-α-syn and anti-ubiquitin 
antibodies (Figure III-3.A). To verify the formation of a native isopeptidic bond between 
ubiquitin and α-syn, we incubated T7-Ub-α-syn(K 6) with ubiquitin C-terminal-
carboxyhydrolase (UCH-L3) to see if it can be hydrolyzed. Upon addition of UCH-L3, we 
observed the generation of T7-ubiquitin monomers and WT α-syn (Figure S III-5). 
  
 
 
 
Figure III-2. Analytical HPLC of the crude desulfurization reaction peak 
Analytical HPLC analysis corresponding to the desired monoubiquitinated α-Syn with the observed mass of 
24532.8 Da (calcd m/z 24531.7 Da). The progress of the reaction was analyzed using RP-HPLC (C4 column) with 
a gradient of 5%-60% B over 30 min. Reported mass is for total protein. 
 
 
III.5.2. Effect of monoubiquitination at K6 on the secondary structure 
Having verified the chemical integrity of T7-Ub-α-syn(K6), we then focused on elucidating the 
effect of ubiquitination on the secondary structure, membrane binding and aggregation 
properties of α-syn in vitro using circular dichroism (CD), thioflavin T binding assay, and 
transmission electron microscopy (TEM). As expected, WT α-syn exhibited a CD spectrum 
consistent with a random coil structure, while T7-Ub-SR showed a spectrum that reflects a 
mixture of α-helices, β-sheets and random coil, consistent with the structure of ubiquitin 
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(Jenson et al., 1980). T7-Ub-α-syn(K6) showed a CD spectrum that is virtually identical to that 
obtained from a solution containing an equimolar mixture of T7-Ub-SR and WT α-syn, 
suggesting that the native structures of ubiquitin and α-syn are preserved in the ubiquitinated α-
syn, T7-Ub-α-syn(K6).  
 
Figure III-3. Characterization of monoubiquitinated α-syn at K6 
A) SDS-PAGE analysis of T7-Ub-SR, α-syn WT and T7-Ub-α-syn. 15% gel, Silver staining. Immunoblots of T7-
Ub-SR and T7-Ub-α-syn using anti-T7 and anti-ubiquitin antibodies (Zymed) and of α-syn WT and T7-Ub-α-syn 
using anti-asyn antibody. B) CD data of T7-Ub-SR, ubiquitin (Sigma), mix of ubiquitin and α-syn WT, α-syn WT 
and T7-Ub-α-syn. CD spectra of α−syn WT and T7-Ub-α-syn bound to POPG vesicles. C) ThT fluorescence assay 
of samples taken at time 0, 5, 7 and 10 days. D) Quantification of monomeric α-syn using SDS-PAGE analysis at 
time 0 and 10 days after filtration through a 100 kDa membrane. EM images of α-syn WT and T7-Ub-α-syn at day 
7; scale bar represents 200 nm. The figures are representative of 2 independent experiments 
 
 
In neurons, α-syn shows a cytoplasmic and membrane localization. The N-terminal region 
comprising residues 1 to ~ 100 (Bisaglia et al., 2005, Ulmer et al., 2005, Bodner et al., 2010) has 
been shown to mediate α-syn interaction with membranes and adopt an α-helical structure upon 
interaction with lipid vesicles in vitro. The effect of ubiquitination on α-syn membrane binding 
has not been investigated. Figure III-3.B shows that α-syn WT and monoubiquitinated α-syn 
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adopt a similar α-helical structure upon binding to POPG vesicles, suggesting that the 
conjugation of a ubiquitin moiety on K6 does not induce major changes in the structure of α-syn 
in solution or alter its interaction with synthetic lipids. 
III.5.3. Effect of monoubiquitination at K6 on fibril formation 
To determine the effect of N-terminal ubiquitination on α-syn fibril formation, we compared the 
fibrillization of the monoubiquitinated α-syn at K6 to that of the WT protein using the ThT 
fluorescence assay and TEM.  Figure III-3.C and D demonstrate that ubiquitination at K6 results 
in significant inhibition of α-syn fibril formation as evidenced by the absence of any changes in 
the ThT signal after incubation at 37 ºC for 10 days under rotating conditions (Figure III-3.C). 
Consistent with the ThT data, WT α-syn formed extensive mature fibrillar structures, whereas 
no fibrils were detected in samples containing the monoubiquitinated protein. These findings are 
consistent with previous reports demonstrating that not all α-syn inclusions in transgenic mouse 
models are ubiquitinated (van der Putten et al., 2000, Sampathu et al., 2003), which suggests 
that ubiquitination is not required for inclusion formation and could be a late event that occurs 
after synuclein fibrillization (Sampathu et al., 2003). 
On the other hand, our data contradict other studies reporting that ubiquitination enhances α-syn 
aggregation in vitro and in cell cultures (Lee et al., 2008b, Rott et al., 2008). However, it is 
noteworthy that none of these studies examined the aggregation of homogenous preparations of 
mono-ubiquitinated α-syn, instead the samples used contained heterogeneous mixtures of 
unmodified as well as α-syn ubiquitinated at different lysine residues.  
 
III.5.4. Effect of monoubiquitination at K6 on phosphorylation 
The semisynthesis of α-syn provides unique opportunities to explore cross-talk between 
different post-translational modifications and how it influences α-syn aggregation and LB 
formation in synucleinopathies. For example, several studies have reported close association 
between ubiquitination and phosphorylation of α-syn at S129 within LB (Hasegawa et al., 2002, 
Tofaris et al., 2003, Anderson JP, 2006), suggesting that S129 phosphorylation may play a role 
in regulating α-syn ubiquitination and degradation. Studies by Nonaka et al suggested that the 
effect of S129 phosphorylation on α-syn ubiquitination in vitro is minor (Nonaka et al., 2005). 
However, the effect of ubiquitination at each of the putative lysine residue on α-syn 
phosphorylation has not been investigated. 
To explore the interplay between these two modifications, we investigated the effect of 
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ubiquitination at K6 on the extent of α-syn phosphorylation at S87 and S129 by three kinases, 
caseine kinase I, polo like kinase 3 and G-protein-coupled receptor kinase 5, which are known to 
phosphorylate α-syn at these residues (Okochi M, 2000, Arawaka et al., 2006, Mbefo et al., 
2010). We took advantage of the difference in size between WT and T7-Ub-α-syn(K6) and 
included both proteins in the phosphorylation reaction to assess the activity of the kinases and 
allow for direct comparison between the two proteins under identical phosphorylation 
conditions. We show that ubiquitination at K6 does not influence significantly the extent of α-
syn phosphorylation at S87 (by CK1) and S129 (by CK1, GRK5 and PLK3) (Figure S III-6). 
 
 
III.6. Conclusion 
In summary, we report, for the first time, the semisynthesis and characterization of site-specific 
(K6) monoubiquitinated form of α-syn (T7-Ub-α-syn(K6)). The strategy has yielded sufficient 
quantities that allowed us to perform biochemical and biophysical studies to elucidate the effect 
of this modification on the structure, membrane binding, and fibrillization of α-syn. In addition, 
we were able for the first time to investigate the cross-talk between two disease-associated post-
translational modifications (ubiquitination and phosphorylation at specific residues). The ability 
to site-specifically introduce ubiquitin modifications into α-syn represents a major advance 
towards elucidating the role of ubiquitination in regulating α-syn’s function(s) in health and 
disease. Our findings present strong evidence in the support of the hypothesis that N-terminal 
ubiquitination of α-syn stabilizes the monomeric form of the protein, thus preventing its 
oligomerization and fibrillogenesis in vitro.  
The results presented within highlight the potential of applying advances in semisynthesis of 
proteins approaches to dissect the role of post-translational modifications in modulating α-syn 
function in health and disease. Current efforts in our laboratories are focused on elucidating the 
effect of ubiquitination at other lysine residues as well as other post-translational modifications 
and extending our studies to examine the consequences of these modifications on the subcellular 
localization, life-time, and toxicity of α-syn in cellular models of synucleinopathies.  
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III.7. Supporting information 
 
 
 
Figure S III-1. Analysis of α-syn fragment A19C-140 
Analytical RP-HPLC and MALDI-Tof analysis of the purified N-terminal truncated α-syn fragment A19C-140. 
The purity of the protein was analyzed by RP-HPLC (C4 column) using a gradient of acetonitrile/0.1%TFA 5% to 
80% over 30min. The MALDI spectrum shows the observed mass 12657 and 12699 Da (calc. m/z 12631 Da) and 
the double charged 6332 Da. The addition of +26 and +70Da corresponds to the formation of thiazolidine adducts 
that form upon the spontaneous protection of the N-terminal cysteine residue during protein expression in E. Coli. 
 
 
 
 
Figure S III-2. Analysis of T7-ubiquitin-thioester 
Analytical RP-HPLC and MALDI-Tof of purified T7-ubiquitin-thioester. The purity of the protein was analyzed by 
RP-HPLC (C4 column) using a gradient of acetonitrile/0.1%TFA 5% to 80% over 30min. The MALDI spectrum 
shows the observed mass 10215 Da (calc. m/z 10216 Da) and the double charged 5107 Da.  
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Figure S III-3. Analytical data on the semisynthesis of monoubiquitinated α-Syn 
A) Analytical HPLC of the Acm removal reaction after 15 hr ; peak a corresponds to the desired product with the 
observed mass 14523 Da (calcd m/z 14524 Da); B) Analytical HPLC of the ubiquitination reaction after 12 hr; peak 
b corresponds to the hydrolyzed ubiquitin thioester and the remaining expressed T7-Ub-SR (methansulfonate 
derivative), peak c corresponds to benzylmercaptan exchange thioester, peak d corresponds to the desired product 
with the observed mass 24593.9 Da (calcd m/z 24595.8 Da), ; C) Analytical HPLC of the crude desulfurization 
reaction peak; peak e corresponds to the desired monoubiquitinated α-Syn with the observed mass of 24532.8 Da 
(calcd m/z 24531.7 Da). The progress of the reaction was analyzed using RP-HPLC (C4 column) with a gradient of 
5%-60% B over 30 min. Reported mass is for total protein. 
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Figure S III-4. SDS-PAGE analysis of rotofor fractions.  
15% SDS-PAGE silver stained gel (Invitrogen) illustrating the separation of T7-Ub-α-syn from unmodified α-syn 
using the micro-rotofor system. WT α-syn eluted pure in fraction 5 of the micro-rotofor chamber and mixed with 
T7-Ub-α-syn in fraction 6. T7-Ub-α-syn eluted pure in fraction 7. 
 
 
 
 
 
Figure S III-5. De-ubiquitination of T7-Ub-α-syn  
15% SDS-PAGE gel, coomassie staining.  
 
 
 
 
Figure S III-6. Phosphorylation of monoubiquitinated α-syn  
Immunoblots of monoubiquitinated α-syn in presence of CK1, GRK5 and Plk3 or no kinase. Detection was made 
with anti-α-syn antibody to detect total α-syn proteins and with antibodies against phospho Ser129 and phospho 
Ser87.  
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IV. Conclusion  
Despite more than two decades of intensive resarch on α-syn, our knowledge about its 
physiological functions and the mechanisms by which it contributes to neurodegeneration in PD 
and other synucleinopathies remains limited. That being said, the conceptual and technical 
advances that were made by the scientific community have certainly brought us closer to 
addressing this knowledge gap and are paving the way for exciting discoveries to be made in the 
coming years.   
A better understanding of the molecular determinants that trigger α-syn aggregation is essential 
for developing effective therapeutic strategies to inhibit this process and treat or protected 
against neurodegeneration in PD and related synucleinopathies. The discovery that some of α-
syn’s PTM (phosphorylation at S87, S129 and ubiquitination) were present mainly in LB 
suggests that these modifications play important roles in inducing α-syn aggregation and LB 
formation. Several approaches have been applied to determine the effect of these modifications 
in regulating α-syn aggregation and toxicity in different animal models of synucleinopathies.  
However, most of these approaches relied on the use of natural mutations to mimic 
phosphorylation or on the co-expression of α-syn with inefficient or non-specific kinases, in the 
case of phosphorylation. Similarly, studies aimed at addressing the role of ubiquitination relied 
on the use of E3 ligases that lack specificity and ubiquitinate α-syn at multiple lysine residues. 
While these studies have been informative, they do not allow addressing the roles of specific 
modifications in regulating α-syn’s biology in health and disease.  
Motivated by these challenges and the desire to develop novel strategies to study post-
translational modifications in neurodegenerative diseases, we sought to develop efficient 
methods for the generation of homogenous, site-specifically modified α-syn for the investigation 
of α-syn serine/tyrosine phosphorylation and ubiquitination.   
Inspired by the pioneering work of Dawson, Muir and others on the native chemical ligation of 
proteins (section I.5.3.1), we developed two strategies based on expressed protein ligation for 
the introduction of PTM in the N-terminal or the C-terminal domain of α-syn that allowed us to 
produce milligram quantities of pY125 α-syn (section II) and monoubiquitinated α-syn at K6 
(section III). These advances have allowed us to investigate, for the first time, the effects of 
selective phosphorylation at Y125 and ubiquitination at K6 on the structure, aggregation, 
membrane binding and subcellular localization of α-syn. The development of semisynthetic 
methods for the site-specific introduction of single or multiple PTM represents an important 
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advance towards determining the roles of such modifications on α-syn structure, aggregation 
and functions in health and disease. In addition, we were able to investigate cross-talk between 
phosphorylation at residues S129, Y125, and S87 by determining the relative activity of each 
phosphorylated form of α-syn as a substrate for the kinases that phosphorylate at the other 
residues. In the case of monoubiquitinated α-syn at K6, our studies demonstrated for the first 
time that ubiquitination, which was thought to enhance α-syn aggregation and LB formation, 
stabilizes instead the monomeric protein and inhibits its fibrillization. It is noteworthy that the 
semisynthesis of monoubiquitinated α-syn represents the second successful attempt to prepare 
ubiquitinated proteins via a native isopeptide bond.  
The different strategies outlined in this thesis represent powerful methodologies that can be 
extended to other proteins implicated in neurodegenerative diseases (e.g. Tau, Huntingtin) and 
allow the introduction of site-specific chemical modifications and/or PTMs. These approaches 
can also be used to site-specifically introduce fluorescent probes, fluorescence resonance energy 
transfer (FRET) fluorophores pairs, or affinity handles to allow for selective labeling at specific 
residues using small probes or the covalent immobilization or cross-linking of proteins using the 
handles (for review: (Muir, 2003a)). Non-hydrolyzable phosphonate amino acids have been 
synthesized and incorporated into proteins to prevent rapid dephosphorylation at Ser or Tyr and 
facilitate the investigation of the consequences of phosphorylation in living cells or complex 
biological samples. Furthermore, the availability of semisynthetic homogeneous post-
translationally modified forms of α-syn as substrates should aid in the development of assays to 
identify the natural enzymes (kinases, phosphatases, E3 ligases, deubiquitinases) involved in the 
regulation of these modifications and will facilitate the development of quantitative assays to 
measure the levels of these modification during disease progression. These studies are likely to 
lead to the identification of novel therapeutic targets for the treatment of PD and the 
development of diagnostic tools for early detection and monitoring of neurodegeneration in PD 
and other neurodegenerative diseases.    
  
Future Directions 
We are currently applying our semisynthetic strategy for the generation of monoubiquitinated α-
syn at K12 and K23 and, taking advantage of the native isopeptide bond in our system, we are 
investigating the effect of monoubiquitination at K12 on the degradation of α-syn by the 
proteasome, in collaboration with Aaron Ciechanover’s group. Preliminary data using purified 
proteasomes reveal an ubiquitination-dependent proteasomal degradation of α-syn (Shabek et 
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al., 2012), in contrast to previous reports which suggested that unmodified α-syn can be 
degraded by the proteasome (Bennett et al., 1999, Tofaris et al., 2001, Machiya et al., 2010).  
Recent advances and novel synthetic tools developed by our collaborators in Ashraf Brik’s 
group have enabled for the first time the generation of diubiquitin and tetraubiquitin chains by 
total chemical synthesis. These advances have enabled the generation of tetraubiquitinated α-syn 
through K48 linkage, which is currently being investigated as part of a joint collaborative 
project between the two groups. The ability to investigate mono and poly-ubiquitinated forms of 
α-syn will eventually allow us to decipher the code of α-syn ubiquitination. 
The next challenge that is currently being tackled by our group involves the development of 
efficient strategies for the delivery of semisynthetic and chemically synthesized α-syn into living 
cells to assess the effect of PTM on the cellular properties of α-syn in their natural environment. 
Our laboratory is currently investigating the use of cell-penetrating peptides to facilitate the 
delivery of the proteins into cells. TAT-peptide fusion to α-syn has been previously shown to 
transduce efficiently in cell-based and animal models (Albani et al., 2004, Recchia et al., 2008). 
If successful, our method, combining chemistry, biochemistry and biology, would definitely 
pave the way to the systematic study of all α-syn PTM in vivo.  
To expand our methodology for cell-based and animal applications for the study of cross-talks 
between phosphorylation at these two residues, we were inspired from the seminal work of 
Imperiali’s group who reported the synthesis of two photocleavable protecting groups of 
phosphorylated residues that can be cleaved using different wavelengths (Goguen et al., 2011).  
We thus plan to introduce photocaged phosphorylated serine and tyrosine residues that can, 
through irradiation at 420 and 365 nm respectively, be exposed sequentially. Moreover, the use 
of other photo-sensitive amino acid derivatives is very appealing since the near-UV wavelengths 
that are commonly used do not alter the cell’s DNA. A large panel of photo-caged and photo-
crosslinking amino acids can thus be used in cell culture and animal studies. The latter could 
furthermore benefit from the use of two-photon excitable photosensitive amino acids, due to the 
deeper tissue penetration of the lower-wavelength light used. 
In summary, now that the methodology has been developed for the introduction of any α-syn 
modification at any residue, its potential will be best harvested from the generation of tailor-
made variants to answer specific questions. This can only be achieved through the optimization 
of methodologies to introduce these proteins into cells and animal brains along with 
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development of novel chemistries for the modification of specific residues; and most 
importantly through the fruitful interactions between scientists from different disciplines.  
While semisynthetic approaches were previously used for the study of enzymes and other 
proteins (Muir, 2003a), the field is just starting to bloom for amyloid proteins and proteins 
involved in neurodegenerative diseases with recent reports of the semisynthesis of the Prion 
protein (Olschewski et al., 2007, Becker et al., 2008, Olschewski and Becker, 2008), Tau 
(Broncel et al., 2012a) and Amyloid−β (Bockhorn et al., 2010). We hope that the methodology 
will quickly expand to other laboratories for the study of proteins involved in neurodegeneration 
and that the shadows masking the impact of the different PTM on the pathogenesis of 
neurodegenerative disorders will be removed.    
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